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 ABSTRACT   
Few biomarkers have been identified for prostate cancer diagnosis/prognosis and there are 
clinical difficulties in distinguishing between relapsing and non-relapsing tumours. 
Therefore, identifying new biomarkers for prostate cancer has become a priority. Recently, 
potential stem cells found within a tumour have received a lot of attention and it is thought 
that these cells may have a role in cancer initiation, progression and drug resistance. The 
major goal of this study was to focus on proteins linked to stem cells, cellular differentiation 
and/or tumour formation and progression and establish if they are differentially expressed 
between normal and malignant prostate tissues and/or between samples with different 
clinical features, including relapsing vs non-relapsing tumours.  
Eight potential biomarkers were identified using literature searching. These were β-catenin, 
NDRG1, ABCG2, ALDH1A1, RS1, Sox7, Sall4 and Zscan4. Their expression was 
evaluated by immunohistochemistry using 39 prostate tissue samples from a Bath cohort and 
the staining was then repeated using a much larger tissue microarray cohort that consisted of 
96 cases. The data from both cohorts was then tested for association with different clinical 
features. Finally, the expression of three of the potential biomarkers, Sox7, Sall4 and Zscan4 
was further validated by staining tissues from both cohorts with either a second independent 
antibody and /or for the biomarkers’ mRNA using RNAscope®.  
β-catenin, Sox7, ABCG2, membranous and cytoplasmic NDRG1 staining was found to be 
reduced in prostate cancer samples, whereas, Zscan4, nuclear NDRG1 and Sall4 staining 
was increased. There was a negative association between β-catenin, Sox7, ABCG2 and Sall4 
staining and increasing Gleason grade, whereas, nuclear NDRG1 staining was positively 
associated with Gleason grade. There was also a negative association between Sox7, ABCG2 
and stromal ALDH1A1 staining and biochemical relapse. In contrast, there was no 
significant association between RS1 staining and prostate cancer clinical features. Therefore, 
this data identified seven proteins that may play a role in prostate tumour formation and/or 
aggressiveness and three that may be implicated in PCa relapse. These candidates warrant 
further investigation to understand their functions and establish if they could represent 
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1. Introduction  
Prostate cancer (PCa) is a heterogeneous disease and represents a global healthcare issue that 
is mostly a diagnosis of elderly men (Dunn and Kazer, 2011). A few diagnostic and 
prognostic biomarkers have been identified for PCa, including prostate-specific antigen 
(PSA) (Qu et al., 2014). However, there is a need for more specific and/or sensitive 
biomarkers in PCa diagnosis and especially for measuring PCa prognosis, for example, to 
distinguish between relapsing and non-relapsing cases. Cancer stem cells (CSCs) have been 
linked to PCa relapse and so analysis of expression of proteins that have been linked to stem 
cells (SCs) represents an interesting new avenue for future biomarker studies. This thesis 
will take this approach and examine the expression of proteins linked to SCs in PCa to try 
and identify potential new biomarkers for the disease.  
This introduction will describe the structure and cell types of the normal and malignant 
prostate, the diagnostic methods for PCa, and the main molecular processes that are involved 
in PCa formation and progression and finally provide information about SCs and CSCs in 
prostate tissue. 
 1.1 Normal prostate  
This section will provide information about the anatomy, physiology and histology of the 
normal prostate (NP).  
1.1.1 Prostate anatomy 
The prostate is the largest accessory gland in the male reproductive system. It is a glandular 
organ surrounding the neck of the urinary bladder and urethra and the normal weight of the 
adult prostate is about twenty grams (Epstein, 2010). The prostate consists of glandular and 
non-glandular regions. The glandular region can be divided into three zones: peripheral, 
central and transitional zones (Figure1.1) and most pathological lesions of prostate arise 
from the glandular region. For example, 75% of PCa develop in the peripheral zone and less 
frequently in the transitional and the central zones (McNeal, 1984; Applewhite et al., 2001; 
Hammerich et al., 2008; Mocarska et al., 2014). The non-glandular region consists of a 
single zone, called the anterior fibromuscular stroma (McNeal, 1984) (Figure1.1). The 
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prostate is also surrounded by a fibromuscular tissue layer, called the prostate capsule (Fine 
and Reuter, 2012).  
 
Figure 1.1 Prostate anatomy as described by McNeal. The NP consists of several distinct regions, including 
three glandular regions: the peripheral zone (PZ), transition zone (TZ) and central zone (CZ). In addition to a 
non-glandular region of anterior fibromuscular stroma (AFS). Through the ejaculatory duct (labelled), Seminal 
vesicles (SV) secrete their fluid into the urethra. Adapted from (McNeal, 1984; Sharpe, 2016). 
1.1.2 Prostate physiology 
The major role of the prostate gland is the production of an alkaline fluid that forms part of 
the seminal fluid and promotes sperm movement and activity (Frick and Aulitzky, 1991; 
Abate-Shen and Shen, 2000; Khan, 2011; Bhavsar and Verma, 2014). In addition, prostate 
muscles assist in discharging the semen at the time of ejaculation (Khan, 2011). Previous 
studies have reported that the prostate gland represents a manufacturer of PSA which plays 
a role in dissolving the seminal clots and promoting sperm motility in the female 
reproductive tract as well as to nourish sperm (Dunn and Kazer, 2011; Khan, 2011). The 
prostate can be regulated by dihydrotestosterone which is normally produced from a key 




1.1.3 Prostate histology 
The histological architecture of the prostate glands shows that there are multiple epithelial 
glands surrounded by abundant fibromuscular stroma. The normal epithelial-stromal- ratio 
in human prostate tissue is  1:2 (Prajapati et al., 2013).  
The epithelial layer of the prostate contains three cell types; basal, secretory (luminal), and 
neuroendocrine cells (Signoretti and Loda, 2007; Goldstein et al., 2010a) (Figure 1.2). Basal 
cells are small flattened or cuboidal undifferentiated cells located on the basement membrane 
of the prostate gland, these cells don’t have a secretion action (Lang et al., 2009b). The 
second type of epithelial cells that form the majority of cells in the epithelium of the prostate 
gland, is called luminal cells and these cells are fully differentiated columnar cells and have 
the ability to secrete materials into a glandular lumen of the prostate, including PSA and 
prostate acid phosphatase (PAP) (McNeal, 1984; Lang et al., 2009b). In addition, there is a 
small population of fully differentiated cells located in the basal layer called neuroendocrine 
“endocrine-paracrine” which play a role in secreting serotonin (McNeal, 1984; Bonkhoff et 
al., 1995; di Sant'Agnese and Cockett 1996) and a number of neuropeptides such as 
chromogranin, calcitonin family peptides, parathyroid-like hormone and somatostatin  (Di 
Sant'Agnese and Cockett, 1996; Parimi et al., 2014). Surrounding the epithelial cells are 
several types of cells in the stromal layer of the prostate, including smooth muscle cells, 
fibroblasts, and myofibroblasts (Takao and Tsujimura, 2008) (Figure 1.2).  
Figure 1. 2 Histology of the NP epithelium. The NP consists of an epithelial structure with three types of 
epithelial cells (Basal, Luminal and Neuroendocrine cells), a basement membrane and surrounding stroma. In 
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the ductal lumen, there are secretary substances (labelled) such as zinc, citrate, and PSA that are produced by 
luminal cells. Histologically, both basal and neuroendocrine cells are normally found in the basal cell layer and 
cannot be distinguished microscopically.  Adapted from (Abate-Shen and Shen, 2000).    
There are three most common pathological disorders which affect the prostate glands, 
including prostatitis (inflammation of the prostate), benign prostate hyperplasia (BPH) 
(enlargement of the prostate gland) and cancers (Epstein, 2010). The current study will focus 
on carcinoma of the prostate. 
1.2 Prostate cancer 
1.2.1 Introduction  
PCa can broadly be defined as an abnormal growth that usually begins in the prostate glands. 
In the United Kingdom, PCa represents the second most frequent malignancy and is the 
second highest cause of death in males after lung cancer (Lang et al., 2009b; Kirby, 2012).   
Adenocarcinoma is the most common type of PCa which represents more than 90% of PCa, 
and it originates from the glandular regions of the prostate gland (Bagnall, 2014; Dunn and 
Kazer, 2011). Other types of carcinoma are also observed but are rare in the prostate gland, 
including small cell (neuroendocrine) carcinoma, squamous cell carcinoma, urothelial cell 
carcinoma and sarcomatoid carcinoma (Li and Wang, 2016).  
1.2.2 Risk factors of prostate cancer 
Although the main causes of PCa are still being fully established, several risk factors have 
been linked to the development and progression of PCa (Bostwick et al., 2004), including 
age (Kirby, 2012), race (Dunn and Kazer, 2011), family history (Kirby, 2012), hormones 
and diets (Bostwick et al., 2004).  
Previous studies found over half (54%) of PCa cases are diagnosed in males over the age of 
75, whereas, this risk generally is reduced in males under the age of 50 (Bostwick et al., 
2004) suggesting PCa is an illness of elderly men. This may be because of the slow-growing 
nature of PCa, as well as the activity of the immune system which reduces with advanced 
age. In addition, Ben-Shlomo et al. identified an increased risk of PCa in black UK males 
compared to those with white skin, however, this risk is still lower than black American 
males (Ben-Shlomo et al., 2008). Another study by Metcalfe et al. found that Asian men 
have a higher risk of PCa after they emigrate to the United Kingdom compared to the general 
population (Metcalfe et al., 2008). This evidence suggests that race plays a role in PCa 
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development. Family history is also found to play a role in increasing the risk of PCa 
development in the next generation.  A previous report found that approximately 9% of PCa 
cases have an inherited basis and the risk of PCa rises 2.5 fold for men who have a family 
history with PCa (Kirby, 2012). This evidence suggests that this difference may be due to 
genetics and environmental factors.  
Hormonal changes may promote the growth of PCa and it has been found that androgens 
have a significant role in the alteration of PCa development. PCa progression from 
preclinical to clinical form may occur as a result of androgen metabolism changes (Bostwick 
et al., 2004). Another study found that testosterone has an essential role in the progression 
of PCa and castration of men plays a role in preventing PCa progression (Kirby, 2012). Diet 
is also found to be implicated in PCa development. For example, fat intake, particularly 
polyunsaturated fat, has a positive correlation with the rate of PCa development and its 
mortality rate. The reasons for this are proposed to be that fat induces changes in the hormone 
profile, along with metabolic effects such as a generation of protein or DNA reactive 
intermediate due to increased oxidative stress (Bostwick et al., 2004). In addition, high 
consumption of red meat increases the risk of PCa, this might be due to increasing the 
carcinogenic substance during cooking the meat at a high temperature (Khan, 2011). The 
risk of PCa also increases in people who consume egg and foods which have sources of egg 
(Richman et al., 2011). The reason for this correlation may be that eggs contain a high 
cholesterol concentration, which represents a precursor for androgen production and may 
promote the development of tumours due to its effect on steroidogenesis (Pelton et al., 2012).  
1.2.3 Steps in the development of prostate cancer  
PCa grows slowly and is normally a disease of elderly males over the age of 50 (Leitzmann 
and Rohrmann, 2012). However, PCa is also identified in young men (Salinas et al., 2014), 
suggesting PCa progression and the initiation of pre-neoplastic disorders may develop in the 
early stage of life.  
Proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia (PIN) have 
proposed to be potential precursor lesions to PCa (Woenckhaus and Fenic, 2008; Bostwick 
and Cheng, 2012).  PIA is an atrophic lesion in the prostate architecture marked by increased 
proliferation, reduced apoptotic rate, detection of molecular-biological abnormalities 
specific for oxidative stress or malignancy (Woenckhaus and Fenic, 2008), and increased 
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inflammatory cells in both epithelial and stromal prostate regions (De Marzo et al., 1999; 
DeMarzo et al., 2003). PIA normally occurs in the peripheral prostate zone that represents 
the area in which most clinically important prostatic adenocarcinomas develops (De Marzo 
et al., 1999). The inflammatory nature of PIA could potentially promote carcinoma either 
directly or indirectly through first developing into high grade PIN (HGPIN), which 
subsequently progresses to carcinoma (De Marzo et al., 1999; DeMarzo et al., 2003). 
However, the direct evolving from PIA to carcinoma is thought to be rare (Epstein, 2009). 
PIN is thought to be another precursor of PCa development and to represent an intermediate 
stage between BPH and PCa (Bostwick and Cheng, 2012). PIN arises primarily from the 
peripheral zone of the prostate and the cytological features of the lesions are similar to those 
of PCa (Sakr and Grihnon, 1999). The histological feature of PIN is characterised by the 
presence of luminal epithelial hyperplasia, enlarged nuclei and nucleoli, the partial absence 
of basal cell layers, basement membrane (Jaworska et al., 2015) and stromal reactivity 
(Packer and Maitland, 2016). In addition to the similarities to PCa, the histological features 
of PIN resemble benign glands with a basophilic appearance because of enlarged, crowded 
nuclei and increased nuclear to cytoplasmic ratio (Epstein, 2009). Based on the histological 
architecture and cytologic features, two different grades of PIN, low and high grade have 
been identified (Ayala and Ro, 2007; Bostwick and Cheng, 2012; Tolkach and Kristiansen, 
2018). HGPIN is a potential source of PCa (Ayala and Ro, 2007; Bostwick and Cheng, 2012; 
Tolkach and Kristiansen, 2018). However, it has been found that not all PCa arises from 
HGPIN (Epstein, 2009). 
There are a number of significant changes which are identified during the transformation of 
prostate cells from NP to PIN to carcinoma, including histological and molecular changes 
(Packer and Maitland, 2016). Firstly, the basal cell layer and basement membrane normally 
present within the NP gland. This histological architecture, however, is disrupted by the 
disappearance of the basal cell layer and basement membrane of the prostate gland either 
partially in a PIN  or completely in PCa (Epstein, 2009; Liu et al., 2009). Secondly, PCa 
tissues are also histologically characterized by hyperproliferation of the secretory cells 
(Goldstein et al., 2010a) and increased immune cell infiltration (Packer and Maitland, 2016).  
PCa patients are normally initially treated with surgery, a radical prostatectomy, or 
radiotherapy. This is successful for many patients, but roughly a third will suffer relapse 
(Tan et al., 2015b; Xie et al., 2014), which is defined as an increase in the PSA level in the 
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blood following the surgery or radiation treatment. Relapsing patients are often treated with 
hormonal therapy which is normally based on blockage of androgens by medicines that 
prevent androgen production and/or block the function of androgen receptor AR (Tan et al., 
2015b), but the tumours can become resistant to the treatment and progress to a clinical 
condition that is called castration-resistant PCa (CRPC) (Tan et al., 2015b). This has 
previously been named as a hormonal refractory or androgen-independent PCa. CRPC 
patients will be shifted to second-line treatments, including chemotherapy such as docetaxel 
(Tan et al., 2015b). However, chemotherapy is a non-curable treatment for the majority of 
CRPC patients (Petrylak, 2007) and CRPC normally represents a lethal form of PCa.  
1.2.4 Prostate cancer  diagnosis and prognosis  
This section will describe the methods used for PCa diagnosis and assessing prognosis, 
including clinical symptoms, PSA testing, Gleason grades, clinical stages and biomarkers; 
along with the main diagnostic method used IHC staining. 
1.2.4.1 Clinical  symptoms 
PCa is usually an asymptomatic (silent) disease as a result of its slow-growing nature 
(Hammerich et al., 2008). However, some PCa patients show clinical symptoms such as 
frequent urination especially at night, bloody urine or semen, painful urination (Khan, 2011), 
urinary hesitancy (Hamilton and Sharp, 2004) and feeling of a not fully emptied bladder, as 
well as erectile dysfunction (Wlliamson, 2015). These symptoms, however, are not specific 
for PCa and may lead to misdiagnosis with other prostate disorders such as BPH (Khan, 
2011), which represents a common hyperplastic disease in males (Hamilton and Sharp, 
2004). Therefore, there are no specific clinical symptoms that can be used for PCa diagnosis. 
1.2.4.2 Early diagnosis, screening and prostate-specific antigen  
PSA is a protein produced by normal and malignant prostate epithelial cells (Adhyam and 
Gupta, 2012) and forms a part of semen contents. It is measured with a blood test and used 
clinically for PCa diagnosis and management (Epstein, 2010). The normal value for PSA in 
serum of men ranges from 0- 4 ng/ml (Dunn and Kazer, 2011) and these levels can increase 
in elderly men (Adhyam and Gupta, 2012)  as well as in some pathological disorders of the 
prostate, such as bacterial prostatitis, BPH and PCa (Kawakami et al., 2004; Lilja et al., 
2008; Dunn and Kazer, 2011). The increased PSA level seen in the serum of PCa patients is 
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thought to occur as a result of structural damage to the prostate epithelium, caused by events 
such as loss of the basal cell layer, ductal lumen architecture and epithelial cell polarity (Lilja 
et al., 2008; Qu et al., 2014).  
The fact that PSA can be increased by bacterial prostatitis and BPH means that it is not a 
specific marker for PCa (Lilja et al., 2008). There are also PCa patients who do not have 
increased PSA (Thompson et al., 2004). For these reasons the United States prevention 
services task force doesn’t recommend it to be used for routine screening, because of its low 
specificity in the PCa detection (Bensalah et al., 2007) and routine screening is not currently 
carried out in the UK (Tikkinen et al., 2018).  
PSA tests are used for helping diagnose PCa in individual patients. These patients, who often 
present with the clinical symptoms described above, normally also have a rectal examination 
of the prostate. This is an additional diagnostic method and represents a more robust 
indicator of PCa than an abnormal level of PSA (Hamilton and Sharp, 2004). However, the 
detection of early stage PCa cases with an examination is hard.  
In addition to being used for diagnosis, PSA testing is commonly used to monitor PCa 
patients after treatment (Kawakami et al., 2004). PSA levels drop following surgery or 
radiotherapy, patients then have ongoing PSA monitoring as a subsequent increase in levels 
can be a sign of potential relapse. 
Patients suspected to be at risk of PCa, based on clinical symptoms, a PSA test or a rectal 
examination normally then undergo a tissue biopsy, which is often taken with 18-gauge 
needles under transrectal ultrasound guidance (Heidenreich et al., 2008). The biopsies allow 
confident diagnosis of PCa by analysing tissue architecture and staining for biomarkers with 
IHC. These two approaches are discussed below in sections 1.2.4.3 and 1.2.4.5.   
1.2.4.3 The Gleason grading system 
The tissue taken from a biopsy is normally stained using haematoxylin and eosin (H&E) to 
show the general structure of the tissues, such as the glands and stroma of the prostate 
(Varma et al., 2002; Epstein, 2004) as well as to detect the pathological disorders such as  
BPH, PIN and PCa. (Dunn and Kazer, 2011). The tissue is also commonly stained with IHC 
to look at the expression of biomarkers (See section 1.2.4.6). 
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Having stained the tissue with H&E, the most common histopathological grading scheme 
which is used to measure the progression of PCa is the Gleason grading system (Kirby, 2012; 
Penney et al., 2013). This system was developed by Donald F. Gleason in the 1960s and 
1970s (Matoso and Epstein, 2016). It relies on an assessment of the histopathological 
architecture of the prostate and describes how much of the prostate tissue looks normal or 
abnormal. It is divided into five different Gleason grades (numbered from 1 to 5) (Gleason 
and Mellinger, 1974; Kirby, 2012) and the main histological changes are summarised below 
in (Figure 1.3 and Table 1.1). In a well-differentiated tumour, which represents the Gleason 
grade 1, the prostate glands are small, uniform in size, do not infiltrate, and the main 
characteristic features of tumour cells include small and uniform nuclei with pale cytoplasm 
(Delahunt et al., 2012). At the other end of the scale, the architectural pattern of grade 5 is 
poorly differentiated glands with the tumour cells infiltrating the stroma of the prostate as 
cords, sheets, and nests. Between these are intermediate grades (named 2, 3, 4) (Epstein, 
2010) (Figure 1.3).  
PCa is a heterogeneous disease and can have two or more histopathological patterns in the 
same PCa sample, so a Gleason score which represents a combination or summation of the 
first and the second most predominant grades of PCa, is used (Matoso and Epstein, 2016).  
The first predominant (primary) grade in this system is given to describe the cells that form 
the largest area in cancer tissues, whereas, the second most predominant (secondary) grade 
is given to describe the cells of the next large area PCa (Matoso and Epstein, 2016). This 
scoring system ranges from 2 to 10 (Penney et al., 2013) but clinically, most Gleason scores 
in PCa patients are 6 or more (Matoso and Epstein, 2016).  
A more recent study has suggested a significant modification in this system (Matoso and 
Epstein, 2016).  The new modified grading system consists of five grade groups named 1-5 
and the first two Gleason scores from the original system are not applied  (Matoso and 
Epstein, 2016). The lowest grade in this new system is called grade group 1 which represents 
a Gleason score (≤3 + 3) from the original one (Matoso and Epstein, 2016). Some of the 
specific morphological changes, which have been shown in Gleason score 6 from the 
original, are transferred into grade group 2 in the modified Gleason system to give a better 





Figure 1. 3 Five Gleason grades of PCa. (grade 1) tumours consist of small, uniform glands with minimal 
nuclear changes. (grade 2) tumours have medium sized acini, still separated by stromal tissue. (grade 3) 
tumours show marked variation in glandular size, organization, and infiltrating stroma. (grade 4) tumours show 
marked cytological atypia an extensive infiltration. (grade 5) tumours are characterized by sheets of 
undifferentiated cancer cells. Adapted from (Tabesh et al., 2007). 
The second modified grade group 2 represents a Gleason score 7 (3+4), whereas, the third 
one represents a Gleason score (4+3) from the original one (Matoso and Epstein, 2016). This 
is because patients with a Gleason score 7 (4+3) have a worse prognosis compared to those 
a Gleason score 7 (4+3) (Matoso and Epstein, 2016). The original Gleason score  8 (4+4) is 
called a grade group 4 and it has a worse prognosis value compared to the previous grading 
groups  (Matoso and Epstein, 2016). Finally, Gleason score 9 ( 4+5 and 5+4) and Gleason 
score 10 (5+5)  are both referred to as grade group 5 and represent the most histologically 
dedifferentiated tumour types in this system (Matoso and Epstein, 2016). The main 
histological changes in the new system are summarised in Table 1.1 
The original and modified Gleason scoring systems are widely used to provide prognostic 
information and to determine the aggressiveness of the disease.  For example, a high Gleason 
score is correlated with a higher risk of progression to a worse prognostic disease, elevated 
risk of metastasis, and reduced survival rate. In addition, the probability of tumour recurrence 
after radical prostatectomy is another phenomenon directly associated with a high percentage 
of grade 4 or 5 in the sample (Kirby, 2012).  However, this system cannot always distinguish 
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between aggressive and indolent tumour types (Penney et al., 2013). It also cannot predict 
those patients who will suffer from recurrence following primary therapy vs those that will 
remain in remission.  








≤3 + 3 = 6 
Only individual discrete well-formed glands 
Grade group 
2 
3 + 4 = 7 




4 + 3 = 7 
Predominantly poorly formed/fused/cribriform glands with lesser 




Only poorly formed/fused/cribriform glands - Predominantly well-formed 
glands and a lesser component lacking glands (b).  




Lack of gland formation (or with necrosis) with or without poorly 
formed/fused/cribriform glands (a) 
Note : (a) For cases with >95 % poorly formed/fused/cribriform glands or lack of glands on a core or at radical 
prostatectomy, the component of <5 % well-formed glands is not factored into the grade. (b) Poorly 
formed/fused/cribriform glands can be a minor component. 
 1.2.4.4 Pathological staging system  
There is another system used in PCa diagnosis and progression, in addition to a Gleason 
score, which is called the Tumor-Node-Metastasis system (TNM). This system was 
developed by the American joint committee on cancer / International Union against cancer 
(AJCC/ UICC) and depends on the size of the PCa and the amount of spreading that has 
occurred (Edge and Compton, 2010; Kirby, 2012).  
The TNM system has three parameters, the amount of primary tumour progression in the 
prostate and other surrounding organs (T), the lymph node status (N) and presence or 
absence of metastasis (M) (Khan, 2011). The first parameter (T) in this system is based on 
the size of the tumour and amount of tumour spreading in the pelvic region. It is classified 
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into four subgroups (T1-4) (Figure 1.4) (Kirby, 2012) and a high score (T3 and T4) may 
suggest a greater chance of recurrence. The second parameter describes a spreading of the 
tumour to the lymph node and can be classified into two categories, including N0, which 
means that regional lymph nodes are not affected, and  N1 which means the tumour has 
spread to the local lymph nodes (Epstein, 2010). Finally, the third parameter (M) refers to 
the metastatic status of diseases and can be divided into two categories M1 and M0, which 
means a tumour extends to other organs or not, respectively (Edge and Compton, 2010).   
The benefit of this system is that it may be used in evaluating the prognosis of patients with 
PCa and can be used to assess the likely development of their cancer (Hammerich et al., 
2008), and may have a role as a guide for patient treatment planning (Cheng et al., 2012). 
There are several modifications to the PCa staging system. This study used the 7th edition, 
from 2010 (Table 1.2) (Edge and Compton, 2010). 
 
Figure 1. 4 Four stages of primary tumour progression, from T1 (incidental) to T4 (invasion of neighbouring 
organs). In T1, tumour size is small and is still inside of the prostate gland. Tumour size in T2 is larger than a 
T1 and involves more than one lobe. In stage T3, tumour involves prostatic capsule extends to another 
neighbouring organ, including seminal vesicles. Addition to seminal vesicle invasion, tumour invades other 
adjacent organs in the final stage (T4) such as bladder neck, external sphincter, rectum and elevator muscles 
and or pelvic wall. Adapted from (Kirby, 2012). 
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Table 1. 2 The TNM classification of prostate cancer (2010).  Adapted from (Edge and Compton, 2010) 
 Primary tumours 
TX A primary tumour cannot be assessed 
T0 No evidence of a primary tumour 
T1 
Clinically inapparent tumour not palpable or visible by imaging 
T1a: Tumour incidental, histological finding in 5% or less of tissue resected. 
T1b: Tumour incidental, histological finding in more than 5% of tissue resected. 
T1c: Tumour identified by needle biopsy (for example, because of elevated PSA). 
T2 
Tumour confined within prostate*. 
T2a: Tumour involves one-half of one lobe or less. 
T2b: Tumour involves more than one-half of one lobe but not both lobes. 
T2c: Tumour involves both lobes 
T3 
Tumour extends through the prostate capsule ±. 
T3a: Extracapsular extension (unilateral or bilateral). 
T3b: Tumour invades seminal vesicle(s). 
T4 
A tumour is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. 
Regional lymph nodes 
NX Regional lymph nodes were not assessed. 
N0 No regional lymph node metastasis. 
N1 Regional lymph node metastasis. 
Distant metastasis++ 
MX distant metastasis cannot be assessed 
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M0 No distant metastasis  
M1 
Distant metastasis ǂ. 
M1a: Non regional lymph node(s). 
M1b: bone(s). 
M1c: other site(s). 
*: Tumour found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is 
classified as T1c. 
±: invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified as 
T3 but as T2. 
ǂ: when more than one site of metastasis is present, the most advanced category should be used  
1.2.4.5 Biomarkers for the diagnosis of prostate cancer 
A key step required for the accurate diagnosis of PCa is the demonstration of a loss of the 
basal cells (Goldstein et al., 2010a). However, H&E staining used for the Gleason grading 
(discussed above), may not be able to reliably detect basal cells in the prostate glands (Varma 
et al., 2002) and because of that, it is necessary to show the loss of staining for biomarkers 
that detect basal cells in prostate tissues. Biomarkers that are expressed in PCa, rather than 
being lost, are also used. 
Previous study has identified several biomarkers that can detect the presence or absence of 
basal cells in normal and malignant prostate tissues (Brustmann, 2015). 
High molecular weight cytokeratin (HMWCK) represents the first differential diagnostic 
biomarker for PCa vs. BPH and is also called 34βE12 (Paner et al., 2008). It is a specific 
marker that is expressed in the cytoplasm of basal cells. However, this marker is not used in 
isolation, but is used with other basal cell-associated markers (Paner et al., 2008). P63 is 
another diagnostic biomarker for basal cells and represents a p53 homologous protein that is 
expressed in the nuclei of basal cells (Signoretti et al., 2000). The specificity and sensitivity 
of p63 in detecting basal cells in benign tissues, especially for transurethral resection of the 
prostate (TURP) specimen, is higher than HMWCK (Shah et al., 2002). This might be 
because p63 is a nuclear protein, whereas HMWCK is a cytoplasmic protein, 
and nonspecific staining for some cytoplasmic proteins can be significantly higher than 
nuclear ones (Paner et al., 2008). However, a  few PCa cases have a positive expression of 
44 
 
p63 (Tan et al., 2015a) and the use of a basal cell-associated marker cocktail (a mixture of 
p63 and HMWCK ) gives better results than using either marker alone (Shah et al., 2004; 
Paner et al., 2008).  
A different approach to diagnose PCa is to use tumour cell biomarkers to show the presence 
of PCa tissue, rather than use basal cell biomarkers to show the loss of normal cells. Alpha 
methyl acyl coenzyme A racemase (AMACR) is a promising PCa cell biomarker (Luo et al., 
2002). It is an enzyme that plays an essential role in peroxisomal beta-oxidation of branched-
chain fatty acid molecules (Luo et al., 2002). Luo et. al. reported that AMACR is highly 
expressed in both PCa and HGPIN, whereas, the majority of NP tissues was a negative (Luo 
et al., 2002).  
Using a combination of  AMACR and basal cell markers such as p63 and HMWCK  can 
help the differentiation between malignant prostate cells and PIN. This combination is called 
a triple PIN cocktail (Paner et al., 2008). A PIN cocktail has many advantages, including a 
greatly sensitive detection of PCa and reducing microscopic workload for pathologists 
(Tolonen et al., 2011). However, Zhou et al showed that 18 % of PCa previously diagnosed 
by H&E and with a negative basal cell marker, had negative AMACR staining. These 
findings would suggest that accurate diagnosis of PCa requires a combination of biomarkers 
used together and no single marker can be used to distinguish PIN from PCa (Zhou et al., 
2004). 
1.2.4.6 IHC in prostate cancer diagnosis  
IHC is a method that is routinely used to stain for PCa biomarkers in clinical pathology 
laboratories. It is also extensively used in this thesis. It is a technique that can be used to 
stain components of cells and tissues in cancerous and non-cancerous conditions (Oliver and 
Jamur, 2010), including basal cells in prostate tissues (Brustmann, 2015). The IHC principle 
depends on antigen-antibody interactions (Oliver and Jamur, 2010). The antigens that are 
normally present in cells or tissues (Oliver and Jamur, 2010) can be detected by using 
antibodies which can bind to these antigens. The site of antibody binding can be identified 
by using a directly labelled antibody or using a secondary labelling method (Figure 1.5).  
Direct IHC is is a quick method that depends on a direct interaction between an enzyme- 
labelled primary antibody and antigens in tissues (Ramos-Vara, 2017) ( Figure 1.5 A). The 
sensitivity of this method is weak compared to the other IHC types due to lack of signal 
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amplification and can be only used for detecting highly expressed antigens (Boenisch, 2001). 
Another weakness is that a label for each primary antibody is necessary (Ramos-Vara, 2017).  
Indirect IHC has been developed to avoid these problems. During indirect IHC a tissue 
antigen interacts directly with an unconjugated primary antibody which is then bound by an 
enzyme- labelled secondary (Magaki et al., 2019) (Figure 1.5 B). This method is more 
sensitive than the direct one because of a number of labelled secondary antibodies can bind 
to different epitopes, allowing for amplification steps increase signal intensity (Boenisch, 
2001). However, the use of a secondary antibody that needs additional blocking steps and 
controls. There is another indirect IHC method called EnVision in which tissue antigens can 
bind directly to a primary antibody which is followed by a spine polymer molecule which 
contains an average of 10 molecules of secondary antibodies and 70 molecules of peroxidase 
(Boenisch, 2001) (Figure 1.5 C). This method is very sensitive compared to the previous 
methods due to increased amplification and it was the IHC method used in this study. 
The antigen-antibody interaction in all these IHC methods is normally visualised by using a 
chromogenic substrate which uses enzymatic labels to generate an insoluble, coloured 
deposit at the site of interaction. The most common system depends on using either 
diaminobenzidine/  horseradish peroxidase (DAB/HRP)  or alkaline phosphatase/ Fast Red 
(AP/FR)which can give colour for a positive interaction (Figure 1.5).  
Figure 1. 5 Principle of immunohistochemistry. (A) Direct IHC: An enzyme- labelled primary antibody reacts 
directly with tissue antigen. (B) Indirect two-step IHC: An antigen binds directly with a primary antibody, 
which binds with an enzyme- labelled secondary antibody. (C) Indirect EnVision IHC: An antigen binds 
directly with a primary antibody which is followed by a spine polymer molecule which contains an average of 
10 molecules of secondary antibodies and 70 molecules of peroxidase). The reaction is visualised by using a 
DAB substrate- chromogen solution. Adapted from (Boenisch, 2001). 
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1.2.5 Molecular changes in prostate cancer 
In this section, the most common genetic alterations and signalling aberrations that appear 
during the transition from NP to PIA, PIN, carcinoma and finally to CRPC (Figure 1.7) will 
be discussed.  
1.2.5.1 Glutathione S - transferase   
 Glutathione S - transferase  (GSTP1) is a carcinogen-detoxifying enzyme that is normally 
expressed in basal cells of the prostate gland and is also found to be highly expressed in 
luminal and basal cells of  PIA (De Marzo et al., 1999). In contrast, 90% of PCa tissues show 
non-significant staining for GSTP1 (De Marzo et al., 1999) (Figure 1.7).   
Functionally, GSTP1 plays a role in protecting cells from carcinogenic factors as a result of 
its role as a detoxifying enzyme which is able to catalyse the conjugation of glutathione with 
harmful, electrophilic molecules that are endogenously or exogenously produced (Porkka 
and Visakorpi, 2004). The presence of GSTP1 in NP tissues may play an important role in 
protecting cells from oxidative or electrophilic DNA damage (De Marzo et al., 1999). A 
previous study reported that GSTP1 CpG island hypermethylation is frequently detected in 
the majority of PCa cases (>90%) as well as in DNA of 69% of PIN and only 6% of PIA 
(Nakayama et al., 2003), resulting in downregulation of GSTP1 protein level. In contrast, 
hypermethylation has not been detected in DNA of all non-malignant prostate cases, such as 
normal and BPH (Nakayama et al., 2003). The data suggest that methylation of GSTP1 may 
control its expression and GSTP1 hypermethylation represents an early step in PCa 
progression.  
1.2.5.2 NKX3.1 
Homeobox NKX3.1 is a transcription factor and is thought to be a prostatic tumour 
suppressor. It appears to represent one of the earliest markers identified for the prostate 
epithelium during embryogenesis (Bhatia-Gaur et al., 1999). Its expression depends on 
androgen signalling (Tan et al., 2012). It is expressed in benign tissues of the prostate 
(Bhatia-Gaur et al., 1999; Bowen et al., 2000; Gurel et al., 2010), but its expression levels 
in PCa cases are decreased and this reduction may represent one of the most critical events 
for PCa initiation (Abate-Shen et al., 2008). Bowen et al have also found that NKX3.1 was 
expressed in 95% of NP, but its expression has been lost in 20% of HGPIN, 6%  of early 
47 
 
stage PCa (T1) and 22% advanced stage of PCa (T3/4) (Bowen et al., 2000). In addition, it 
was also found to be lost in 35 % of CRPC and 78% of advanced stage PCa (Bowen et al., 
2000), suggesting that the loss of NKX3.1 expression is an early event in PCa formation and 
is strongly associated with CRPC and advanced PCa stages (Figure 1.7).   
The gene encoding NKX3.1 is localised at chromosome 8p21 (Gurel et al., 2010), which is 
commonly deleted in PIN lesions (Irshad et al., 2013). A study on mice has also found that 
a single NKX3.1 allele deletion is capable of generating PIN lesions (Bhatia-Gaur et al., 
1999). Another study showed that the NKX3.1 locus is also frequently deleted in PCa 
(Voeller et al., 1997), but no mutations were found in the remaining allele of NKX3.1 
(Voeller et al., 1997), suggesting that haploinsufficiency (i.e. inactivation of only one allele) 
could be the tumour suppressor mechanism for NKX3.1 in PCa (Porkka and Visakorpi, 
2004).   
Functional studies using mouse models have shown that NKX3.1 has a critical regulatory 
role in the proliferation of prostate epithelial cells and differentiation of bulbourethral glands. 
For example, it has been found that NKX3.1 is required for prostatic epithelial differentiation 
in mice and plays a regulatory action in NP development, whereas its mutation in mice may 
lead to having a defect in ductal morphogenesis and production of secretory proteins (Bhatia-
Gaur et al., 1999). Another study has suggested that NKX3.1 deficiency in mutant mice may 
lead to an increase in the oxidative damage to DNA and protein as well as decreased 
expression of oxidative enzymes, suggesting that NKX3.1 protein may have a role in 
regulating the response to oxidative stress which can play a significant role in tumour 
initiation (Ouyang et al., 2005). This study also reported that NKX3.1 plays a role in 
maintaining the integrity of prostate epithelial layers through regulation of the expression of 
genes which protect DNA from oxidative damage (Ouyang et al., 2005). Taken together, 
this evidence suggests that NKX3.1 is downregulated at an early stage of prostate 
tumorigenesis, that more complete loss of NKX3.1 might be associated with PCa relapse 
and metastatic diseases, and that reduction of its function contributes to PCa formation and 
progression. 
1.2.5.3 Myc  
The Myc proto-oncogene is a transcription factor located on chromosome 8q24 (Yoshida, 
2018) which is frequently altered in human carcinogenesis, including PCa (Koh et al., 2010; 
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Yoshida, 2018). Previous studies have reported that Myc genes are overexpressed in PIN 
lesions (Gurel et al., 2008; Iwata et al., 2010), as well as in prostate tissues with malignancies 
compared to NP or BPH (Buttyan et al., 1987; Fleming et al., 1986; Gurel et al., 2008) 
(Figure 1.7).    
Functionally, it has been found that Myc could play a role in regulating cell proliferation, 
metabolism, protein synthesis function and SC renewal (Gurel et al., 2008) as well as cancer 
initiation (Koh et al., 2010). Several mechanisms have been suggested for Myc to induce 
pre-neoplastic or neoplastic lesions such as PCa. First, a study has found that increased Myc 
plays a vital role in transforming normal mice prostate cells to PIN lesions. Knockdown of 
Myc by siRNA increased  NKX3.1 protein and mRNA levels in human PCa cell lines (Iwata 
et al., 2010), suggesting Myc induces PIN through repression of  NKX3.1. In addition, 
Ellwood-Yen et al found that overexpression of Myc in transgenic mice induces a rapid 
formation of PIN and then invasive adenocarcinoma (Ellwood-Yen et al., 2003). There is a 
significant association between PI3K-pathway alterations and Myc multicopy gain in PCa 
metastases and there is a cooperation between Myc and AKT to accelerate the progression 
of PIN to invasion in a murine PCa model (Clegg et al., 2011). In addition, it has been found 
that Myc can bind with its coactivator Max ( Myc associated factor X), to form a Myc- Max 
complex which acts to activates transcription of a large cohort of target genes and promote 
cell growth and proliferation (Weinberg, 2007). Taken together, Myc could play an essential 
role in PCa formation and progression through its collaboration with other driver pathways.  
1.2.5.4 Phosphatase and tensin homolog  
Phosphatase and tensin homolog (PTEN) is a tumour suppressor gene which is commonly 
mutated or deleted in different types of human cancer, including PCa (Jamaspishvili et al., 
2018; Salmena et al., 2008). This gene is located on chromosome 10q23, a region that is 
commonly altered in PCa (DeMarzo et al., 2003). PTEN expression was observed in 92% 
of PIN (24/26), and 86% of PCa ( 50/51) using IHC (Fenic et al., 2004). This reduction was 
also positively associated with a risk of biochemical recurrence (Chaux et al., 2012) (Figure 
1.7). This evidence suggests that loss of PTEN in the prostate gland drives tumorigenesis 
and is associated with the emergence of recurrence (Shen and Abate-Shen, 2007; Irshad and 
Abate-Shen, 2013). A previous study has reported decreased PTEN expression in a Sall-like 
4 (Sall4) B transgenic mice compared to wild-type control (Lu et al., 2009), suggesting 
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PTEN level can be regulated by Sall4 and increased Sall4 level represses PTEN followed by 
activation of  PI3K/AKT pathway and enhanced PCa formation. 
Functionally, PTEN is a lipid phosphatase that converts phosphatidylinositol 3, 4, 5 
triphosphates (PIP3) to Phosphatidylinositol 4,5 phosphate (PIP2), thereby directly 
inactivating the PI3K/AKT pathway that plays a role in promoting cell survival and 
inhibiting apoptosis (Bertrand et al., 2014; Leevers et al., 1999; Porkka and Visakorpi, 
2004). Increased proliferation and decreased sensitivity to apoptosis have also been found in 
mutant PTEN mice (Stambolic et al., 1998).  
In addition to its role in promoting proliferation and apoptosis, PTEN  in the nucleus plays 
an important role in chromosome stability, DNA repair, cell cycle arrest and cellular stability 
(Planchon et al., 2008). In addition, other studies have reported inactivation of PTEN 
cooperated with other mutated genes to promote progression of HGPIN to invasive 
adenocarcinoma, including loss of NKX3.1 (Kim et al., 2002), increased c-Myc (Kaur and 
Cole, 2013; Kim et al., 2009) and Transmembrane protease, serine 2- ETS- regulated gene 
(TMPRSS-ERG) fusion (Carver et al., 2009). Taken together, PTEN loss is one of the most 
important mechanisms for PCa formation and progression through its cooperation with other 
genes.  
1.2.5.5  TMPRSS2-ERG gene fusion  
Another key alteration that has been identified in PCa is increased expression of E26 
transformation-specific (ETS) transcription factor family target genes, including the ETS 
proteins ERGs (Smith et al., 2012). ERG genes are located on the same chromosome, 
21q22.2, as TMPRSS2 (Demichelis and Rubin, 2007) and TMPRSS2-ERG gene fusion 
represents one of the most common genetic alteration identified in PIN (19%) and more than 
a half of PCa patients (Perner et al., 2007; Squire, 2009; Hagglof et al., 2014; Yang et al., 
2016). It is also associated significantly with biochemical recurrence (Nam et al., 2007). 
This fusion, however, has not been detected in NP or PIA tissues (Demichelis and Rubin, 
2007). The evidence suggests that TMPRSS2-ERG fusion is an indicator of PCa formation, 
aggressiveness and relapse (Figure 1.7).    
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There are two possible mechanisms that have been proposed to explain the fusion between 
TMPRSS2 and ERG genes. First, a large genetic area of chromosome 21, which is located 
between these two genes is deleted (Hossain and Bostwick, 2013). Second, a translocation 
of these two genes may occur (Hossain and Bostwick, 2013) (Figure 1.6). 
Figure 1. 6 Mechanisms of TMPRSS2–ERG gene fusions at chromosome 21. (A)  Deletion: A large part of the 
chromosome between these genes (ERG and TMPRSS2) is deleted. (B) Translocation: TMPRSS2 gene is 
translocated to be fused with ERG. Adapted from (Hossain and Bostwick, 2013). 
Previous studies have reported mechanisms that may explain the possible role of this fusion 
in PCa. TMPRSS2 is regulated by AR activity which means that after fusion TMPRSS2 
promoter elements drive ERG expression in PCa (Tomlins et al., 2005). Another study has 
found that AR signalling might be disrupted by ERG through its role in inhibiting AR 
expression and interacting to and inhibiting AR downstream targets at gene-specific loci, 
and increased EGR, which may occur as a result of this fusion in PCa may lead to increased 
PCa cell invasion and growth in the existence or absence of androgens, independent of AR 
(Yu et al., 2010). This fusion might disrupt also the capability of cells to differentiate into 
NP cells as well as play an essential role in PCa development (Yu et al., 2010). This evidence 
suggests that TMPRSS2–ERG fusion may play a role in CRPC development through its 
inhibitory role to AR signalling. Finally, transcriptional downstream checkpoint genes can 
be induced by a combination of ERG and PTEN loss, promoting cell proliferation, DNA 
repair and survival (Squire, 2009). ERG and PTEN may, therefore, deliver selective benefit 
to permit PIN lesions to progress to PCa and ultimately CRPC (Squire, 2009).  
1.2.5.6  Phosphoprotein 53  
Phosphoprotein 53 (p53) is a tumour suppressor gene that resides on the short arm of 
chromosome 17 (17q13.1) (Chappell et al., 2012; Heidenberg et al., 1996). It has been 
observed that p53 is frequently mutated in cancer (Hainaut et al., 1998), and its mutation is 
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found to be associated with poor outcomes following hormone therapy in advanced prostate 
(Chappell et al., 2012)  and risk of recurrence (Hamid et al., 2018) (Figure 1.7).    
Several studies have examined the expression of p53 in normal and malignant prostate, 
including recurrence and non- recurrence. Some of these have described an increase in P53 
expression. For example, a previous study found increased p53 in PCa compared to BPH 
(Kuczyk et al., 1998). Other studies looking at p53 protein levels found that increased p53 
is also significantly associated with PCa Gleason grade and clinical stage (Aprikian et al., 
1994) as well as recurrence (Aprikian et al., 1994; Brewster et al., 1999; Porkka and 
Visakorpi, 2004). In addition, there is a negative association between increased p53 
expression and long term survival following radical prostatectomy (Kuczyk et al., 1998).  
In addition to increased expression of p53, it is well established that it can be reduced in 
PCa. This reduction occurs frequently as a result of the loss of one allele, coupled with 
inactivation of the second allele by an intragenic mutation (Hruban et al., 1999) and p53 is 
mutated in about  35 % of advanced PCa cases (Ecke et al., 2010). In addition, a previous 
study on PTEN null transgenic model found that inactivation of p53 may lead to progress of 
a PIN lesion to invasive carcinoma (Chen et al., 2005). Navone, et al have demonstrated that 
p53 gene mutation is observed in late-stage PCa and metastasis and is also significantly 
associated with loss cell differentiation and the transition from androgen-dependent to 
androgen-independent growth (Navone et al., 1993). In contrast, this alteration was not 
observed previously in BPH or PIN (Navone et al., 1993).  
Exposure of cells to a variety of cell physiologic stress such as UV radiation, ionizing 
radiation, hypoxia, oncogene signalling and transcription blockage can result in increased 
p53 levels that can induce a number of processes such as cell cycle arrest, mobilisation of 
DNA repair proteins, block of angiogenesis and triggering of apoptosis  (Weinberg, 2007). 
p53 plays an essential role in regulating cell proliferation and apoptosis and loss of its 
function may have a strong effect on cell cycle regulation (Hruban et al., 1999). Decreased 
p53 transcriptional activity is negatively associated with PCa colony growth (Chappell et al., 
2012), suggesting it could play a vital role in PCa progression. The evidence shows that p53 
is a critical element in regulating a cells ability to control the cell cycle and could play an 
essential role in PIN transition to carcinoma, as well as for tumour progression to metastasis 
or relapse.   
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1.2.5.7 Androgen receptor  
It is known that androgens and their receptor have an essential role in the development of 
the prostate (Shen and Abate-Shen, 2010). Androgens are also necessary for PCa growth and 
survival as a result of its key role as the main regulator of cell proliferation and apoptosis 
ratio in prostate cells (Tan et al., 2015b) (Figure 1.7).    
The main circulating androgen in the human body is testosterone, which is synthesised by 
the testis, but there is also another source of androgen which comes from the adrenal gland 
(Tan et al., 2015b; Zhu and Garcia, 2013). Inside prostate cells, the majority of testosterone 
becomes converted by 5α-reductase enzyme to the more active hormone dihydrotestosterone 
(DHT), which has a strong affinity for the AR (Feldman and Feldman, 2001). AR is a nuclear 
receptor that is normally bound to proteins, including heat shock protein (HSP) in a 
conformation that stops DNA binding and receptor phosphorylation (Feldman and Feldman, 
2001). However, DHT binding to the AR can induce changes in AR that play a role in 
promoting the dissociation of  HSP from AR (Tan et al., 2015b). After these changes, the 
complex translocates to the nucleus and then binds to androgen response elements (AREs) 
in the promoter regions of target genes, including PSA and TMPRSS2 (Tan et al., 2015b). 
In addition, various coactivators (such as ARA70), corepressors, TATA box binding protein 
(TBP) and transcription factor IIF (TFIIF) can be recruited by AR at promoter regions 
(Feldman and Feldman, 2001; Tan et al., 2015b). This activated complex can lead to 
induction of biological responses including growth, survival and the production of PSA 
(Feldman and Feldman, 2001; Tan et al., 2015b). 
Mutant AR has been observed rarely in untreated PCa (Culig et al., 2001). In contrast, other 
studies found that frequent mutation for AR was observed in CRPC (Gaddipati et al., 1994). 
In addition, a quarter of PCa patients who are treated with anti-androgen drugs have mutant 
AR (Wallen et al., 1999) that is thought to help promote the transition to CRPC. There are a 
number of mechanisms that explain how these mutations in AR, and other changes, can 
cause CRPC which are discussed below. 
The first possible mechanism for triggering the transition to CRPC is called the 
hypersensitive pathway. The AR gains sensitivity, which may be achieved through genetic 
alteration or amplification of AR or increased 5α reductase enzyme levels, so it responds to 
the very low concentration of androgens that may be found after castration or medical 
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androgen blockage (Dutt and Gao, 2009). The second mechanism is called the promiscuous 
pathway, in which mutant AR can interact with alternative ligands other than DHT, including 
oestrogen, progesterone and glucocorticoids and /or AR antagonists, resulting in PCa growth 
due to reactivation of the AR  (Buchanan et al., 2001). The outlaw pathway (alternatively 
known a ligand-independent pathway) is the third possible mechanism driving CRPC, in 
which a number of growth factors, including fibroblast growth factor, Insulin-like growth 
factor1, vascular endothelial growth factor; transforming growth factor-β, epidermal growth 
factor, and keratinocyte growth factor or tyrosine kinase such as HER-2/neu  can bind and 
activate AR when androgen is absent or present at sub-physiological concentration (Culig et 
al., 1995; Zhu and Kyprianou, 2008; Dutt and Gao, 2009), resulting PCa growth. The fourth 
mechanism which is called the AR-independent bypass pathway supports proliferation and 
survival of CRPC by a couple of proteins, including anti-apoptotic protein  Bcl-2 (B cell 
lymphoma 2) and GR (Glucocorticoid receptor) (Hoang et al., 2016). A previous study, 
using the LNCap prostate tumour model found decreased expression level of Bcl-2 delayed 
the growth of CRPC (Gleave et al., 1999), suggesting increased Bcl-2 levels in cancer cells 
may play a role in the transition to CRPC. In addition, it has been demonstrated that GR is 
upregulated in  CRPC and could play an important role as a substitute for AR in binding 
with androgen response elements and is necessary for cancer cells survival under certain 
circumstances (Arora et al., 2013). A very recent study reported that immunostaining of a 
forkhead transcription factor (FoxA 2), whose expression is normally driven by AR-
responsive promoters, is detected and localised in CRPC cells that show negative staining 
for AR, using  IHC and IF, respectively (Connelly et al., 2018). This study reported that 
regardless of the presence of androgens, FoxA 2 cells were fast growing compared to control 
cells. This suggested FoxA 2 may play a role in activating  CRPC (Connelly et al., 2018). 
Overall, AR plays an important role in the development of both normal and malignant 
prostate through its regulatory role in cellular events, including proliferation, invasion, and 
differentiation. In addition, changes in AR signalling play a pivotal role in driving the 
progression from PCa to CRPC through many different mechanisms, including AR 
amplification, AR mutation, ligand-independent AR activation, bypass AR signalling 
mechanisms as well as activation of AR by FoxA 2.  
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1.2.5.8 AR coactivators and regulators  
Previous studies have found many AR coactivators linked to PCa. However, in this section, 
a couple of AR co-activators which are frequently altered in PCa, including CRPC are 
described (Figure 1.7). For example, a recent in vivo study done by Blattner et al. has 
reported that a mutant Speckle-Type POZ Protein (SPOP) can drive PCa through its a role 
in activating PI3K/mTOR pathway as well as upregulation of AR network of AR-associated 
transcription factors and co-activators (Blattner et al., 2017). SPOP mutations have been 
reported in about 10% of PCa (Barbieri et al., 2012; Blattner et al., 2014; Blattner et al., 
2017), which are ETS- fusion negative (Barbieri et al., 2012). This co-activator can play a 
role in targeting AR for degradation,  however, this role is lost in the event of a mutation 
(An et al., 2014). In addition to SPOP, another AR coactivator called steroid receptor 
coactivator-3 (SRC-3) has been found to be increased in tumours and has an essential role 
in androgen-dependent and androgen independent cell proliferation in PCa cell lines in vitro 
and xenografts in vivo as a result of its coordinate role with AR in promoting cell cycle gene 
expression (Zou et al., 2006). SRC-2 is a third AR coactivator that is found to be amplified 
frequently in PCa, and amplification of the chromosomal region of 8q, the region of  SRC-
2  gene, is shown in 20% in primary and 63% in metastatic prostate tumours (Taylor et al., 
2010a).  
1.2.5.9 Summary 
PIA is an atrophic lesion in prostate architecture and is thought to be a precursor source of 
PCa formation through PIN, which represents the intermediate state between cancerous and 
noncancerous prostate. A couple of histological and genetic changes have been shown to 
occur during the transition from P1A to PIN, including a partial loss of both basal cells and 
basement membrane, a reduction of GSTP1, NKX3.1and PTEN expression as well as 
increased cell proliferation and inhibition of the apoptotic rate (Figure 1.7).  
A number of significant changes have been identified during the transformation from PIN 
to carcinoma, including histological and molecular changes. The main histological changes 
are the total loss of basal cells and the basement membrane. Genetic alterations been reported 
in this transition include the loss of genes, such as NKX3.1, PTEN and p53, a high rate of 
TMPRSS2-ETS gene fusion, increased amplification and expression of Myc. These changes 
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play a vital role in regulating of PI3K-AKT, AR and other pathways important for PCa 
progression.  
Finally, the transition to CRPC is driven by genetic alterations that alter AR signalling 
through its amplification or mutation or via AR-independent mechanisms, such as ligand-
independent or bypass AR signalling mechanisms (Figure 1.7).  
Figure 1. 7 Key oncogenic events in the carcinogenesis of the prostate. The key molecular changes such as 
gene mutations, losses and rearrangements, are shown next to a visual representation of each stage of prostate 
carcinogenesis. This model has the main stages of prostate carcinogenesis, including PIA (green cells), PIN, 




1.3 Stem cells  
The work described above has begun to describe the molecular basis of PCa initiation and 
progression, but there are many avenues that remain to be investigated. One exciting area of 
current research is the role that SCs play in PCa initiation and progression. 
The term SCs has come to be used to refer to immature cells normally found in embryos and 
in small populations in both normal and malignant tissues, including prostate (Majumder, 
2009; Tu and Lin, 2012). Previous work has found the main properties for these cells, include 
self-renewal and pluripotency (Isaacs, 2008; Tu and Lin, 2012). Self-renewal means that 
SCs have the ability to divide and create new SCs with the same development and replicative 
potential, while pluripotency means these cells are able to differentiate into specialised cell 
types (Lobo et al., 2007). 
SCs are often found in a cellular location called a niche, which probably offers a 
microenvironment necessary for the maintenance of the SC properties described above via 
a combination of intracellular and intercellular signalling (Lang et al., 2009a; Prajapati et 
al., 2013). Specific factors provided by the niche can include growth factors, cytokines, 
chemokines, and adhesive molecules which can regulate the balance between proliferation, 
differentiation, and quiescence in SC populations (Whetton and Graham, 1999; Spradling et 
al., 2001). 
SCs can be divided into two broad types, embryonic (ESC) and adult SCs (Tuch, 2006).  
ESCs, which are derived from the inner cell mass (ICM) of a growing mouse or human 
blastocyst (Majumder, 2009; Findikli, 2012) have the potential to become all cell types of 
the body because they are pluripotent (Tuch, 2006). During embryogenesis, tissue-restricted 
SCs, called adult SCs are created (Isaacs, 2008). Adult SCs, alternatively known as somatic 
or non-embryonic SCs, are found in many organs including the skin, intestine, bone marrow 
and the prostate. Adult SCs have a limited potential to differentiate and are normally 
restricted to forming the cell types of the tissue of their origin (Tuch, 2006). Interestingly, 
adult SCs have also been described in tumour tissue, including PCa tissue. The next section 
will focus on prostate SCs (PSCs) and prostate CSCs (PCSCs) 
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1.3.1 Prostate stem cells  
The study of PSCs is at a fairly early stage and two main models for their location and 
properties have been described (Figure 1.8).  
The first model, which represents the best-accepted description of PSCs suggests that PSCs 
are located in the prostate basal layer and can generate intermediate cells called transient 
amplifying (TA) (immature cells) which subsequently differentiate into the mature and fully 
differentiated luminal cells (Isaacs and Coffey, 1989; Takao and Tsujimura, 2008). This 
model has been confirmed by previous studies which found that there is a cell population 
located on the basal layer of the prostate gland of both human and mouse that possessed self-
renewal capabilities and can generate both basal and luminal cells (Goldstein et al., 2010b; 
Taylor et al., 2010b). For example, previous work done by Goldstein et al. has separated the 
luminal cells (Trop2+/CD49f−) from the basal (Trop2+/CD49f+) cells in digests of benign 
human prostate tissues and these cells (luminal and basal) were then injected subcutaneously 
into immunodeficient mice (Goldstein et al., 2010b). The basal cell population give rise to 
prostate-like structures containing both basal and luminal cells, whereas the luminal 
population did not grow (Goldstein et al., 2010b). In addition, it has been found that basal 
cells have the ability for survival following androgen ablation (Wang et al., 2013). Another 
study on BPH suggested that basal cells might be able to give rise to luminal cells because 
actively dividing cells were predominantly localized to the basal compartment (Dermer, 
1978). In addition, several SC characteristics have been found in the basal cells, including 
their relatively undifferentiated state, high proliferative capacity, protection from apoptosis, 
and a long life span (Bonkhoff et al., 1994; De Marzo et al., 1998; Foster et al., 2002; Wang 
et al., 2013). The TA cells are able to express both luminal and basal cell markers such as 
CK5, CK8, CK14, CK18, AR, and PSA (Bonkhoff et al., 1994; Bonkhoff and Remberger, 
1996; Xue et al., 1998).  
The second model suggests that both prostate gland luminal and basal layers have a small 
population of PSCs which subsequently differentiate into mature basal and luminal cells, 
respectively  (Takao and Tsujimura, 2008) (Figure1.8). The evidence for this model is that 
the majority of cells present in PCa are luminal-like cells and unlike normal luminal cells, 
these cells are not fully differentiated cells (Jaworska et al., 2015), suggesting that  PCa most 
often arises from luminal, undifferentiated cells and these cells could be SCs or CSCs. It has 
been reported that long-term BrdU label (3H-thymidine or 5-bromo-2-deoxyuridine) 
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retention experiments label cells of both basal and luminal mouse prostate, even after many 
cycles of androgen ablation (Tsujimura et al., 2002), suggesting that PSCs may be not 
restricted to the basal compartment. 
Figure 1. 8 The possible models of PSCs. The first model suggests that PCSc occur in the basal cell layer and 
generate TA cells to be able to produce fully differentiated luminal cells (left side). In contrast, the second 
model is thought that both the basal and luminal layers have a small population of stem cells which are able to 
differentiate into mature basal or luminal cells, respectively (right side). Adapted from (Takao and Tsujimura, 
2008).  
1.3.2 Prostate cancer stem cells  
PCa consists of a heterogeneous population of cells with varying degrees of tumorigenic 
potential, and only a subset of cancer cells, which are called PCSCs can initiate and 
propagate a tumour. CSCs, including PCSCs, have been defined according to the American 
Association for Cancer Research (AACR) as “a cell within a tumour that possesses the 
capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise 
a tumour”(Clarke et al., 2006). They possess most of the properties of adult SCs, they are 
long-lived, slow cycling, self-renewing cells that can differentiate (Jaworska et al., 2015).  
The existence of PCSCs has been examined and as with many cancers is still open for 
discussion. However, several approaches have been used to identify and isolate CSCs such 
as side populations (SP) (Patrawala et al., 2005), sphere formation (Zhang et al., 2012) and 
surface markers (Hurt et al., 2008). First, a previous study done by Patrawala et al. has 
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analysed SP in several PCa cell lines, including Du145, LAPC-4, and LAPC-9 and found 
that LAPC-9 xenograft tumours contained detectable SP cells whereas the other cell lines 
did not (Patrawala et al., 2005). This work found that LAPC-9 cells have a higher 
tumorigenicity than those cell lines without SP, with as few as 100 SP cells giving rise to 
tumors (25% incidence), whereas 300,000 non-SP cells were wanted to create a tumour 
(Patrawala et al., 2005), suggesting the SP cells had SCs properties (Patrawala et al., 2005). 
Second, a sphere formation assay has been used for the enrichment of populations of CSCs 
from PCa cell lines (Zhang et al., 2012) or PCa tissues (Castellon et al., 2012).  Zhang and 
colleagues reported less than 5% of PCa cells, which are cultured in non-adherent suspension 
condition with serum-free medium, are capable of  forming prostatosphere in culture 
suspensions and these small population cells have a high self-renewal and tumour initiation 
properties, using LNCaP, 22RV1, DU145 and PC-3 cell lines (Zhang et al., 2012). A small 
population of cells obtained from prostatospheres showed SC marker expression such as 
CD133+/CD44+/ABCG2+ (Castellon et al., 2012).  
The discovery of CSCs has changed the way PCa tumour development is understood. 
(Jaworska et al., 2015). Prior to their discovery, it was assumed that PCa grew via a 
stochastic model in which each cell in a heterogeneous cancer is able to randomly give rise 
to new carcinoma cells (Jaworska et al., 2015). Since the discovery of CSCs, a new model 
has developed, the hierarchical model, in which a small population of CSCs, which do not 
exceed  5% of the total tumour cells, produce all the  new tumour cells and are responsible 
for driving disease progression (Jaworska et al., 2015; Leao et al., 2017) (Figure 1.9).  
It has also been suggested that the presence of residual CSCs may lead to recurrence and 
disease progression to the eventual CRPC state (Chen et al., 2013). The CSC hypothesis has 
generated excitement as it clarifies our understanding of the heterogeneity of cancer and 
suggests new avenues that could be explored in the diagnosis and treatment of cancer (Guzel 
et al., 2014).  
60 
 
Figure 1.9 The possible models of prostate formation. In the stochastic model (left side), each cell in a 
heterogeneous tumour has the ability to originate new tumours when it develops the capability to self-renew. 
In contrast, in the hierarchical model (right side), a small number of cells called CSCs are able to originate new 
tumours.  
1.3.3 The origins of prostate cancer and prostate cancer stem 
cells  
The discovery of PCSCs has implications for two crucial and related questions. First, what 
is the cellular origin of PCa? Second, what is the cellular origin of PCSCs? 
The cellular origins of PCa remain unclear, however, it has been suggested that PCa might 
arise from a number of different cell types (Jaworska et al., 2015). The luminal cells may 
represent the origin of tumorigenicity in prostate because the majority of prostate epithelial 
cells in the tumour mass are luminal cells but, unlike the normal luminal cells, these cells 
are not fully differentiated cells (Jaworska et al., 2015). It has been proposed that PCa could 
result from a more restricted cell type, such as the transit-amplifying cells (intermediate 
cells), which have the ability of self-renewal (van Leenders and Schalken, 2001). The basal 
cells have also been suggested by several studies because they have the ability to rapidly 
differentiate into luminal cells following oncogenic transformation (Shen and Abate-Shen, 
2010). It has also been found the majority of metastatic tissues contain basal cells (Liu et al., 
2002), suggesting basal cells might be responsible for PCa metastasis. This model is 
supported by evidence from immunodeficient mice, showing that PCa can arise from basal 
cells in NP and this might be because basal cells are expressing oncogenes such as AR, AKT 
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and ERG (Goldstein et al., 2010a). Finally, a study has suggested that the PSCs that are 
responsible for PCa formation, through their abnormal proliferation and differentiation 
(Takao and Tsujimura, 2008).  
A related question is where do PCSCs arise from and several lines of evidence have 
identified three suggestions for the source of PCSCs. First, a study done by Mani et al 
suggests that CSCs are generated from cancer cells that undergo epithelial-mesenchymal 
transition (EMT), which represents a key development program that may contribute to 
invasion and metastasis (Mani et al., 2008). Second, another hypothesis suggests that cancer 
cells may undergo a process similar to that which produces pluripotent stem cells (iPS) 
(Corominas-Faja et al., 2013). Finally, the most common hypothesis, which is supported by 
several studies, suggests that CSCs originate from normal adult prostate SCs that have been 
exposed to oncogenic genomic alterations (Jaworska et al., 2015). These mutant SCs are 
transformed into CSCs during the process of carcinogenesis (Jaworska et al., 2015). This is 
supported by the fact that CSCs have most of the stem-like properties found in adult SCs, 
including long-lived, slow cycling, (Jaworska et al., 2015), self-renewal and differentiation 
(Lobo et al., 2007), and that they express SC markers (Collins et al., 2005). This final model 
suggests that adult SCs are the cell type responsible for the production of CSCs and that 
these CSCs then give rise to all the cells of a heterogeneous tumour. 
1.3.4 Stem cell biomarkers 
SCs are thought to be involved in cancer initiation, progression, metastasis, recurrence and 
drug resistance and as a result of that, finding candidate biomarkers that can identify these 
cells has become an urgent necessity. It has been found that different ESC factors can be 
expressed in both adult SCs and CSCs such as Nanog, OCT4, SOX2 (Ben-Porath et al., 
2008). A previous study has found that Nanog, OCT4, Sox2 are highly expressed in tumour 
tissues and cancer cell lines, including colon, bladder and prostate tumours using PCR and 
IHC (Amini et al., 2014). However, these proteins were found to have broad expression so 
do not appear to exclusively mark prostate SCs. Several other candidate biomarkers have 
been used to try and identify and distinguish PSCs and/or PCSCs from other cell types 
(Jaworska et al., 2015), including cell surface markers: CD24, CD44 (Hyaluronic acid 
receptor) (Hurt et al., 2008), CD49f, Trop 2 (Goldstein et al., 2008) CD133 ( Prominin-1 or 
AC133) (Collins et al., 2005), CD166 (Jiao et al., 2012), and α2β1 (Collins et al., 2005), 
stem cell antigen-1 (Ssca-1) (Reiter et al., 1998) and aldehyde dehydrogenase (ALDH) 
62 
 
(Kahlert et al., 2012). These candidate biomarkers are summarised in (Figure 1.10). In 
addition, increased PCa proliferation rate and invasion was found in CD44+, α2β1high, 
CD133+ cells compared to CD133-negative cells (Collins et al., 2005). Increased α2β1 
expression was observed in PSCs compared to other prostate cell types in the basal 
compartment (Collins et al., 2005) and there is increased activated leukocyte cell adhesion 
molecule (ALCAM/CD166) expression in castrated mice compared to intact mice (Jiao et 
al., 2012). ALCAM/CD166 is also expressed in a subset of adult human prostate cells as 
well as in PCa tissues (Ofori-Acquah and King, 2008). Jiao et al. found that increased CD166 
expression was localised to foci in NP tissues, which overlaps with a subset of  TROP2 and 
CD49f  positive cells (Jiao et al., 2012) (Figure 1.10).  
Despite the studies described above, currently no single biomarker has so been shown to be 
able to identify and sort PSCs and/or PCSCs, so combinations of makers are normally used 
(Burger et al., 2005) and none of these biomarkers is used clinically in PCa diagnosis and 
progression. In addition, some of the most common biomarkers for CSCs, such as Sca-1, are 
mouse genes and don’t have a direct homologue in humans (Xin et al., 2005). The mouse 
biomarker panel is used often for basic research, but it might not necessarily translate easily 
into a human panel. Therefore, there is still a pressing need to find biomarkers that can 
identify PSCs and/or PCSCs. 
Figure 1. 10 Cellular identities of SCs in the prostate.  SCs markers that are expressed in NP (left side) or PCa 
(right side).  The majority of markers are expressed in both normal and malignant prostate tissues. However, 
some markers are specific to NP, including p63 and CK5 or to PCa such as AR. Adapted from (Prajapati et al., 
2013).   
1.3.5 Summary  
SCs are cells capable of self-renewal and differentiation into specific lineages, with adult 
SCs capable of differentiating into a restricted range of cell types. SCs are also thought to be 
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the origin of CSCs, which in turn are believed to be the origin of new tumour cells and able 
to drive disease progression, including relapse and resistance to therapy.  
Although several potential biomarkers for SCs and/ CSCs have been studied, there is still a 
pressing need for discovering new biomarkers that can distinguish between normal PSCs 
and PCSCs. If these cells are key to driving disease progression, then these potential SC 
biomarkers might be used to distinguish between different grades and clinical stages, such 
as biochemical relapse, of PCa.    
1.4 Aims of the study  
The primary goal of this project is to identify proteins that are differentially expressed 
between normal and malignant prostate tissues and/or between different grades, stages and 
relapsed vs non-relapsed prostate tumours. This is because differentially expressed proteins 
may represent new clinically useful biomarkers for PCa. Identifying proteins with 
differential expression is also a key step in improving our understanding of the molecular 
basis of prostate cancer formation and progression and may potentially help in the 
development of future therapies. 
The aims for this thesis are; 
 Select potential biomarkers to study by identifying proteins with links to SCs, the 
regulation of cellular differentiation and/or a suggested role in cancer initiation, 
progression or relapse using literature searching.    
 Use IHC to determine the expression patterns of the potential biomarkers in normal 
and malignant prostate tissues from two independent cohorts of patients. 
 Confirm the specificity of the staining with independent antibodies or alternative 
staining approaches. 
 Test if the expression of these candidate biomarkers correlates with clinical features 
of PCa, including primary Gleason grade and clinical stage in both cohorts. 
 Decide if any of the proteins could be potential clinical biomarkers or warrant future 



















MATERIALS AND METHODS  
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2. Materials and Methods  
2.1 Materials 
All general laboratory chemical reagents were purchased from Sigma-Aldrich, Fisher 
Scientific UK Ltd, DAKO and Advanced Cell Diagnostic (ACD) unless otherwise specified. 
Room temperature was the standard temperature that was used to store all buffers and 
solutions unless otherwise stated.  
2.1.1 Patient samples 
In this retrospective study, two different sources of prostate samples were used, including a 
Bath and a tissue microarray (TMA) cohorts. This work was covered by the National Health 
Service (NHS) ethical and research approval (REC reference: 13/WS/0153; IRAS project 
ID: 112241). The composition of the two cohorts of tissue is summarised below and the 
clinical characteristics are described in more detail in Chapter 3 for the Bath cohort and 
Chapter 4 for the TMA cohort. 
2.1.1.1 Bath cohort samples 
A total of 34 paraffin-embedded blocks of PCa, including those from patients who had, and 
had not, undergone recurrence, and 5 NP tissue samples, were obtained from the 
histopathological laboratories of the Royal United Hospital (RUH), Bath/ UK. The samples 
were collected between 1997 and 2018. This study also used normal testis, placenta, liver 
and kidney tissue samples obtained from the RUH as positive controls. This cohort is 
described in details in Chapter 3.  
2.1.1.2 Tissue microarray cohort samples    
TMA slides were obtained from US Biomax (PR1921). Each tissue array slide had 96 cases, 
80 of them were a prostate carcinoma, whereas, the rest were normal or normal tissues that 
were adjacent to the PCa, termed adjacent normal (8 cases for each). Each case was 
represented with two core tissue biopsies to form a total of 192 cores. This cohort is 





2.1.2 Primary antibodies  
Details of the primary antibodies used in this study, including the supplier, catalogue 
number, species and dilution are shown in Table 2.1.  
Table 2. 1 The antibodies used in this study.  
Primary 
antibody 
Supplier Type of antibody Catalogue no. Antigen retrieval Applied 
dilution 
ABCG2 Abcam Mouse monoclonal Ab3380 Citrate buffer (pH6) 1:100 
ALDH1A1 Abcam Rabbit monoclonal Ab52492 Citrate buffer (pH6) 1:100 




Rabbit polyclonal SAB1100315 Citrate buffer (pH6) 1:500 
Sall4 
Novus bio Mouse monoclonal H00057167-
M03 
Tris/ EDTA (pH9) 1:100 
Sall4 Abcam Rabbit polyclonal Ab29112 Tris/ EDTA (pH9) 1:100 
Sall4 Abcam Rabbit monoclonal Ab181087 Tris/ EDTA (pH9) 1:50 
Sox7 Abcam Rabbit polyclonal Ab80331 Citrate buffer (pH6) 1:200 






Citrate buffer (pH6) 1:200 





Rabbit polyclonal 95625 Citrate buffer (pH6) 1:100 
2.1.3 mRNA Probes 
Details of the mRNA probes used in this study, including supplier and catalogue number are 
shown in Table 2.2.  
Table 2. 2 The mRNA probe used in this study. 
Probes Catalogue no. Supplier 
Hs- Sall4 5050701 ACD 
Hs-Zscan4 421091 ACD 
Positive control (Hs-PPIB)  313901 ACD 





2.1.4 Additional materials  
Other materials that were used in this study are as described in Table 2.3  
Table 2.3 Additional materials used in this study. 
Materials Supplier Catalogue no. 
3-Aminopropyl triethoxysilane Sigma Aldrich A3648-100 mL 
Acetone  Sigma- ALDRICH 24201-2.5 L.R 
Ammonia solution  BDH laboratory supplies 452394U 
Antibody diluent  DAKO S0809 
Bovine serum albumin (BSA)  Sigma A4503-50g 
Compound microscope with digital image 
accessories  
Nikon E800 
Coverslips (22x50)  Scientific laboratory supplier NO 1 
Dako Envision™ +system-HRP (DAB)  Dako K4010 
Dako liquid DAB+ substrate chromogen system  DAKO K3468 
DPX mountain for histology  Sigma 06522-100mL 
Eosin  Raymond Alamb S1153 
Ethanol Absolute  VWR chemicals 20821 330 
Glass slides  VWR 631 - 1551 
Haematoxylin  Vector H-3401 
HCL  Sigma Aldrich 25,812-8 
Histoclear  National diagnostic H5-200 
Hybez II oven ACD 240200ACD-2 
Immuneedge pen  Vector Laboratories H-4000 
MB22 Premier Microtome blade  Thermo Scientific 12647896 
Microtome Leica RU 2155 
Normal Goat Serum (NGS)  Sigma G9023-10ml 
Phosphate buffered saline ( PBS) tablets  OXOID BR00140 
Prostate cancer tissue microarray slide  US Biomax PR1921 
RNAscope®  control slides- human HeLa cell 
pellet 
ACD 310045 
RNAscope®  H2o2 & protease pulse reagents  ACD 322330 
RNAscope®  target retrieval reagents  ACD 322000 
RNAscope®  wash buffer reagents ACD 310091 
RNAscope® 2.5. HD detection reagent –Brown ACD 322310 
Sodium hydroxide  Sigma Aldrich S8045-500g 
Tri-sodium citrate  Sigma- ALDRICH S1804-500ML 
Tris (hydroxymethyle) methylamine  Fisher scientific T/p630/90 
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Triton X100  Sigma T8787-100ML 
Tween 20  Sigma P9416-100ML 
2.1.5 Preparation of reagents  
In this study, numerous reagents were used as a part of both IHC and RNAscope®                                                                                                                                                                                  
methods. The methods used to prepare these reagents are described in Table 2.4. 
Table 2. 4 The reagents used in this study with the methods of preparation.  
Reagents Preparation method 
1 x and 10x PBS 
solution pH 7.4  
To prepare 1x PBS, 1x PBS Dulbecco’s tablet was dissolved in 100 mL of distilled 
water (ddH20), whereas, 10 tablets of Dulbecco’s PBS (Thermo Scientific) were 
dissolved in 100 mL of ddH20 to prepare10x PBS. These solutions were then 
sterilised by the autoclave. 
2% (3 Aminopropyl) 
triethoxysilane 
(APTS)  
10 ml of silane was dissolved in 500 mL acetone. This solution is unstable and was 
stored for 8 hours only.    
50% Haematoxylin 
staining solution  
100 mL Gill’s Haematoxylin was added to 100 mL ddH20 in a dish. The solution 
was then filtered by a filter paper.  
70% Ethanol  30 mL ddH20 was added to 70 ml of absolute ethanol.  
90% Ethanol  10 mL ddH20 was added to 90 ml of absolute ethanol.  
95% Ethanol 5 mL ddH20 was added to 95 ml of absolute ethanol.  
Ammonia water  1.43 mL of ammonium hydroxide was added to 250 mL ddH20, then mixed well, 
and then stored at room temperature.  
Blocking buffer  10% NGS and 0.5% BSA were added to PBS and then mixed well, using a roller 
mixer to dissolve completely. Blocking buffer was then stored in the fridge at 4°C 
before using.    
Bluing solution  1% NH3 was added to 70% ethanol.  
Citrate buffer (pH 6)  To prepare a citrate pH6 buffer, 2.941 gm of tri-sodium citrate was dissolved in 1L 
ddH20. The pH of the solution was then adjusted to pH6 by adding few drops of 
HCl.  500μL of Tween-20 then was added to the solution and mixed well to dissolve 
completely and then stored at room temperature.   
Differentiate solution  I% HCl was added to 70% ethanol.  
Permeabilisation 
solution  
0.5% of Triton was added to 1x PBS and then mixed well.  
Phosphate buffer 
saline with 0.05% 
tween 20 (PBST)  
10 PBS Dulbecco’s tablets were dissolved in 1L ddH2O and mixed well. 500 µl of 
Tween 20 then was added to the solution. Finally, this solution was dissolved 






20 mL 10X target retrieval reagent was added to 180 mL ddH20, then mixed well. 
This solution was then stored at room temperature before using.  
RNAscope® 1X 
Wash Buffer   
To prepare 3L of 1X wash buffer, a bottle (60 mL) of RNAscope® washing buffer 
(50X) was warmed up to 40 °C for 10-20 minutes, then added into 2.94 L ddH20 
and mixed well. This solution was then stored at room temperature.    
Tris/EDTA buffer 
(pH9)  
To prepare a Tris / EDTA pH6 buffer, 1.21 g of Tris hydroxymethyl methylamine 
and 0.37223 g of ethylenediaminetetraacetic acid disodium salt dihydrate were 
added into a litre of ddH2O and stirred to dissolve, then the pH of the solution was 
adjusted to pH9 by adding few drops of sodium hydroxide. 500μL of Tween-20 
was also added to the solution and mixed well to dissolve completely. This solution 
was stored at room temperature before using.  
2.2 Methods 
There are different methods used in this study, including silane coating of slides, H&E, IHC, 
and RNAscopes® are described in detail below.  
2.2.1 Coating Slides with (3-aminopropyl) triethoxysilane  
APTS coating is a method used to enhance the adherence of tissue sections on the 
microscope slides to avoid lifting of the tissue from slide especially during the antigen 
retrieval step in both IHC and RNAscope®. The APTS coating procedure had three different 
steps: First, the slides were cleaned by immersion in absolute acetone for 2 minutes, then 
left to dry in a fume hood. Second, the dried slides were then dipped for two minutes into a 
2% solution of APTS that has been prepared previously (see Table 4.2). Finally, the slides 
were washed twice with absolute acetone for 2 minutes each, then left to dry completely.  
2.2.2 Sectioning  
Formalin-fixed paraffin-embedded (FFPE) prostate tissue blocks were chilled in a fridge at 
4°C before using and then 5µm thick sections were cut by using a microtome blade mounted 
in a microtome from Leica RU Company.  The cut sections were then put into a water bath 
at 37°C to allow them to flatten and then picked up onto microscope slides.  Slides were then 
dried and baked overnight at 37°C on a hot plate. Next day, the baked slides were then stored 
at room temperature to be used later.  
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2.2.3 Haematoxylin and Eosin staining protocol  
H&E staining is a common method used to highlight the morphological architecture of 
tissues under the light microscope and can be used to detect the abnormal changes in the 
tissue architecture that may be observed in many diseases, including cancer. H&E was 
carried out as follows:  
Two pre-treatment steps were carried out prior using H&E staining. First, a dewaxing step 
was performed by soaking the slides into two changes of Histoclear for 2 minutes each to 
remove the paraffin from tissues. Second, rehydration of tissue sections was then carried out 
using two washes in each of a graded series of ethanol solutions (100%, 95%, 90%, 70% and 
50% respectively) for a minute each time and then rinsed with ddH20 for 2 minutes. 
After the pre-treatment steps described above, the tissue sections were then ready to stain, 
using haematoxylin which is used to stain the nucleus of cells. In this step, drops of 
haematoxylin were added onto tissue sections for 2 minutes and then rinsed under tap water 
for three minutes. To differentiate the haematoxylin stain, the slides were then soaked three 
times in 70% ethanol with 1% HCl.  The slides were also immersed for a minute in an 
alkaline solution that was prepared by adding 1% ammonium hydroxide to 70% ethanol to 
restore the blueing stain of haematoxylin. Drops of 0.5% eosin in ddH20 then were added to 
slides for three minutes to stain the rest of tissue architectures. At this point, the staining 
steps were finished.  
After that, the slides were washed with two changes of different ethanol concentration 95% 
and 100% for 15 seconds and 1 minute, respectively.  Slides were then washed twice with 
Histoclear for 2 minutes each. Three drops of DPX mounting media were applied onto the 
slides and then these slides were covered with coverslips and left to dry. Next day, the slides 
were ready to examine under a light microscope (Nikon Eclipse E800) equipped with a 
Nikon digital camera (DS-U1 CCD).   
2.2.4 Immunohistochemistry assay 
IHC is a method used to identify specific tissue components, including proteins and is 
routinely used in cancer research. This assay can be completed within two days, and the 
procedure was carried out as follow:  
Prior to IHC, pre-treatment steps, including deparaffinization and rehydration, were 
necessary to remove the paraffin from tissues and to rehydrate tissue samples respectively. 
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A dewax step was performed by soaking the slides into two changes of Histoclear for 7 
minutes each. Rehydration of tissue sections was then carried out using two washes with a 
graded series of ethanol solutions (100%, 95% & 70% respectively) for a minute each time. 
These slides were then immersed in ddH20 for 2 minutes, followed by two times PBS 
washing for 5 minutes each.  Tissues were then permeablised by adding 0.5% Triton X-100 
in PBS for 30 minutes. After that, the sections were washed three times with PBS for 5 
minutes each.  
To carry out the antigen retrieval, tissue sections were pre-treated in a water bath at 90 ⁰C 
for 30 minutes with heat-induced epitope retrieval buffer, citrate or Tris/EDTA, at pH 6 or 
9 respectively. These sections were left to cool inside the retrieval buffer jar at room 
temperature for 20 minutes and then washed twice with PBS for 5 minutes each. The slides 
were then allowed to dry. The tissue sections were circled using an ImmunEdge hydrophobic 
barrier pen to be sure that reagents covered the whole tissue sections on the slides. To remove 
the endogenous peroxidase activity, drops of peroxidase block were added onto the tissue 
sections, then the slides were placed in a humid chamber and incubated at room temperature 
for 10 minutes, followed by rinsing gently three times with PBS buffer for 5 minutes each. 
Drops of blocking buffer that had been prepared previously (Table 2.4) were then added onto 
tissue sections and incubated in the humid chamber at room temperature for 30 minutes, 
followed by two times PBS washing for a minute each.  At this point, the pre-treatment steps 
were finished.  
After finishing the pre-treatment steps described above, the tissue sections were ready to 
stain with a DAKO EnVision IHC staining kit. IHC had three main steps; primary antibodies 
were diluted to the appropriate dilution (see Table 2.1) using Dako antibody diluent, and 
100-150 µM of diluted primary antibodies were applied to each section and incubated in a 
humid chamber at 4⁰C overnight. The next day, slides were washed three times with PBS 
buffer for 10 minutes each. Drops of goat anti-mouse or goat anti-rabbit labelled polymer –
HRP conjugated secondary antibodies were added onto the slides and then incubated at room 
temperature with gentle rocking for 30 minutes. Slides then were washed three times with 
PBS buffer for 5 minutes each. To prepare the chromogenic reagent solution that was used 
to visualize the antigen-antibody reaction, a drop of DAB chromogen was added into 1mL 
of the substrate buffer and then mixed well. After preparation, drops of the prepared solution 
were added onto the tissue sections and then incubated in the humid chamber for 5 minutes 
at room temperature. To terminate the chromogenic reaction, slides then were washed three 
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times with ddH2O for 5 minutes each. Drops of the Vector haematoxylin solution, as a 
counterstain, were applied and then incubated at room temperature for a minute to stain the 
nucleus of cells. Slides then were rinsed thoroughly under running tap water for 3 minutes. 
The rest of the IHC steps, including differentiation and bluing of the haematoxylin, 
rehydration, Histoclear, mounting and slides examination was required, were carried out as 
described above. 5 random images were taken using Nikon Digital camera (DS-U1 CCD) 
attached to a Nikon Eclipse E800 microscope. 
2.2.5 RNAscope®  
RNAscope® is a new method used to identify specific tissue components, including mRNA. 
This study used a RNAscope® 2.5 HD assay-brown kit which uses ACD patented signal 
amplification and background suppression technology. This method uses a novel double Z 
probe that binds to the target RNA and then bound to a cascade of a preamplifier, amplifier, 
and label probe (Wang et al., 2012).  The version of RNAScope® that was used in a uniplex 
assay that detects individual mRNA molecules as brown dots in the cells and this assay can 
be completed within two days, and the procedure was carried out as follows:  
The RNAscope® assay was carried out following manufacturer instructions and as described 
below: During the first day, slides were baked in a dry oven for an hour at 60°C, and during 
this time all reagents were prepared. After baking, slides were soaked two times in fresh 
Histoclear for 5 minutes each. Tissues were then washed with two absolute ethanol changes 
for a minute each. Slides were allowed to dry at room temperature for 5 minutes. To block 
any endogenous peroxidase in the tissue, 5-8 drops of H202, a first pre-treatment, was applied 
on the tissue sections for 10 minutes at room temperature. Slides were then washed by 
moving the rack up and down 3-5 times and repeated washing with fresh ddH20. Target 
retrieval, a second pre-treatment, was then carried out. The slides were placed in a heat-
resistant jar with the 1x target retrieval solution and then heated at 98-100°C on a hot plate 
for 15 minutes. The slides rack was immediately transferred from a hot plate to a jar 
containing ddH20 and then washed several times by moving the rack up and down, followed 
by a fresh 100% ethanol washing and then allowed to air dry. Finally, tissue sections were 
circled using an ImmunEdge hydrophobic barrier pen and allowed to dry overnight. 
Next day, a Hybez II oven from ACD was set to 40°C to be used to warm the probes for 10 
minutes to ensure any salts in probe diluent that may have precipitated were dissolved then 
allowed to cool at a room temperature before use and RNAscope® amplifier reagents were 
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also moved from the fridge and then kept at room temperature before use. After the 
preparation steps mentioned above, drops of protease pulse, a third pre-treatment, was added 
onto the tissue sections and then incubated in the humid sealed tray containing HybEZ™ 
Slide rack at 40°C for 30 minutes to remove RNA-binding proteins. This makes it easier for 
the probes to bind to the mRNA transcripts and also permeablises the tissue/cells to enable 
good penetration and reduce trapping of any of the reagents used in the assay. After that the 
slide rack was moved from the oven, then slides were washed many times by moving the 
rack up and down in ddH20.  
Drops of mRNA probes were added onto tissue sections and then incubated in a humid tray 
inside the oven at 40 °C for 2 hours. Slides were washed twice with 1x wash buffer for two 
minutes each.  Six amplifiers (1-6 AMP) steps then were applied to the tissue sections, and 
then incubated in a sealed tray containing HybEZ™ Slide rack at 40 °C for 30, 15, 30, 15, 
30, 15 minutes respectively. Each amplifier step was followed by two times washing with 
buffer solution for 3 minutes each.   
To detect the signal, DAB was prepared by adding an equal amount of brown A & B and 
mixed well.  120µl of the DAB solution was dropped onto the tissue sections and incubated 
in a sealed tray containing HybEZ™ on a slide rack for 10 minutes at RT. Slides were 
washed by moving the rack up and down inside a ddH2O jar. To stain the nucleus of cells, 
50 % haematoxylin solution were applied onto tissue sections and incubated at room 
temperature for 2 minutes. Slides then were rinsed thoroughly with running tap water for 2 
minutes, followed by 0.02% ammonia water washing for a few seconds.  After that, slides 
were washed twice with different alcohol concentrations, 70% and 100%, for a minute each 
time. These slides were then washed twice with Histoclear for 5 minutes per change. Three 
drops of DPX mounting media were applied onto the slides and then these slides were 
covered with coverslips and left to dry. Finally, the slides were examined under a light 
microscope and 5 random images were taken using Nikon Digital camera slight (DS-U1 
CCD) that attaches with a Nikon Eclipse E800 microscope. 
2.3 IHC Quantification  
Prior to quantification, 5 random fields were taken at 20x magnification for each potential 
biomarker. The images were then scored using one or more of a number of different scoring 
systems to quantify the expression of the candidate proteins in the epithelial, and in some 
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cases, the stromal cells of the prostate tissues. The most appropriate scoring system for IHC 
was selected for each biomarker based on the previous studies. 
2.3.1 H-Score method 
The H- Score method is one of the most common scoring systems that are normally used to 
score the protein signal in IHC. The score given depends on the proportion of positive cells 
and staining intensity. To carry out the scoring, nuclei of epithelial cells were counted based 
on four DAB staining intensity categories (0: No nuclear staining 1: Weak nuclear staining, 
2:  Moderate nuclear staining and 3: Strong nuclear staining). After scoring, the H-score was 
calculated as the following formula:  
H score= 3 x % of strongly nuclear staining + 2 x % of moderately nuclear staining + 
% of weakly nuclear staining.  
The range of H-score can vary between 0 and 300 (Aye Thike, 2001). This system was used 
to score the nuclear expression of β- catenin, Sall4 and Zscan4 only. 
2.3.2 Other IHC scoring methods  
Six other types of semi-quantitative scoring were used to score the expression patterns of 
candidate proteins in the tissue sections. The scoring system (proportion and intensity 1) was 
used unless otherwise specified.  The alternative scoring system was used when the previous 
studies were used in the specific scoring system. The full details were shown in Table 2.5. 
Table 2. 5 The scoring systems used for each antibody. 








RS1 and  the 
cytoplasmic 
β-catenin 
and  Zscan4 
 The Percentage of positive cells was scored as: (0: 0; 
1: 1-25%; 2: 26-50%; 3:51-75%; and 4: 76-100%). 
 The intensity was graded as (0: negative, 1: weak, 2: 
moderate; and 3: strong). 
 The final score represents the sum of the proportion 
and intensity scores, which ranged from 0 to 7. 







 The proportion of stained cells (nuclear and 
cytoplasmic) was scored as follows: (0: negative, 1: 1-
10%, 2: 11-50 % and 3: 51-100 %.). 
Adapted from  




 The intensity of nuclear and cytoplasmic staining was 
scored as follows: (0: negative, 1: weak, 2: moderate and 
3: strong). 
 The final score represents the sum of proportion and 
intensity scores of cytoplasmic and nuclear staining, 






The localization of NDRG1 was scored as Pattern 1: 
predominantly in the cell membrane. Pattern2: 




(Caruso et al., 
2004; Hosoya 










 The proportion of stained cells (nuclear and 
cytoplasmic) was scored as follows: (0: negative, 1: 1-
33%, 2: 34-65 % and 3: 66-100 %.). 
 The intensity of nuclear and cytoplasmic staining was 
scored as follows: (0: negative, 1: weak, 2: moderate and 
3: strong). 
 The final score represents the sum of proportion and 
intensity scores of cytoplasmic and nuclear staining, 










 The proportion of stromal stained cells was scored as 
follows: 











The intensity of nuclear and cytoplasmic staining was 






2.4 RNAscope® quantification 
Two different scoring systems were used to quantify the Sall4 and Zscan4 mRNA levels in 
the prostate tissue samples. For both systems, 5 random fields were taken at 20x 
magnification and then the number of brown dots in the prostate cells was scored.  Scoring 
of RNAScope used manufacturer recommended approaches to score mRNA sall4, using five 
different criteria depending on the number of brown dots on prostate epithelial cells. The 
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modified scoring system was used to score Zscan4 mRNA because the number of positive 
cells and brown dots were few. The different scoring systems and which candidates they 
were used for are described in detail below in Table 2.6.  
Table 2. 6 The scoring systems used for each mRNA probe. 
mRNA probe Scoring system References 
mRNA Sall4  The positive cells were scored as : 
0: no staining 
1: 1-3 dots/cell 
2: 4-9: dots/ cell 
3: 10-15 dots/cell and <10% dots are in clusters 
4: >15 dots/cell and >10% dots are in clusters   




mRNA Zscan4  The positive cells were scored as : 
0: no staining 
1: 1-10% positive cells 
2: 11-30% positive cells 
3: 31-100% positive cells    
Modified according to advice by 
email from Dr Bradley Spencer-
Dene, Technical Support/ FAS 
Europe, ACD. 21/7/2017. 
 
 
2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.00 for Windows, 
GraphPad Software, La Jolla California USA, www.graphpad.com, including mean, 
standard error and standard deviation values as well as the other statistical analysis such as 
a frequency distribution test and histogram. Statistical analysis was carried out either using 
unpaired T-test, Chi-Squared and /or one-way ANOVA with Tukey’s multiple comparisons 


























ASSESSMENT OF CANDIDATE 
PROTEINS IN PROSTATE TISSUES 
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3. Identification and assessment of candidate 
proteins in prostate tissues from the Bath cohort  
3.1 introduction 
The primary goal of identifying new biomarkers for PCa is to improve diagnostic and 
prognostic accuracy. Identification of potential new biomarkers that can help to detect PCa 
in early stage and/or distinguish between an aggressive tumour requiring radical intervention 
and those that have a good prognosis is the long term goal of this study. The first step in this 
process is to identify the proteins whose expression would be examined. The criteria used to 
select proteins was a link to SCs and the regulation of cellular differentiation and/or a 
suggested role in cancer initiation, progression or relapse. The second step was to determine 
the association between the staining patterns of the potential biomarkers and PCa clinical 
parameters, including primary Gleason grade, clinical stage and relapse, using tissues from 
the Bath cohort of patients. This introduction will review the different approaches that can 
be used for biomarkers identification and set out the aims for this chapter. 
3.1.1 Approaches to identify potential biomarkers for further 
analysis 
Identification of biomarkers was the first step in this study and there are a number of 
approaches that can be used. Each approach has advantages and disadvantages which are 
reviewed below.    
3.3.1.1 Transcriptomics 
 Transcriptomic is an approach that investigates the transcriptome changes in tumour 
samples to identify new biomarkers in a large cohort, using cDNA microarray or high 
throughput RNA sequencing (Long et al., 2014; Sowalsky et al., 2015; Trost et al., 2015; 
Lowe et al., 2017). 
Previous studies used transcriptomic methods to identify potential new biomarkers for 
cancer, including PCa.  For example, Long et al reported 24 biomarkers identified to predict 
PCa relapse, using a global transcriptomic analysis of formalin-fixed PCa samples (Long et 
al., 2014). Another study reported that a series of un-spliced mRNA was found to predict 
metastatic CRPC, using whole transcriptomic sequencing (RNA seq) (Sowalsky et al., 
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2015). This approach had some success in identifying genes that were expressed differently 
in different grades of cancer, including breast and prostate tumours (Ben-Porath et al., 2008; 
Long et al., 2014). Despite the advantages of transcriptomic technique in identifying new 
biomarkers, this technique, however, is a complex method and also needs high throughput 
approaches and costly materials to assess patient samples.  
3.3.1.2 Proteomics  
Proteomics represents an approach used to study the structure and function of proteins in the 
biological samples (Chandramouli and Qian, 2009). This approach is used to identify 
potential biomarkers by measuring the protein levels in tissue (Adeola et al., 2017; Shields 
and Wu, 2018), serum (Larkin et al., 2016; Adeola et al., 2017; Chandramouli and Qian, 
2009) and urine (Beasley-Green, 2016) samples, using different techniques, including IHC 
and Enzyme-linked immunosorbent (ELISA).  
There are several publications that have used this method for biomarker identification. For 
example, a previous study used proteomics successfully to identify sex biomarkers which 
could be used for PCa diagnosis from high-quality serum samples (Larkin et al., 2016). 
Another proteomic study identified thousands of proteins from BPH and PCa samples, 
including macrophage inhibitory cytokine-1, which was found to be increased in PCa 
compared to PBH cells (Hood et al., 2005). In contrast, Kim et al failed to identify a single 
biomarker that could be used to distinguish between PCa subgroups from prostate fluid and 
urine samples, using proteomics analysis (Kim et al., 2016). 
It can be seen from the previous studies that this approach has several advantages; including 
providing a wealth of the potential biomarkers that could be used for further follow-up 
studies. However, like transcriptomics, it is a complex method that needs expensive 
equipment and costly materials to assess patient samples.  
3.3.1.2 Literature searching  
Literature searching represents perhaps the simplest approach for identifying new potential 
biomarkers for further analysis. In this approach, a series of keyword searches are carried 
out and returned the literature reviewed to identify proteins warranting analysis.  
This approach has many advantages and disadvantages. One advantage is that there is no 
requirement for knowledge of text mining or specific methods or equipment (Mahood et al., 
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2014). In addition, this approach can be exhaustive and time-consuming, but it does not 
require any laboratory work compared to the previous methods that require extensive 
laboratory work and need time to accomplish (Grewal et al., 2016). However, the 
investigator needs to use their knowledge or experience to select and then assess the literature 
used to make the decision and it relies on existing information, no new experimental results 
are generated to inform the decision.  
This study used the literature searching approach as a simple and affordable method for 
identifying new potential biomarkers that link to SCs and the regulation of cellular 
differentiation and/or a suggested role in cancer initiation, progression or relapse. IHC 
protocols for the markers can then be established and the expression of these potential 
biomarkers assessed in normal and malignant prostate tissues. In this chapter, this will be 
carried out using samples collected at the RUH in Bath city/UK. 
3.1.2 Aims  
 Identify proteins that have links to SCs, the regulation of cellular differentiation 
and/or a suggested role in cancer initiation, progression or relapse using literature 
searching.    
 Establish IHC staining protocols for the proteins of interest.  
 Determine the expression patterns of the potential biomarkers in normal and 
malignant prostate tissues from the Bath cohort patients. 
 Test if the expression of these candidate biomarkers correlates with clinical features 
of PCa, including primary Gleason grade, clinical stage and relapse. 
3.2 Results 
3.2.1 Identification of potential biomarkers using literature 
searching 
Identification of potential biomarkers that warranted further analysis was the first step in this 
study. A literature searching approach was carried out using PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed. Data accessed: June 2015) and the criteria for 
selection included a link between the protein of interest and SCs and the regulation of cellular 
differentiation and/or a suggested role in cancer initiation, progression or relapse. The 
research began with searches using terms including “prostate cancer recurrence or relapse”, 
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“cancer recurrence or relapse”, “prostate cancer stem cells”, “stem cell biomarker”, “stem 
cell biomarkers or cancer stem cell biomarkers”. The searches returned publications 
containing hundreds of potential biomarkers and eight were selected for evaluation in this 
thesis. Five potential biomarkers are examined in this Chapter and the rationale for selection, 
against the criteria described above, is described below and summarised in (Table 3.1). The 
three other potential biomarkers are described in Chapters 5, 6 and 7. 
A hypothesis describing the predicted changes in expression was proposed for each potential 
biomarker. This hypothesis was based on the expression changes that were supported by the 
literature. In some cases, conflicting evidence meant a number of hypotheses could have 
been proposed, with these, the hypothesis used were selected based on the expression 
changes that seemed best supported by the existing literature, for example, changes 
supported by more than one study or by studies with larger sample sizes. These hypotheses 
were then tested by examining the expression of these proteins in the Bath cohort (This 
Chapter) and a larger TMA cohort (Chapter 4). 
3.2.1.1 β-Catenin 
-catenin is a multifunctional protein that plays an important role in cadherin-mediated 
adhesion and the Wnt signalling pathway (Willert and Nusse, 1998; Bismar et al., 2004). 
Wnt/ -catenin pathway dysregulation is found to be associated with many human diseases, 
including a range of cancers (Kim et al., 2013). Of particular importance for this study, 
altered expression levels and localisation (nuclear vs. cytoplasmic) of -catenin has been 
suggested to play a role in PCa progression and relapse (described below and summarised 
in Table 3.1). 
There are several publications that have studied β-catenin level and localisation in PCa 
compared to NP and/or BPH, however, in many cases, these studies had different findings. 
In terms of nuclear β-catenin staining, a recent study found that nuclear β-catenin localisation 
was increased significantly in PCa compared to BPH (Ipekci et al., 2015).  In contrast, other 
studies showed decreased nuclear staining or localisation of β-catenin significantly in PCa 
compared to BPH (Horvath et al., 2005; Whitaker et al., 2008). Importantly, the Whitaker 
et al study had a larger sample size (225) than the recent Ipekci et al paper. Another study 
with a small number of PCa samples (17) showed no significant staining for β-catenin in 
PCa tissue samples (Bismar et al., 2004).  
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In addition to nuclear β-catenin staining, membranous and cytoplasmic β-catenin staining 
has been examined in cancerous and noncancerous prostate tissues.  For example, one study 
found that membranous β-catenin staining was reduced significantly in localized PCa 
compared to BPH, whereas, cytoplasmic β-catenin staining did not show a significant 
difference between benign and malignant prostate groups (Horvath et al., 2005). Other 
studies found membranous β-catenin expression was reduced in PCa compared to BPH 
(Bismar et al., 2004; Jaggi et al., 2005).  
The published evidence is also complicated and often at least partially contradictory for PCa 
Gleason grades. Nuclear β-catenin expression was found to be reduced significantly in PCa 
tissues with a high Gleason grade compared to those with a low grade (Whitaker et al., 2008). 
In addition, other studies found membranous staining of β-catenin in PCa significantly 
reduced with increasing Gleason grades (Kallakury et al., 2001a; Jaggi et al., 2005; 
Aaltomaa et al., 2005). In contrast, increased nuclear β-catenin staining was significantly 
associated with increasing Gleason grade (Jaggi et al., 2005). This study, however, had a 
small number of PCa cases (17 cases). Other data showed no significant association between 
β-catenin staining patterns or nuclear localisation with Gleason grades (Horvath et al., 2005; 
Ipekci et al., 2015). Therefore, these studies came to different conclusions about the changes 
that occur in β-catenin expression and localisation in different Gleason grades.  
There are a large number of published studies that describe the association between β-catenin 
expression and PCa stage. For example, nuclear β-catenin staining was found to be 
significantly increased in advanced PCa (T3-4) compared to localised disease (T3-4) 
(Aaltomaa et al., 2005; Ipekci et al., 2015). In contrast, a small sample size study reported 
no association between nuclear or membranous β-catenin expression and PCa stage (Jaggi 
et al., 2005). Finally, Horvath, et al. found that patients who had an advanced PCa had a 
significant reduction in nuclear β-catenin staining compared to those with a localised PCa 
(Horvath et al., 2005). This study had the largest cohort suggesting that the results are more 
likely to be reliable than some of the studies based on smaller cohorts.  
Finally, in terms of a link to biochemical relapse, a reduction of nuclear β-catenin 
localisation has been suggested to be significantly associated with a higher risk of 
biochemical relapse (Horvath et al., 2005). In addition, Whitaker, et al. found reduction of 
nuclear β-catenin localisation in hormone recurrent PCa compared to non-recurrent, but the 
data was not significant (Whitaker et al., 2008). In contrast, there was no association between 
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membranous β-catenin expression and PCa biochemical relapse (Kallakury et al., 2001; 
Horvath et al., 2005).  
Given the conflicting evidence, described above, it was decided that it would be worthwhile 
to re-examine the expression of β-catenin in PCa. Specifically, to examine nuclear β-catenin 
expression in normal and malignant prostate tissues, including recurrent and non-recurrent. 
Nuclear staining was selected as it appeared to have the strongest evidence to support a link 
between it and PCa formation and progression. Cytoplasmic staining was also analysed to 
provide a comparison to the results obtained for nuclear staining. It was decided not to study 
membranous staining as there were fewer links between changes in membranous expression 
and disease. This localisation could be examined in future.  
The conflicting evidence meant a number of hypotheses could have been proposed, the ones 
used in this study were mainly based on the studies with the larger sample sizes as it was felt 
they were more likely to be reliable. The hypothesis used proposed that that nuclear, but not 
cytoplasmic, β-catenin staining will be decreased in PCa compared to NP and will be 
negatively associated with histopathological parameters of PCa, including primary Gleason 
grade, stage and relapse.  
3.2.1.2 NDRG1 
 NDRG1 is an intracellular protein that is thought to be a tumour suppressor that plays a role 
in inhibiting cell proliferation and invasion (Li et al., 2015b). NDRG1 expression and/or 
localisation has been studied in several kinds of malignancy, including PCa. Of particular 
importance for this study, altered expression levels and localisation of NDRG1 has been 
suggested to play a role in PCa progression and relapse (described below and summarised 
in Table 3.1). 
NDRG1 expression and/or localisation have been studied in both normal and malignant 
tissues. Cytoplasmic NDRG1 expression was increased significantly in a range of cancer 
types, including colorectal (Koshiji et al., 2007), hepatocellular (Angst et al., 2006; Sibold 
et al., 2007), thyroid (Gerhard et al., 2010) and prostate tumours (Symes et al., 2013) 
compared to normal or benign tissues. In contrast, a recent study showed reduced 
cytoplasmic NDRG1 significantly in PCa tissues and PCa cell lines compared to BPH and 
NP cell lines, respectively (Li et al., 2015b). In terms of  NDRG1 membranous expression, 
a previous study showed decreased membranous NDRG1 expression in PCa compared to 
NP tissues (Song et al., 2010). NDRG1 expression has been reported in the nucleus of NP 
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tissues (Li et al., 2015) and in a small number of PCa cases (11 of  148 cases) (Song et al., 
2010). However, to our knowledge, if there is an association between levels of nuclear 
NDRG1 expression in normal vs. malignant tissues, it has not been investigated before. 
Therefore, there is evidence to suggest that altered cytoplasmic/membranous, but not 
nuclear, NDRG1 expression is linked to PCa.   
The published evidence on NDRG1 expression in different Gleason grades is also 
complicated. For example, there was no significant association reported between NDRG1 
expression and Gleason grade (Caruso et al., 2004; Symes et al., 2013). In contrast, other 
publications showed that there was an association between NDRG1 staining and cancer 
grade, including PCa. For example, a previous PCa study in 2010 found increased 
cytoplasmic NDRG1 expression significantly associated with increasing Gleason grades 
(Song et al., 2010), whereas, Bandyopadhyay et al. reported decreased cytoplasmic NDRG1 
expression significantly with increasing Gleason grades (Bandyopadhyay et al., 2003). 
Membranous NDRG1 staining was also detected in PCa and was negatively associated with 
increasing Gleason grade (Song et al., 2010). There was no previous study that studied 
nuclear NDRG1 expression in normal vs. malignant prostate tissues. A study on renal cell 
carcinoma tissues showed that nuclear NDRG1 staining was negatively associated with 
increasing grades (Hosoya et al., 2013). Therefore, there is conflicting evidence to suggest 
that changes in nuclear, membranous and cytoplasmic NDRG staining are linked to Gleason 
grade of PCa. On balance, there seems to be slightly more evidence to support a reduction 
in higher grades. 
There are a number of published studies that describe the association between NDRG1 
staining and cancer stage, including PCa. For example, PCa patients with advanced stage 
had low NDRG1 staining compared to those with localised PCa (Bandyopadhyay et al., 
2003). In contrast, two other studies showed membranous and cytoplasmic NDRG1 
expression not associated significantly with the clinical stage of PCa. (Caruso et al., 2004; 
Song et al., 2010). Therefore, there is greater evidence to suggest that alterations in NDRG1 
expression are not linked to PCa stages.  
Finally, in terms of a link to PCa relapse, a study has found NDRG1 predominately expressed 
in PCa patients who had a recurrence compared those who had not. However, the authors 
did not show which localisation of the protein was associated with PCa recurrence (Symes 
et al., 2013). NDRG1 level was also increased in hepatocellular carcinoma recurrence 
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compared to non-recurrence (Cheng et al., 2011). Therefore, there are two studies suggesting 
there might be a link between higher NDRG1 expression and PCa relapse. 
Given the evidence, described above, to suggest a link between NDRG1 
expression/localisation and PCa it was decided to examine nuclear, membranous and 
cytoplasmic NDRG1 staining and localisation in normal and malignant prostate tissues, 
including recurrence and non-recurrence.  
The hypothesis used predicted that membranous and cytoplasmic NDRG1 staining will be 
decreased in PCa compared to NP tissues. Membranous and cytoplasmic NDRG1 staining 
will be negatively associated with Gleason grade, but not stage, and positively associated 
with biochemical relapse. These hypotheses are based on the direction of association that 
was supported by of the most convincing of the studies, but as the evidence is contradictory 
other possible hypotheses could also have been proposed. There is little evidence regarding 
the nuclear expression of NDRG1 and PCa, so no hypothesis was proposed, but its 
expression was examined to see if an association was observed. 
3.2.1.3 ATP binding cassette group 2  
ATP binding cassette group 2 (ABCG2)/ Breast cancer resistance protein (BCRP), a member 
of the ABC transporter family, is a transmembrane protein that plays a vital role in promoting 
proliferation and maintaining the undifferentiated phenotype of SCs (Ding et al., 2010). It is 
linked to drug-resistance and is thought to be a potential biomarker that can predict clinical 
progression and prognosis of different kinds of tumours, including breast cancer (Xiang, et 
al 2011) as well as identifying CSCs (Ding et al., 2010). Of particular importance for this 
study, altered expression levels of ABCG2 has been suggested to play a role in PCa 
progression and relapse (described below and summarised in Table 3.1).   
There are a number of publications that have studied ABCG2 protein or mRNA levels in 
both normal and cancer tissues. Previous studies showed that membranous and cytoplasmic 
ABCG2 was expressed in breast and oesophageal squamous cell carcinomas (Xiang et al., 
2011; Hang et al., 2012). Cytoplasmic ABCG2 expression was significantly decreased in 
PCa compared to NP and seminal vesicle (Thompson et al., 2008). In contrast, another study 
showed no significant difference in ABCG2 mRNA levels between normal and malignant 
prostate samples, using real-time PCR (Guzel et al., 2014). Therefore, there is evidence to 
suggest that decreased cytoplasmic ABCG2 protein expression, but possibly not mRNA, is 
linked to PCa formation. 
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A number of published studies have described the association between ABCG2 expression 
with tumour grade, clinical stage and biochemical relapse. Increased cytoplasmic ABCG2 
staining was observed in PCa tissues with a medium Gleason grade compared to those with 
either a lower or a higher Gleason grade (Castellon et al., 2012). In other cancers, a previous 
study found ABCG2 levels in breast cancer significantly associated with clinical stages and 
lymph node metastasis (Xiang et al., 2011). In contrast, membranous and cytoplasmic 
ABCG2 expression was not associated significantly with grades of breast and oesophageal 
squamous cell carcinomas (Xiang et al., 2011; Hang et al., 2012). There was also no 
significant difference between ABCG2 levels and oesophageal squamous cell carcinomas 
stages (Xiang et al., 2011). In terms of relapse, ABCG2 mRNA level was significantly 
increased in PCa relapse compared to non-relapsed (Guzel et al., 2014), and was also higher 
in CRPC compared to metastatic PCa (Pfeiffer et al., 2011). Therefore, there are conflicting 
results regarding a link between ABCG2 expression and Gleason grade or clinical stage, but 
according to previous PCa studies (Pfeiffer et al., 2011; Guzel et al., 2014), its expression 
might be associated significantly to biochemical relapse.  
Given the evidence, described above, to suggest a link between ABCG2 expression and PCa 
it was decided to examine cytoplasmic ABCG2 staining in normal and malignant prostate 
tissues, including recurrence and non-recurrence. The hypothesis used predicted that 
cytoplasmic ABCG2 staining will be decreased in PCa, and will be positively associated 
with PCa relapse, but not with grade and stage.  
3.2.1.4 Aldehyde hydrogenase 1 family member A1 
 Aldehyde hydrogenase 1 family member A1 (ALDH1A1) represents a marker of CSCs 
(Kahlert et al., 2012; Li et al., 2014). This protein is localized in the cytosol of different 
kinds of human tissues, including prostate (Tomita et al., 2016). It has been reported that 
ALDH1A1 plays a role to catalyse the oxidation of retinal to retinoic acid that represents a 
regulator of cell differentiation during the development process (Yoshida et al., 1992; 
Tomita et al., 2016), and is thought to have an essential role in a cancer progression (Li et 
al., 2014). Of particular importance for this study, altered expression levels and localisation 
of ALDH1A1 has been suggested to play a role in PCa progression, and relapse (described 
below and summarised in Table 3.1). 
There are several publications that studied ALDH1A1 expression/localisation in cancer 
tissues, including PCa compared to normal tissues. Two studies reported that glandular and 
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stromal ALDH1A1 staining was observed in cancerous and non-cancerous human tissues 
such as breast, lung, colon, gastric, liver, pancreas and prostate (Deng et al., 2010; Matsika 
et al., 2015). In terms of ALDH1A1 glandular nuclear and cytoplasmic expression, previous 
studies found that cytoplasmic ALDH1A1 staining was increased in cancerous tissues, 
including PCa compared to non-cancerous tissues (Ting et al., 2009; Kalantari et al., 2017). 
Nuclear ALDH1A1 expression has not been studied in prostate tissues, however, a study on 
colon and rectal cancers reported that nuclear ALDH1A1 staining was expressed in only 3% 
(21/659) colon cancer and only 1% (3/337) rectal cancer (Kahlert et al., 2012). Therefore, 
there is evidence that suggests alterations in cytoplasmic, but not nuclear, ALDH1A1staining 
is linked to PCa. 
In terms of the association with PCa histopathological and clinical features, increased 
cytoplasmic ALDH1A1 staining has been suggested to be associated with increasing 
Gleason grade and advanced stage of PCa (Ting et al., 2009; Kalantari et al., 2017). Another 
study has reported that there is a significant association between cytoplasmic ALDH1A1 
expression and tumours stage, including T and N. In other cancer types, cytoplasmic 
ALDH1A1 expression was also significantly associated with gastric cancer stages, but not 
with grades  (Li et al., 2014). Less work has focused on nuclear ALDH1A1, but staining was 
found to be significantly associated with colon cancer grades as well as with lymph node 
status in rectal cancer (Kahlert et al., 2012). There is currently no study that describes the 
association between ALDH1A1 expression and PCa relapse, but a study on gastric cancer 
tissues showed there was a positive association between cytoplasmic  ALDH1A1 staining 
and relapse (Li et al., 2014).  
The studies described above focus on the glandular expression of ALDH1A1. However, as 
mentioned the protein is also expressed in the stromal cells which surround the gland. A link 
between stromal ALDH1A1 and histopathological parameters of PCa, including Gleason 
grades, clinical stages and biochemical relapse has not been described before.  
Given the evidence, described above, to suggest a link between ALDH1A1 expression/ 
localisation and PCa (Ting et al., 2009; Kalantari et al., 2017) it was decided to examine 
cytoplasmic ALDH1A1 in the glands as there was the strongest evidence to support a link 
between changes in this expression and clinical aspects of PCa. It was also decided to 
examine nuclear ALDH1A1 in the glands, to provide a comparison to the cytoplasmic 
expression. Finally, stromal levels were examined in both normal and cancer tissues of the 
prostate, including recurrence and non- recurrence, as no previous study had looked at the 
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link between this expression and PCa formation/progression. The hypothesis used predicted 
that cytoplasmic, but not nuclear, glandular ALDH1A1 will be increased in PCa and 
positively associated with grade, stage and relapse. No hypothesis was proposed for the 
stromal expression due to a lack of previous work. 
3.2.1.5 Retinoschisin 1 
Retinoschisis 1 (RS1) is a protein that is secreted from retinal cells and plays a role in 
regulating ERK signalling and apoptosis in retinal cells (Tolun et al., 2016; Plössl et al., 
2017). X-linked juvenile retinoschisis (XLRS) is a genetic disease that causes vision 
impairment in young men due to a RS1 mutation (Plössl et al., 2017). Interestingly for this 
study, previous work in our laboratory suggested that increased RS1 levels might play a role 
in PCa relapse (described below and summarised in Table 3.1). 
According to our knowledge, there is no published study that examines RS1 expression and 
its association in normal vs. malignant prostate, Gleason grades, clinical stages and 
biochemical relapse. However, in our laboratory, a PhD student found that nuclear and 
cytoplasmic RS1 staining was observed in normal and malignant prostate tissues (Sharpe, 
2016). The statistical analysis showed that no significant difference in expression of RS1 
was observed when comparing malignant prostate tissues to those with a normal nature or 
between different Gleason grades. However, the cytoplasmic expression of RS1 trended to 
be higher in relapsed PCa tissues compared to non-relapsed (Sharpe, 2016), but the 
association was not statistically significant. The main limitation of this study, however, was 
a small sample size and this result might have been more statistically significant if it had a 
larger cohort. Therefore, although this protein has not been extensively studied there is some 
preliminary evidence to suggest that increased cytoplasmic intensity staining of RS1 might 
be associated with PCa relapse.  
Given the preliminary evidence, described above, to suggest a link between RS1 staining 
and PCa it was decided to examine nuclear and cytoplasmic RS1 staining in a large cohort 
of normal and malignant prostate tissues, including recurrence and non-recurrence. The 
hypothesis used, which was based on the previous work from our lab (Sharpe, 2016), 
predicted that cytoplasmic RS1 staining will be positively associated with PCa relapse, but 





Table 3. 1 Candidate protein summary: the type of protein, key publications and the hypothesis for each 
candidate protein. In some cases, there are contradictory reports on the association between expression of the 
markers and disease and a range of hypothesis could have been proposed. The hypothesis selected for this study 
were based on what was felt to be the most convincing data. See text for details. 
Name & type of 
Protein  




in adhesion and 
Wnt signalling.    
 Membranous -catenin staining was reduced in PCa and 
was negatively associated with PCa grade (Kallakury et al., 
2001a; Jaggi et al., 2005), but not with recurrence (Kallakury 
et al., 2001) 
 
 Membranous -catenin staining was increased in PCa 
tissues with a low grade, whereas, nuclear staining was 
increased at an advanced stage of PCa (T3-T4) (Aaltomaa et 
al., 2005). 
 
 In localized PCa, nuclear and membranous -catenin 
staining is significantly reduced compared to BPH. Reduction 
of nuclear -catenin staining was associated significantly with 
advanced stage and a short biochemical recurrence (Horvath et 
al., 2005). 
 
 Membranous β-catenin expression was reduced in PCa 
compared to BPH (Bismar et al., 2004; Jaggi et al., 2005).  
Nuclear -catenin expression was highly expressed in high 
grade tissues compared to those with a low grade, whereas, 
membranous intensity staining was reduced (Jaggi et al., 2005). 
 
 -catenin showed increased levels of nuclear localisation in 
BPH compared to low and high grades of PCa. Nuclear -
catenin localisation was significantly reduced with increasing 
grade.  There was a reduction of nuclear - catenin localisation 
in hormone recurrent PCa compared to non-recurrent, but the 
data was not significant (Whitaker et al., 2008). 
 
 Nuclear localisation of - catenin in PCa was higher than 
BPH, but was not associated with Gleason grades and clinical 
stages, whereas, - catenin staining intensity was higher in BPH 
compared to PCa (Ipekci et al., 2015). 
 Nuclear -
catenin staining 
will be reduced in 
PCa compared to 
NP tissues.  
 Nuclear β-
catenin staining 
will be negatively 
associated with 
Gleason grade, 










 Cytoplasmic NDRG1 staining was significantly reduced in 
high grade PCa compared to low grade. This reduction was 
significantly associated with advanced stage PCa 
(Bandyopadhyay et al., 2003). 
 
 Immunohistochemical study showed that NP tissues had a 
predominately membranous expression of NDRG1, whereas, 
decreasing membranous and increasing cytoplasmic expression 
of NDRGI was significantly associated with increasing Gleason 
grades. Nuclear NDRG1 staining was only seen in 11 out of 




will be decreased 
in PCa compared 









 NDRG1 level was increased in hepatocellular carcinoma 
recurrence compared to non-recurrence and was significantly 
associated with tumour stage (Cheng, et al 2011). 
 
 Reduction nuclear NDRG1 staining is significantly 
associated with increasing grades and advanced stage of renal 
cell carcinoma, whereas, membranous expression was not 
associated with both grades and stages of renal cell carcinoma 
(Hosoya et al., 2013). 
 
 Immunohistochemical study showed increased NDRG1 
expression in PCa compared to benign prostate tissues and was 
positively associated with biochemical relapse, but not with 
Gleason grade, clinical stage (Symes et al., 2013).  
 
 Both NDRG1 protein and mRNA levels were significantly 
higher in NP cell lines (RWRG1) compared to PCa cell lines 
(PC3 and LNCap), using IHC, western blot and RT-Q PCR. 
Cytoplasmic NDRG1 expression was also higher in BPH 
compared to PCa (Li et al., 2015b). 
associated with 





not be associated 






protein.   
 Cytoplasmic ABCG2 expression was significantly reduced 
in PCa compared to NP and seminal vesicle (Thompson et al., 
2008). 
 
 ABCG2 mRNA level in CRPC was higher compared with 
metastatic PCa cases (Pfeiffer et al., 2011). 
  
 Cytoplasmic and membranous ABCG2 expression was 
observed in breast cancer tissues and was associated with 
clinical stages and lymph node metastasis, whereas, its 
expression was not associated with grades (Xiang et al., 2011). 
 
 ABCG2 was expressed in membranous and cytoplasm of 
oesophageal squamous cell carcinoma, but was not associated 
with grades and stages (Hang et al., 2012). 
 
 Increased cytoplasmic ABCG2 staining was observed in 
PCa tissues with a medium Gleason grade compared to those 
with a low and high Gleason grade (Castellon et al., 2012). 
 
 ABCG2 expression showed no significant difference 
between cancerous and non- cancerous prostate tissues. In PCa, 
ABCG2 expression was significantly increased in relapse cases 
compared to non- relapse (Guzel et al., 2014). 
 Cytoplasmic 
ABCG2 staining 
will be decreased 
in PCa compared 




will be positively 
associated with 
PCa relapse but 






 ALDH1A1was only expressed in the cytoplasm of basal 
cells of NP, whereas, it was expressed in luminal and 
neuroendocrine cells of PCa tissues. This cytoplasmic 
expression was increased in PCa compared to NP tissues and 
was positively associated with increasing Gleason grades and 
clinical stages (Ting et al., 2009). 
  
 Cytoplasmic, 
but not nuclear, 
glandular 
ALDH1A1stainig 
will be increased 
in PCa compared 
to NP tissues.  
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 Cytoplasmic ALDH1 expression was higher in tumour 
tissues such as breast, lung, colon, gastric, liver and pancreas 
compared to normal tissues. (Deng et al., 2010). 
 
 Nuclear and cytoplasmic ALDH1A1 expression was 
observed in normal colon, and a few cases showed stromal 
expression of ALDH1A1. Colon and rectal cancer tissues had a 
cytoplasmic expression of ALDH1A, but was not associated 
with all histopathological parameter of the colon and rectal 
cancers except lymph node status of rectal cancer. In addition, 
3% (21/659) colon cancer and only 1% (3/337) rectal cancer 
tissues showed positive nuclear ALDH1A1 staining.   Nuclear 
ALDH1A1 staining was significantly associated with colon 
cancer grades and lymph node status (Kahlert et al., 2012). 
 
 Half of the gastric cancer samples showed cytoplasmic 
ALDH1A1 expression. Increasing cytoplasmic expression of 
ALDH1A1 was significantly associated with advanced stages, 
and relapse, but not with grades. (Li et al., 2014).  
 
 An IHC study showed cytoplasmic ALDH1A1 expression 
in about half of PCa samples (67/142). This study reported that 
there was a patch of positive ALDH1A1 in the stroma of PCa. 
Cytoplasmic ALDH1A1 expression showed a significant 
association with PCa stages, including tumours stage (T) and 
lymph node invasion (N) (Matsika et al., 2015).  
 
 Cytoplasmic ALDH1A1 expression was significantly 
increased in PCa compared to BPH and PIN. Cytoplasmic 
ALDH1A1 was significantly associated with Gleason score and 




but not nuclear, 
glandular 
ALDH1A1 
staining will be 
positively 
associated with 






 Nucleus and cytoplasm RS1 staining showed no significant 
difference between cancerous and non- cancerous prostate 
tissues. Although there was no significant difference between 
nuclear and cytoplasm RS1 staining and Gleason score and 
biochemical relapse. However, cytoplasmic RS1 staining was 
trended to be higher in PCa relapsed patients compared to a 
non-relapsed (Sharpe, 2016).  
 Cytoplasmic 
RS1 will not be 
altered in PCa 
compared to NP 
tissue. 
 Cytoplasmic 
RS1 will be 
positively 
associated with 
PCa relapse, but 
not with grade and 





3.2.2 Testing prostate tissue morphology using Haematoxylin 
and Eosin staining 
Having chosen the candidate proteins, the next step is to assess their expression using IHC. 
Before this could be carried out the morphology of the tissue from RUH needed to be 
confirmed by staining it with H&E. Both normal and malignant prostate tissue samples were 
stained with H&E (Figure 3.1). NP tissues stained with H&E staining showed prostate glands 
which consist of different cell types, including basal (Figure 3.1A, blue arrows) and luminal 
cells (Figure 3.1 A, red arrow) surrounded by fibromuscular stroma (Figure 3.1 A, black 
arrow). In contrast, PCa tissues had a disruption of the normal structure of prostate glands 
which showed increased luminal cells (Figure 3.1 B, red arrows) and the absence of basal 
cells. These glands were also surrounding by fibromuscular stroma (Figure 3.1 B, black 
arrow). This H&E result confirms that the morphology was as expected and so IHC could 
then be carried out in the next section. 
 
Figure 3. 1 Checking the histological structure of the prostate tissue from the Bath cohort. (A) The NP stained 
with H&E showed prostate gland cells, including basal cells (Blue arrows) and luminal cells (Red arrow) 
surrounding by fibromuscular stroma (Black arrow). (B) PCa consists of prostate gland cells such as luminal 
cells (Red arrows) and fibromuscular stroma (Black arrow). The tissue organisation was as expected for the 
normal and malignant prostate. Scale bar=100μm. 
3.2.3 Establishing IHC protocols for the proteins of interest 
The next steps in establishing IHC protocols for the proteins of interest was to select 
antibodies and then test them with different antigen retrieval protocols to establish if they 
produced staining patterns matching those expected from previous studies reported in the 
literature. Five different antibodies, one against each of β-catenin, NDRG1, ABCG2, 
ALDH1A1 and RS1 were selected in this study (see Chapter 2.1.2), using the CiteAb website 
(https://www.citeab.com). The antibodies were selected based on the following criteria: that 
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they had been used and validated previously for IHC staining, they reacted with human 
tissues and were produced by a well-known company.  
Two different types of antigen retrieval, treatment with citrate (pH6) and Tris/ EDTA (pH9) 
buffers at 90 ⁰C, using a water bath, were tested to see which provided the best staining for 
each antibody. β-catenin had membranous, cytoplasmic and nuclear staining, as expected, 
following both antigen retrieval methods (Figure 3.2). However, a citrate buffer was chosen 
because clearer nuclear and cytoplasmic staining for β-catenin was observed. IHC staining 
showed membranous, cytoplasmic and nuclear NDRG1 staining in both buffers. However, 
the citrate buffer showed clearer nuclear and cytoplasmic NDRG1 staining compared to Tris/ 
EDTA buffer (Figure 3.2). NDRG1 staining was expected to be in the membrane, 
cytoplasmic and nucleus of cells. The citrate buffer was also the best choice for ALDH1A1 
in this study. This is because IHC results after using citrate buffer antigen retrieval showed 
clearer nuclear and cytoplasmic glandular and stromal ALDH1A1 staining compared with 
Tris/ EDTA buffer results, where the samples appeared over stained (Figure 3.2). Nuclear 
and cytoplasmic ALDH1A1staining matched the expected staining pattern for this protein. 
ABCG2 had membranous, cytoplasmic and nuclear staining in both buffers. However, IHC 
results using Tris/ EDTA buffer showed clearer membranous ABCG2 staining and less 
nuclear staining compared to retrieval using citrate (Figure 3.2). ABCG2 is a transmembrane 
transporter protein and is not expected to be in the nucleus of the cells, so this study used the 
Tris/EDTA buffer for antigen retrieval for ABCG2.  Finally, IHC results with both buffers 
showed nuclear and cytoplasmic RS1 staining in prostate tissues. However, the citrate results 
were clearer than Tris/ EDTA results (Figure 3.2). This pattern of staining matched that 
observed previously in our laboratory, although as a secreted protein RS1 would not be 
expected to be found in the nucleus, so this proportion of the staining might be background.  
In summary, after testing antigen retrieval methods, the citrate buffer (pH6) was preferred 
for all candidate biomarkers (β-catenin, NDRG1, ALDH1A1 and RS1), except for ABCG2, 
where Tris/ EDTA was selected and all the antibodies were felt to be suitable for use as the 





Figure 3. 2 Expression of the potential biomarkers after the different antigen retrieval methods. (A) Expression 
of these potential biomarkers after using citrate buffer pH 6. (B) Expression of these potential biomarkers after 
using Tris/EDTA buffer pH 9.  All the potential biomarkers showed a clearer result with citrate buffer, except 
ABCG2 that showed clearer staining in Tris/EDTA. Scale bar=100μm. 
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3.2.4 Structure of the Bath cohort  
The Bath cohort consists of 34 PCa paraffin-embedded blocks, including those from patients 
who had and had not undergone recurrence, and five NP blocks. The samples were obtained 
from the histopathological laboratories of the RUH, Bath, UK. The samples were collected 
between 1997 and 2018. This study also used normal testis, kidney and liver tissues as 
positive controls.  A summary of the Bath cohort clinical data is shown in (Table 3.2). This 
cohort of samples was then stained using antibodies against the different potential 
biomarkers. 
Table 3. 2 Clinical data of the Bath cohort prostate samples. 
 
 
3.2.5 β-catenin  
To test the hypothesis that nuclear β-catenin staining will be decreased in PCa and negatively 
associated with primary Gleason grade, clinical stage and relapse; IHC was carried out with 
the Bath cohort prostate samples.  
The Bath Clinical data  Number % 







Primary Gleason Grade 
Grade 3 15 44.1 
Grade4 16 47 
N/A 3 8.9 
T category 
T1-T2 19 55.9 
T3-T4 9 26.5 
N/A 6 17.6 
N category 
N0 24 70.6 
N1 3 8.8 
N/A 7 20.6 
M category 
M0 20 58.8 
M1 3 8.8 
N/A 11 32.4 
Biochemical recurrence status 
(at 5 years) 
Non-Recurrent 13 38.2 
Recurrent  19 55.9 
N/A 2 5.9 
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3.2.5.1 Immunohistochemical staining of β-catenin in the normal and 
malignant Bath prostate tissues  
β-catenin staining was carried out using IHC on prostate samples from the Bath cohort. In 
NP tissues, IHC staining showed nuclear β-catenin staining which ranged from strong 
(Figure 3.3 A, arrow), moderate (Figure 3.3 B, arrow) and weak in some cases. Nuclear β-
catenin staining was also observed in PCa tissues and the intensity of signal varied widely, 
from strong (Figure 3.3 D, arrow) to weak (Figure 3.3 F, arrow). Membranous β-catenin 
staining was also observed in the Bath prostate tissue samples with variable levels of 
staining, ranging from strong (Figure 3.3 D, red arrowhead), moderate (Figure 3.3 C, red 
arrowhead), weak (Figure 3.3 E, red arrowhead) and negative (Figure 3.3 B, red arrowhead).  
In addition to the nuclear and membranous staining, normal and malignant prostate tissues 
had cytoplasmic β-catenin staining, with variable levels of staining between cases, ranging 
from strong (Figure 3.3 D, arrowhead), moderate (Figure 3.3 A, arrowhead) and weak 
(Figure 3.3 B, C, E & F, arrowheads). β-catenin is expressed in Sertoli, spermatid and 
spermatozoa cells of normal testis tissues (Lee et al., 2005) and so this study used the normal 
testis as a positive control for β-catenin and as expected IHC staining showed nuclear β-
catenin staining in the spermatid and spermatozoa cells of testis tissues (Figure 3.3  G, 
arrow). A negative control, with no primary antibody, showed no significant background 
staining in prostate tissue (Figure 3.3 H, arrow).  
3.2.5.2 Association between β-catenin immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort 
Having carried out IHC staining on normal and malignant prostate samples from the Bath 
cohort, the nuclear and cytoplasmic β-catenin staining was then quantified using H and 
proportion and intensity 1 scores, respectively. The range of nuclear and cytoplasmic β-
catenin scores varied between 0 to 110 and 0 to 7, respectively (Figure 3.4). The potential 
association between β-catenin IHC results and histopathological parameters of PCa was then 
analysed and is described below.  
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Figure 3. 3  β-catenin staining in samples from the Bath cohort. β-catenin was stained heterogeneously in both 
normal and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and moderate cytoplasmic 
(Black arrowhead) β-catenin staining in NP. (B) Weak to moderate nuclear (Black arrow) and cytoplasmic 
(Black arrowhead) β-catenin staining in NP. (C) Weak cytoplasmic (Black arrowhead) and moderate 
membranous (Black arrow) β-catenin staining in PCa. (D) Strong nuclear (Black arrow), membranous (Red 
arrowhead) and cytoplasmic (Black arrowheads) β-catenin staining in PCa. (E) Weak membranous (Red 
arrowhead) and cytoplasmic (Black arrowhead) β-catenin staining in PCa. (F) Moderate nuclear (Black arrow) 
and weak cytoplasmic (Black arrowhead) β-catenin staining in PCa. (G) Nuclear β-catenin staining (Black 
arrowhead) in testis tissue. (H) Negative control (no primary antibody added) was free background staining 
(Black arrow) in PCa. Scale bars=100µm.  
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The first analysis looked at the β-catenin staining in normal vs. malignant prostate tissues. 
Quantification of the IHC staining showed reduced nuclear β-catenin staining significantly 
in PCa compared to NP (p= 0.0066) (Figure 3.4   A & Table 3.3). There appeared to be a 
trend towards decreased cytoplasmic β-catenin scores in PCa compared to NP (Figure 3.4 
B& Table 3.3), although this was not significant (p=0.1923). Nuclear and cytoplasmic β-
catenin staining was also reduced significantly in PCa patients with a primary Gleason grade 
4 compared to those with a Gleason grade 3 (p= 0.0447, 0.0127, respectively) (Figure 3.4 
C&D & Table 3.3). In contrast, nuclear and cytoplasmic β-catenin staining was not 
associated significantly with clinical stage T (T1-2 vs. T3-4) (p=0.2525, 0.9288, 
respectively) and biochemical relapse (p= 0.2808, 0.5135 respectively) (Table 3.3).  
Figure 3. 4 Quantification of nuclear and cytoplasmic β-catenin staining in both normal and malignant Bath 
prostate tissues. IHC staining of β-catenin was quantified in the Bath cohort using H and the proportion and 
intensity 1 score for nuclear and cytoplasmic IHC staining. (A) Nuclear β-catenin staining was significantly 
reduced in PCa compared with NP tissues (p=0.0066). (B) Cytoplasmic β-catenin staining was reduced but not 
significantly in PCa compared with the NP (P= 0.1923). (C) Nuclear β-catenin staining was significantly 
reduced in primary Gleason grade 4 compared with grade 3 (p= 0.0447). (D) Cytoplasmic β-catenin staining 
was also significantly reduced in primary Gleason grade 4 compared to grade 3 (p= 0.0127). The mean of five 
random fields was taken per prostate sample. Statistical significance was determined with unpaired T-test for 
each set of conditions. NP (n=5), PCa (n=27), grade 3 (n=10) and grade 4 (n=15).  
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Table 3. 3 Nuclear and cytoplasmic β-catenin staining results with clinical data. 
In summary, nuclear β-catenin staining was reduced in malignant prostate tissues compared 
to those with a normal nature, whereas, cytoplasmic β-catenin was not associated 
significantly with PCa. Nuclear and cytoplasmic β-catenin staining was negatively 
associated with increasing primary Gleason grade, but not with clinical stage T and 
biochemical recurrence.  
3.2.6 NDRG1 
To test the hypothesis that membranous and cytoplasmic NDRG1 staining will be decreased 
in PCa and will be negatively associated with increasing primary Gleason grade and will be 
positively associated with relapse, but not with the stage; IHC was carried out with the Bath 
prostate samples. 
3.3.6.1 Immunohistochemical staining of NDRG1 in the normal and 
malignant Bath prostate tissues  
IHC staining showed that membranous, cytoplasmic and nuclear NDRG1 staining was 
detected in the Bath prostate tissues. Membranous NDRG1 was expressed predominantly in 
NP tissues (Figure 3.5 A, red arrowhead). In contrast, only one case of PCa showed 
predominant membranous staining (Figure 3.5 F, red arrowhead). NP tissues had 
cytoplasmic NDRG1 staining with variable levels of staining patterns, ranging from strong 
(Figure 3.5 A, black arrowhead) to weak (Figure 3.5 B, black arrowhead). Cytoplasmic 
Comparison Nuclear β-catenin staining Cytoplasmic β-catenin staining 
Results p. value Results p. value 
 
Normal vs malignant 




Primary Gleason grades 
(3 & 4 ) 
Lower in high grade 0.0447 Lower in high grade 0.0127 
















NDRG1 staining was found in PCa tissues with different level of staining, ranging from 
strong (Figure 3.5 C, black arrowhead), moderate (Figure 3.5 F, black arrowhead) and weak 
(Figure 3.5 E, arrowhead). In addition, the Bath prostate tissues showed nuclear NDGR1 
staining with a variable level of staining, ranging from strong (Figure 3.5 B&C, arrows), 
moderate (Figure 3.5 D, arrow), weak (Figure 3.5 E, arrow) and negative (Figure 3.5, F, 
arrow). NDRG1 is expressed in kidney tissues (Lachat et al., 2002) and so this IHC study 
used normal kidney tissue as a positive control for NDRG1 and as expected cytoplasmic 
NDRG1 staining was observed in kidney tissue (Figure 3.5, G arrowhead). A negative 
control, no primary antibody, was clear of background staining in prostate tissue (Figure 3.5 
H, arrow).  
3.3.6.2 Association between NDRG1 immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort 
3.3.6.2.1 NDRG1 localisation 
The analysis of NDRG1 staining started by using a different approach to the other markers. 
The predominant localisation, rather than the amount of staining, was quantified in normal 
and malignant prostate tissues from the Bath cohort. The localisation was divided into three 
different groups: predominant membranous, predominant nucleocytoplasmic and negative 
and each sample scored for its most common localisation. This was carried out to match the 
previous analysis of this protein (Caruso et al., 2004).  
The first analysis looked at the NDRG1 localisation in normal vs. malignant prostate tissues. 
Predominant membranous NDRG was shown in 40% of NP tissues, whereas, only 4% of 
PCa had predominant membranous (Figure 3.6 A).  In contrast, nucleocytoplasmic NDRG1 
was expressed predominantly in 60 % of NP and 92 % of PCa tissues (Figure 3.6 A). Only 
one case of PCa showed no significant staining for NDRG1 (Figure 3.6 A). Quantification 
of the IHC staining showed that there was a significant difference in NDRG1 localisation 
(membranous vs. nucleocytoplasmic) between normal and malignant prostate tissues 
(p=0.0167). There was no significant association between NDRG1 localisation and PCa 
clinical features, including primary Gleason grade, clinical stage T and relapse (Figure 3.6 
B, C, & D). Frequency tests, however, showed that predominant nucleocytoplasmic NDRG1 
was higher with increasing primary Gleason grade. All PCa tissues with a grade 4 showed 
predominant nucleocytoplasmic NDRG1 staining. In contrast, nucleocytoplasmic NDRG1 




Figure 3. 5 NDRG1 staining in samples from the Bath cohort.  NDRG1 was stained heterogeneously in both 
normal and malignant tissues of the prostate.  (A) Predominant membranous (red arrowhead) and cytoplasmic 
NDRG1 staining (Black arrowhead) in NP. (B) Strong nuclear (Black arrow) and weak cytoplasmic (Black 
arrowhead) NDRG1 staining in NP. (C) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) 
NDRG1 staining in PCa. (D) Moderate nuclear (Black arrow) NDRG1 staining in PCa. (E) Weak nuclear 
(Black arrow) and cytoplasmic (Black arrowhead) NDRG1 staining in PCa. (F) Moderate Membranous (Red 
arrowhead) and cytoplasmic (Black arrowhead) with negative nuclear NDRG1 staining in PCa. (G) 
Cytoplasmic NDRG1 staining (Black arrowhead) in kidney tissue. (H) The negative control (no primary 




Figure 3. 6 Localisation of NDRG1 in the Bath PCa samples. IHC staining of NDRG1 localisation was 
quantified in the TMA group using the localisation 1 score. (A) Predominant nucleocytoplasmic was positively 
associated with PCa (P=0.0167). (B) NDRG1 localisation was not associated significantly with primary 
Gleason grade p= (0.2186). (C) There was no clear difference between NDRG1 localisation and clinical stage 
T (p=0.3944). (D) There was no significant difference between NDRG1 localisation and PCa recurrence 
(p=0.4632). The mean of five random fields was taken per prostate sample. Statistical significance was 
determined with a Chi-Square and frequency tests for each set of conditions. NP (n=5), PCa (n=25), grade 3 
(n=10), grade 4 (n=15), T1-2 (n=14), T3-4 (n=9), non-Recurrence (n=9) and recurrence (n=13).   
3.2.6.2.2 NDRG1 staining  
The analysis of localisation suggested a link between NDRG1 staining and clinical 
parameters, so the levels of nuclear and cytoplasmic NDRG1 staining was then quantified 
using the proportion and intensity 2 scores. The range of nuclear and cytoplasmic anti-
NDRG1 scores varied between 0-6.5. The potential association between NDRG1 IHC results 
and histopathological parameters of PCa was then analysed and is described below (Table 
3.4). Nuclear and cytoplasmic NDRG1 staining showed no significant difference between 
normal vs. malignant prostate tissues (P= 0.3051 & 0.0963, respectively) (Table 3.4) as well 




 Table 3. 4 Nuclear and cytoplasmic NDRG1 staining results with clinical data 
 In summary, there was a significant difference in NDRG1 localisation between normal and 
malignant prostate, but was not associated with Gleason grade, stage and relapse. Nuclear 
and cytoplasmic NDRG1 staining was also not associated significantly with PCa and other 
clinical features of PCa. 
3.2.7 ABCG2 
To test the hypothesis that cytoplasmic ABCG2 staining will be decreased in PCa and will 
be positively associated with biochemical relapse, but not with Gleason grade and stage; 
IHC was carried out with the Bath prostate tissue samples. 
3.2.7.1 Immunohistochemical staining of ABCG2 in the normal and 
malignant Bath prostate samples 
The IHC staining showed that normal and malignant prostate tissues had membranous 
ABCG2 staining with variable levels of staining, ranging from strong and widespread 
(Figure 3.7 C, arrow) to moderate and scattered (Figure 3.7 A, arrow) or negative (Figure 
3.7 E, arrow). Nuclear ABCG2 staining was also observed in the Bath prostate tissues with 
different levels of staining, ranging from strong (Figure 3.7 B, arrow) to weak (Figure 3.7 F, 
arrow) or negative (Figure 3.7 D, arrow). ABCG2 would not be predicted to be expressed in 
the nuclei of normal and malignant prostate tissues because it’s a transmembrane transporter 
protein. This suggests that this staining might well be background, however, it was decided 
to quantify it as it might act as an internal control that would not be expected to be linked to 
any disease progression. Normal and malignant prostate tissue samples also had cytoplasmic 
Comparison 
Nuclear NDRG1 staining Cytoplasmic NDRG1 staining 
Results p. value Results p. value 
 
Normal vs malignant 
No statistically significant 
difference 
0.3051 No statistically 
significant difference 
0.0963 
Primary Gleason grades 
(3 & 4) 
No statistically significant 
difference 
0.2534 No statistically 
significant difference 
0.8356 
Clinical Stage (T) 
No statistically significant 
difference 
0.4409 No statistically 
significant difference 
0.8317 
5 years Biochemical recurrence 
No statistically significant 
difference 





ABCG2 staining which, unlike the nuclear staining, is expected. The intensity of signal 
varied widely, ranging from strong and widespread (Figure 3.7 C, arrowhead), moderate 
(Figure 3.7 D, arrowheads), weak (Figure 3.7 A, B& E, arrowheads), and negative (Figure 
3.7 F, arrowhead). ABCG2 is expressed in the membrane and cytoplasm of hepatocyte cells 
(Vander Borght et al., 2006) and so this study used normal liver tissues as a positive control 
for ABCG2 and the IHC staining showed membranous (Figure 3.7 G, arrow) and 
cytoplasmic (Figure 3.7 G, arrowheads) ABCG2 staining in the hepatocyte cells. A negative 
control (no primary antibody) showed no significant background staining in prostate tissue 
(Figure 3.7 H, arrow).  
3.2.7.2 Association between ABCG2 immunohistochemistry and 
histopathological parameters of prostate cancer in the Bath cohort 
In order to evaluate if there was an association between ABCG2 staining in normal vs. 
malignant prostate tissues and/or other PCa histopathological features, nuclear and 
cytoplasmic ABCG2 staining was quantified using the proportion and intensity 1 scores and 
then compared to histopathological and clinical parameters of PCa using the clinical data 
available for the Bath cohort. The range of nuclear and cytoplasmic ABCG2 varied between 
0 - 2.8 and 0 - 7, respectively (Figure 3.8). The potential association between ABCG2 IHC 
results and other PCa histopathological parameters was then analysed and is described 
below.   
The statistical analysis looked at the expression of ABCG2 in normal vs. malignant prostate 
tissues. Quantification of the IHC staining showed no significant difference in nuclear 
ABCG2 scores between NP tissues compared to those with malignancies (p=0.7873) (Figure 
3.8 A Table 3.5) or relapsed vs non relapsed PCa (p = 0.8106) (Figure 3.8 G & Table 3.5). 
In contrast, nuclear ABCG2 staining was positively associated with increasing primary 
Gleason grade and clinical stage T (p = 0.0221& 0.0337 respectively) (Figure 3.8 C, E & 





Figure 3. 7 ABCG2 staining in samples from the Bath cohort. ABCG2 was stained heterogeneously in both 
normal and malignant tissues of the prostate. (A) Moderate membranous (Black arrow) and weak cytoplasmic 
(Black arrowhead) ABCG2 staining in NP. (B) Strong nuclear (Black arrow) and weak cytoplasmic (Black 
arrowhead) ABCG2 staining in NP. (C)  Strong membranous (Black arrow) and cytoplasmic (Black arrowhead) 
ABCG2 staining in PCa. (D) Moderate cytoplasmic (Black arrowhead) and negative nuclear (Black arrow) 
ABCG2 staining in PCa. (E) Weak cytoplasmic (Black arrowhead) with negative nuclear ABCG2 staining in 
PCa. (F) Weak nuclear (Black arrow) and negative cytoplasmic ABCG2 staining in PCa. (G) Membranous 
(Black arrow) and cytoplasmic (Black arrowheads) ABCG2 staining in hepatocyte cells. (H) Negative control 
(no primary antibody added) showed no background staining (Black arrow) in PCa. Scale bars=100µm. 
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Cytoplasmic ABCG2 staining was significantly reduced in PCa compared to NP tissues (p= 
0.048) (Figure 3.8 B & Table 3.5). Cytoplasmic ABCG2 staining was negatively associated 
with increasing primary Gleason grade, but the result was not significant (p=0.1199) (Figure 
3.8 D & Table 3.5). There was no significant association between cytoplasmic ABCG2 
staining and clinical stage (p=0.327) (Figure 3.8 F &Table 3.5). In contrast, cytoplasmic 
ABCG2 staining was reduced significantly in PCa recurrent patients compared to those with 






Figure 3. 8 Quantification of nuclear and cytoplasmic ABCG2 staining in the Bath prostate tissue samples. 
Immunohistochemical staining of ABCG2 was quantified in the Bath cohort using the proportion and intensity 
1 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear ABCG2 staining showed no significant 
difference between normal and malignant prostate tissues (p= 0.7873). (B) Cytoplasmic ABCG2 staining was 
significantly reduced in PCa compared to NP tissues (p= 0.048). (C) Nuclear ABCG2 staining was positively 
associated with increasing primary Gleason grade (p=0.0221). (D) Cytoplasmic ABCG2 staining was 
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negatively associated with increasing primary Gleason grade, but the results were not significant (p=0.1199). 
(E) Nuclear ABCG2 staining was positively associated with increasing clinical stage T (p=0.0337). (F) There 
was no association between cytoplasmic ABCG2 and clinical stage T (p=0.327). (G) There was no association 
between nuclear ABCG2 and risk of recurrence (p=0.8106). (H) Cytoplasmic ABCG2 staining was negatively 
associated with a risk of recurrence (p=0.0141). The mean of five random fields was taken per prostate sample. 
Statistical significance was determined with unpaired T-test for each set of conditions.  NP (n=4), PCa (n=26), 
grade 3(n=9), grade 4(n= 14), T1-2 (n=13), T3-4 (n= 8), recurrent PCa (n=16), non- recurrent PCa (n=8).  
 Table 3. 5 Nuclear and cytoplasmic ABCG2 staining results with clinical data. 
In summary, nuclear ABCG2 staining was not associated significantly with PCa, but was 
positively associated with increasing grade and advanced stage. In contrast, cytoplasmic 
ABCG2 was reduced significantly in PCa and was negatively associated with biochemical 
recurrence, but not with grade and stage.  
3.2.8 ALDH1A1  
To test the hypothesis that cytoplasmic ALDH1A1 staining will be increased in PCa 
compared to NP tissues and will be positively associated with PCa clinical features such as 
Gleason grade, clinical stage and relapse; IHC was carried out with the Bath prostate tissues.  
3.2.8.1 Immunohistochemical staining of ALDH1A1 in normal and 
malignant Bath prostate samples 
Glandular and stromal ALDH1A1 staining was observed in the Bath prostate tissue samples.  
Nuclear ALDH1A1 staining was shown in the glandular regions of both normal and 
malignant prostate tissues and ranged from strong (Figure 3.9 B & F, arrows), moderate 
(Figure 3.9 E, arrow), weak and negative (Figure 3.9 A & C, arrows). Cytoplasmic 
ALDH1A1 staining was also observed in normal and malignant prostate tissues, but the 
Comparison Nuclear   ABCG2 staining Cytoplasmic    ABCG2 staining 
Results p. value Results p. value 
 
Normal vs malignant No statistically 
significant difference 
0.7873 Lower in malignant  0.048 
Primary Gleason grades (3 
& 4) 
Higher in high grade 0.0221 No statistically 
significant difference 
0.1199 
Clinical Stage (T) Higher in T3-4 0.0337 No statistically 
significant difference 
0.327 




0.8106 Lower in recurrence 0.0141 
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intensity of staining was varied, ranging from strong (Figure 3.9 D, arrowhead), moderate 
(Figure 3.9 E, arrowhead), weak (Figure 3.9 B, arrowhead) and negative (Figure 3.9 A& C). 
Interestingly, both nuclear and cytoplasmic ALDH1A1 staining was found to be restricted 
to basal cells of NP tissues (Figure 3.9 B). As was expected in PCa, nuclear and cytoplasmic 
ALDH1A1 staining, however, was found to be in all prostate gland epithelial cells, including 
residual basal (Figure 3.9 F, arrow) and luminal cells (Figure 3.9 D&E).   
In addition to the glandular ALDH1A1 staining, stromal ALDH1A1 staining was also 
observed in the Bath prostate tissue samples, with different staining levels, ranging from 
strong (Figure 3.9 A&C, arrowhead) to weak (Figure 3.9 E). ALDH1A1 is expressed in testis 
tissues (Deng et al., 2010) and so this study used testis tissues as a positive control for 
ALDH1A1 and IHC staining showed nuclear and cytoplasmic ALDH1A1 staining in testis 
tissues (Figure 3.9  G). The negative control showed no significant background staining on 
prostate samples (Figure 3.9 H, arrow).  
3.2.8.2 Association between ALDH1A1 immunostaining with 
histopathological parameters of prostate cancer in the Bath cohort 
Having carried out IHC staining, nuclear and cytoplasmic glandular ALDH1A1 was then 
quantified using the proportion and intensity 3 score, whereas stromal proportion and 
intensity ALDH1A1 staining were quantified using proportion 1 and intensity 1 respectively.  
The range of glandular (nuclear and cytoplasmic) and stromal (proportion and intensity) 
ALDH1A1 staining varied between 0-2.8, 0-3.8, 0-3, and 0-2.8 respectively.  The potential 
association between ALDH1A1 IHC and histopathological parameters of PCa was then 
analysed and is described below.  
The statistical analysis showed that there was no significant association between nuclear and 
cytoplasmic ALDH1A1 staining when comparing normal vs malignant prostate tissues, 
different primary Gleason grades, relapse and clinical stages except T (Table 3.6). 
ALDH1A1 stromal staining was also not associated significantly in normal vs. malignant 
prostate tissue, or other PCa histopathological features (Table 3.7). In contrast, there was a 
negative association between stromal ALDH1A1 (proportion and intensity) staining and 




Figure 3. 9 ALDH1A1 was stained heterogeneously in both normal and malignant tissues of the prostate. (A) 
ALDH1A1 stromal staining (Black arrowhead) and negative glandular region (Black arrow) in NP. (B) Strong 
nuclear AlDH1A1 staining (Black arrow) and weak cytoplasmic (Black arrowhead) in the basal cell of NP. (C) 
Strong Stromal (Black arrowhead) with negative glandular (Black arrow) ALDH1A1 staining in PCa. (D) 
Strong cytoplasmic ALDHIA1 staining (Black arrowhead) in the glandular region of PCa. (E) Moderate 
nuclear (Black arrow) with cytoplasmic (Black arrowhead) ALDH1A1 staining in the glandular region of PCa. 
(F) Strong nuclear ALDH1A1 staining (Black arrow) in basal cells of PCa. (G) Strong nuclear (Black arrow) 
and cytoplasmic (Black arrowhead) ALDH1A1 staining in normal testis tissue. (H) The negative control (no 




Figure 3. 10 Quantification of stromal ALDH1A1 intensity staining in both normal and malignant Bath prostate 
tissues. Immunohistochemical staining of ALDH1A1 was quantified in the Bath cohort using intensity 1 scores. 
(A) ALDH1A1 stromal proportion staining was reduced significantly in PCa recurrent tissues compared to 
non- recurrent (p=0.0483). (B) ALDH1A1 stromal intensity staining was reduced significantly in PCa recurrent 
tissues compared to non- recurrent (p= 0.0304). The mean of five random fields was taken per prostate sample. 
Statistical significance was determined with unpaired T-test for each set of conditions. Recurrent (n=15), non- 
recurrent (n=7). 








Comparison Nuclear ALDH1A1 staining   Cytoplasmic ALDH1A1 staining   
Results p. value Results p. value 
 
Normal vs malignant No statistically 
significant difference 




grades (3 & 4 ) 
No statistically 
significant difference 
0.3285 No statistically significant 
difference 
0.2896 
Clinical Stage (T) No statistically 
significant difference 
0.0337 No statistically significant 
difference 
0.1629 









Table 3. 7 Stromal proportion and intensity ALDH1A1 staining results with clinical data. 
 
In summary, nuclear and cytoplasmic ALDH1A1 was restricted to the basal layer of NP 
tissues, whereas, ALDH1A1 was found to be expressed in all prostate gland epithelial cells. 
Nuclear and cytoplasmic ALDH1A1 staining was not associated with PCa and other 
histopathological features such as primary Gleason grade, clinical stage and biochemical 
relapse. Although ALDH1A1 stromal staining was also not associated significantly with 
PCa, primary Gleason grade and clinical stage, it was negatively associated with biochemical 
recurrence.  
3.2.9 RS1 
To test the hypothesis that cytoplasmic RS1 staining will not be altered in PCa compared to 
NP, but will be positively associated with biochemical relapse, IHC was carried out the TMA 
prostate tissues.  
3.2.9.1 Immunohistochemical staining of RS1 in the normal and malignant 
Bath prostate samples 
In NP tissues, cytoplasmic RS1 staining was found and ranged from strong (Figure 3.11 A, 
arrowhead) to negative (Figure 3.11 B, arrow).  Cytoplasmic RS1 staining was also observed 
in PCa tissues and the intensity of signal varied widely, from strong (Figure 3.11 D, 
arrowhead), moderate (Figure 3.11 E, arrowhead), weak (Figure 3.11 F&C, arrowheads) and 
Comparison ALDH1A1 stromal proportion 
staining 
ALDH1A1 stromal intensity   
staining 
 
Results p. value Results p. value 
 
Normal vs malignant No statistically significant 
difference 




grades (3 & 4 ) 
No statistically significant 
difference 
0.8946 No statistically 
significant difference 
0.9151 
Clinical Stage (T) No statistically significant 
difference 
0.259 No statistically 
significant difference 
0.2349 
5 years Biochemical 
recurrence 
Lower in recurrence 0.0483 Lower in recurrence 0.0304 
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negative (Figure 3.11, G arrowhead). In addition to the cytoplasmic staining, the normal and 
malignant prostate tissue samples all had nuclear RS1 staining, with a variable level of 
staining between cases, ranging from strong (Figure 3.11 A, C & D, arrows), moderate 
(Figure 3.11 E, arrow),  weak  and negative (Figure 3.11 B, F&G, arrows). The negative 
control (no primary antibody) showed no background staining in PCa tissue (Figure 3.11 H, 
arrow). 
 3.2.9.2    Association between RS1 immunostaining and histopathological 
parameters of prostate cancer in the Bath cohort 
The previous PhD student, Ben Sharpe in our laboratory stained 27 PCa and 5 NP tissues 
and this study added 7 new samples to his data to increase the sample size. Data from both 
studies are included in the results presented below. 
Having carried out IHC staining, the nuclear RS1 staining was quantified using the H-score, 
whereas, cytoplasmic staining of RS1 was quantified using the cytoplasmic intensity 1. As 
a secreted protein the nuclear staining might be expected to be background but, as with 
ABCG2, it was decided to score it as it might provide an internal control that would not be 
expected to be linked to disease progression. The range of nuclear and cytoplasmic RS1 
scores varied between 0- 100 and 0-2.5 respectively. The potential association between RS1 
IHC results and histopathological parameters of prostate cancer was then analysed and is 
described below. 
The statistical analysis showed that there was no significant association between nuclear and 
cytoplasmic RS1 scores when comparing NP tissues to those with malignancies as well as 
different primary Gleason grades, clinical stages (Table 3.8). Nuclear RS1 staining was not 
associated with biochemical relapse (Figure 3.12 &Table 3. 8). Cytoplasmic RS1 staining 
was found to be higher in PCa relapsed patients compared to those with non- relapsed, but 





Figure 3. 11 RS1 staining in samples from the Bath cohort. RS1 was stained heterogeneously in both normal 
and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) 
RS1 staining in NP. (B)  Negative RS1 staining in NP. (C) Strong nuclear (Black arrow) and weak cytoplasmic 
(Black arrowhead) RS1 in PCa. (D) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) RS1 
staining in PCa. (E) Moderate nuclear (Black arrow) and cytoplasmic (Black arrowhead) RS1 staining in PCa. 
(F) Weak cytoplasmic (Black arrowhead) and negative nuclear RS1 staining in PCa. (G) Negative nuclear and 
cytoplasmic RS1 staining in PCa. (H) Negative control (no primary antibody added) showed no background 




Figure 3. 12 Quantification of nuclear and cytoplasmic RS1 staining in both normal and malignant Bath 
prostate tissues. Immunohistochemical staining of RS1 was quantified in the Bath cohort using H-score and 
cytoplasmic intensity the scores respectively. (A) Nuclear RS1 staining was not associated with recurrence 
(p=0.4916). (B) Cytoplasmic RS1 was higher in recurrent PCa tissue compared to non- recurrent PCa tissues 
but the result was not significant (P=0.2711). The mean of five random fields was taken per prostate sample. 
Statistical significance was determined with unpaired T-test for each set of conditions. Recurrent PCa (n=17) 
and non-recurrent PCa (n=8).  
Table 3. 8 Nuclear and cytoplasmic RS1 staining results with clinical data 
 
In summary, nuclear and cytoplasmic RS1 staining was not associated significantly with 
PCa and other histopathological and clinical features of PCa. 
Comparison 
Nuclear RS1 staining   Cytoplasmic RS1 staining   
Results p. value Results p. value 
 
Normal vs malignant 
No statistically 
significant difference 
0.3058 No statistically 
significant difference 
0.2492 
Primary Gleason grades 
(3 & 4) 
No statistically 
significant difference 






0.2364 No statistically 
significant difference 
0.8999 









3.4 Discussion  
3.4.1 Summary of the results  
The expression of five candidate biomarkers, β-catenin, NDRG1, ABCG2, ALDH1A1 and 
RS1 were investigated in prostate tissues samples from the Bath cohort, using IHC to 
determine if there was an association between their IHC levels in normal vs. malignant 
prostate tissues and/or with other histopathological and clinical features of PCa, including 
primary Gleason grade, clinical stage and biochemical recurrence. The key findings for these 
potential biomarkers are summarised in Table 3.9. It was decided to discuss the results from 
each potential biomarker in detail in Chapter 4 after the analysis had been carried out with 
the larger cohort, rather than discuss the preliminary results here and repeat the discussion 
in the next Chapter. 
Table 3. 9 Summary of key findings for each candidate biomarker in this chapter 
 
Biomarkers Key Findings 
β-catenin 
 Nuclear Β-catenin, but not cytoplasmic, staining was decreased significantly in PCa. 
 Nuclear and cytoplasmic staining was negatively associated with increasing primary 
Gleason grade, but not stage or relapse. 
NDRG1 
 
 Decreased membranous and increased nucleocytoplasmic localisation of NDRG1 
was significantly associated with PCa, but not with grade, stage and relapse. 
 Changes in nuclear or cytoplasmic NDRG1 levels were not significantly associated 
with clinical features of PCa. 
ABCG2 
 
 Cytoplasmic ABCG2 staining was reduced significantly in PCa and was negatively 
associated with biochemical relapse.  
 Nuclear ABCG2 staining was positively associated with increasing primary Gleason 
grade and stage.  
ALDH1A1 
 Changes in cytoplasmic and nuclear ALDH1A1 staining in the glands was not 
significantly associated with clinical features of PCa.   
 ALDH1A1 stromal proportion and intensity staining were negatively associated with 
biochemical relapse, but not normal vs malignant, grade and stage.  
RS1 
 Changes in Cytoplasmic and nuclear RS1 staining was not significantly associated 




3.4.2 Limitations of using a cohort with a small number of 
clinical samples  
The expression of the five candidate biomarkers has been analysed using samples from the 
Bath cohort and some interesting changes observed. However, a key limitation of this data 
is that the Bath cohort consists of a small number of samples, 5 NP and 34 PCa tissues. In 
addition, NP tissue samples lacked clinical information about age, so they might be from 
different aged patients than the cancer samples.  For this reason, it was decided that the 
results described above should be treated as preliminary until repeated using a cohort with a 
much higher sample size. This was carried out in the next chapter by using a prostate TMA 
with 96 samples (16 NP and 80 PCa).  
It was decided to discuss the results from each potential biomarker in detail in chapter 4 after 
the analysis had been carried out with the larger cohort, rather than discuss the preliminary 
results here and repeat the discussion in the next chapter. 
3.4.3 Conclusion  
The preliminary data presented in this chapter suggests that β- catenin and ABCG2 
expression are reduced in PCa compared to NP and are negatively associated with increasing 
Gleason grade. In contrast, changing the localisation of NDRG1 from membranous to 
nucleocytoplasmic is associated positively with PCa. Three candidate biomarkers showed 
either a negative, such as ABCG2 and ALDH1A1 (stromal) expression, or positive 
association, such as cytoplasmic RS1 expression, with relapse.  No candidate biomarker was 
associated significantly with clinical stage. This interesting preliminary data provided 
support to repeat the staining of these potential biomarkers using a TMA with a much larger 
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4. Assessment of the candidate proteins expression 
in the tissue microarray cohort 
4.1 Introduction 
Having completed a first round of analysis of expression of the candidate biomarkers using 
tissue from the Bath cohort, the next step was to repeat the analysis using a larger cohort of 
samples. One way of efficiently staining large cohorts of tissue is to use a TMA slide. 
A TMA is a high-throughput technique that can be used in histopathological fields to 
evaluate molecular markers in a number of diseases, including cancer, using common 
laboratory methods such as IHC, ISH and fluorescent in situ hybridization  (FISH) (Voduc 
et al., 2008). This technique was first described in 1988 by Kononen (Kononen et al., 1998) 
and there are many scientific and economic benefits, as well as some drawbacks for using 
the TMA technique. First, TMA slides have normally many tissue samples coming from 
different donor samples that were re-embedded in a single microarray block (Jawhar, 2009), 
this is then sectioned, allowing many samples to be analysed on a single slide. Second, the 
use of a tiny core per case reduces the amount of tissue that comes from each block, allowing 
the samples to be used in other TMA slides (Voduc et al., 2008). In addition, all TMA tissues 
samples are on a single slide so are exposed to the same experimental conditions, including 
antigen retrieval, temperature, incubation time, washing and reagent concentration (Jawhar, 
2009; Shergill et al., 2004) and that may reduce technical errors. Finally, the use of this 
technique may have some economic benefits, including low cost and a reduced amount of 
researcher time (Jawhar, 2009; Shergill et al., 2004).  
There are some disadvantages have been noticed from using TMAs in clinical research. The 
use of a tiny core per case may not give a representative description of the whole tissue 
samples (Shergill et al., 2004), especially in heterogeneous diseases such as PCa and for that 
reason a previous comparison between using TMA and a whole section of prostate suggested 
that the optimal number of tissue cores in the TMA which may predict the outcome of the 
whole tissues of PCa is about 3-4 cores (Rubin et al., 2002). However, another PCa study 
with three different sets of TMAs, (1637 PCa cores each ), has reported the use of a single 
0.6 mm core per case sufficient for biomarker evaluation, whereas,  using multiple cores per 
case may give a bias toward marker positivity (Tennstedt et al., 2012). In addition, the tiny 
cores may be lost due to exposure to pretreatment, including antigen retrieval and washing 
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steps. Finally, the slides can lack clinical information which may help to understand the 
outcome of diseases, such as clinical data regarding the relapse and non-relapse status of the 
sample. In general, the advantages of using a TMA appeared to outweigh the disadvantages 
so it was decided to use one for the next stage of this project.  
This study used a commercially available TMA with a large number of prostate tissue 
samples. It contained NP and different grades and stages of PCa. This made it possible to 
test the expression of the candidate biomarkers in a large number of samples and repeat the 
results using a completely independent set of patient samples. One disadvantage of this TMA 
is that it lacks clinical data regarding PCa relapse and non-relapse. This TMA was used to 
examine the potential biomarkers, that have been selected and tested previously in Chapter 
3, and then to analyse the results and test for association with the clinical data and finally 
test the hypothesis proposed in Chapter 3.  
4.1.1 Aims  
1. To detect the expression levels of the potential biomarkers described previously in 
chapter 3 in a large TMA prostate cohort.  
2. To establish if the expression of these potential biomarkers correlates with clinical 
features of PCa, including primary Gleason grade and clinical stage. 
3. Compare to the results from the Bath cohort and test the hypothesis, proposed in 
Chapter 3, regarding the expression of the potential biomarkers in PCa. 
4.2 Results 
In this chapter, the expression of five candidate biomarkers β-catenin, NDRG1, ABCG2, 
ALDH1A1, and RS1 was examined using IHC on the TMA prostate tissues. The structure 
of the TMA cohort and the results for each candidate biomarker are described below. The 
data obtained from the TMA cohort was then compared to that from the Bath cohort and the 
hypothesis, proposed in Chapter 3 that describe their predicted expression in PCa, tested.  
4.2.1 Structure of the TMA cohort 
The TMA slides were obtained from US Biomax and consisted of 96 prostate cases, 80 of 
them were PCa, whereas the rest were normal tissue or normal tissue that was adjacent to 
PCa, termed adjacent normal (8 cases for each). Each prostate case was represented with two 
core tissue biopsies to form a total of 192 cores. The clinical data of the patients are shown 
in Table 4.1. 
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Table 4. 1 Clinical data of the TMA prostate sample cohort.  
The TMA Clinical data  Number  % 







Primary Gleason grade 
 
3 13 16.25 
4 46 57.5 
5 18 23. 75 
ND 3 2.5 
 
Clinical stage 
I 6 7.5 
II 37 46.3 
III 14 17.5 
IV 22 27.5 
ND 1 1.3 
 
T category 
T1-2 51 63.8 
T3-4 28 35 
ND 1 1.2 
 
N category 
N0 65 81.2 
N1 14 17.5 
ND 1 1.3 
 
M category 
M0 64 80 
M1 15 18.7 
ND 1 1.3 
 
4.2.2 β-catenin 
β-catenin IHC was carried out with the TMA prostate tissue samples and, as with the Bath 
cohort, the analysis focused on nuclear and cytoplasmic β-catenin IHC staining. 
4.2.2.1 Immunohistochemical staining of β-catenin in the normal and 
malignant TMA prostate samples 
IHC staining showed membranous, cytoplasmic and nuclear β-catenin staining in the TMA 
prostate tissues (Figure 4.1). Nuclear β-catenin staining was found in NP tissues with a 
variable level of staining, ranging from strong (Figure 4.1 A, arrow), moderate (Figure 4.1 
B, arrow), and weak in some cases (Figure 4.1 C, arrow). Nuclear β-catenin staining was 
also observed in PCa tissues and the intensity of signal varied widely, from strong and 
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widespread (Figure 4.1 D, arrow) to weak and scattered (Figure 4.1 F, arrow) or negative in 
some cases (Figure 4.1 G, arrow).  
In addition to the nuclear staining, the normal and malignant prostate tissue samples had 
cytoplasmic β-catenin staining, with variable staining levels between cases, ranging from 
strong (Figure 4.1. D & E, arrowheads), moderate (Figure 4.1 A, arrowhead) and weak 
(Figure 4.1 B, C, F &G, arrowheads). A negative control (no primary antibody) showed no 
significant background staining in prostate tissue (Figure 4.1 H, arrow). 
4.2.2.2 Association between β-catenin immunostaining and 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, the nuclear and cytoplasmic β-catenin staining was then 
quantified using the H & proportion and intensity 1 scores, respectively, as carried out for 
the Bath cohort samples and then compared between normal vs. malignant prostate tissues, 
primary Gleason grades, clinical stages. The range of nuclear β-catenin and cytoplasmic 
scores varied between 0 - 165 and 2 - 7, respectively (Figure 4.2). The potential association 
between β-catenin IHC results and histopathological parameters of PCa was then analysed 
and is described below.  
The first analysis looked at the β-catenin staining in normal vs. malignant prostate tissues. 
Quantification of the IHC staining showed a significant reduction of nuclear and cytoplasmic 
β-catenin staining in malignant prostate tissues compared to those with a normal nature (p < 
0.0001& 0.0412, respectively) (Figure 4.2 A&B & Table 4.2). Decreased nuclear and 
cytoplasmic β-catenin was also associated with increasing primary Gleason grade (p= 
0.0004, 0.0002 respectively) (Figure 4.2 C&D & Table 4.2). Analysis of data, using the 
multi-comparison Tukey’s tests showed reduced nuclear β-catenin staining significantly 
when comparing PCa tissues with a primary Gleason grade 3 to those with a grade 4  
(p=0.0254) or a grade 5 (p=0.0003). Nuclear β-catenin staining also showed a significant 
difference between primary Gleason grade 5 & 4 (p= 0.0494). Cytoplasmic β-catenin 
staining was decreased significantly in PCa tissues with a primary Gleason grade 5 compared 
to those with a grade 3 (0.0004) or a grade 4 (p= 0.0030), but not between primary Gleason 
grade 3 and 4 (p=0.2284) (Figure 4.2 C&D & Table 4.2). There was no significant difference 
between β-catenin staining (nuclear and cytoplasmic) and clinical stage (TNM) (Table 4.2), 
except nuclear β-catenin staining showed a negative association with PCa metastasis (P= 
0.0014) (Figure 4.2 F & Table 4.2). 
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Figure 4. 1 β-catenin staining in samples from the TMA cohort. β-catenin was stained heterogeneously in 
normal and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and moderate cytoplasmic 
(Black arrowhead) β-catenin staining in NP. (B) Moderate nuclear (Black arrow ) and weak cytoplasmic (Black 
arrowhead) β-catenin staining in NP. (C) Weak nuclear (Black arrow) and cytoplasmic (Black arrowhead) β-
catenin staining in NP. (D) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) β-catenin staining 
in PCa. (E) Strong cytoplasmic β-catenin staining (Black arrowhead) in PCa. (F) Weak nuclear (Black arrow) 
and cytoplasmic (Black arrowhead) β-catenin staining in PCa. (G) Weak cytoplasmic (Black arrowhead) with 
some negative nuclear (Black arrow) β-catenin staining in PCa. (H) Negative control (no primary antibody 
added) showed no background staining (Black arrow)  in PCa. Scale bars=100µm.   
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Figure 4. 2 Quantification of nuclear and cytoplasmic β-catenin staining in both normal and malignant TMA 
prostate tissues. Immunohistochemical β-catenin staining was quantified in the TMA cohort using H and the 
proportion and intensity 1 scores for nuclear and cytoplasmic IHC staining respectively. (A) Nuclear β-catenin 
staining was significantly reduced in PCa compared with NP tissues (p= < 0.0001). (B) A significant reduction 
of cytoplasmic β-catenin staining was in the TMA malignant prostate tissues compared with NP (p= 0.0412). 
(C) Nuclear β-catenin staining showed a significant difference among primary Gleason grades (p= 0.0004). 
Multi comparison Tukey’s tests showed a significant reduction in nuclear β-catenin staining when comparing 
grade 5 tissues to those with a grade 3 (p=0.0004) or grade 4 (p=0.0492). This reduction was significant 
between grade 4 and 3 (p=0.0254). (D) Cytoplasmic β-catenin staining showed a significant difference among 
Gleason grade groups (p= 0.0002). A multi comparison of Tukey’s tests showed that cytoplasmic β-catenin 
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staining was significantly reduced in grade 5 compared to grade 3 (p= 0.0004) or grade 4 (p=0.0030). There 
was no association between cytoplasmic β-catenin staining when comparing Gleason grades 4 and 3 (p= 
0.2284). (E) Nuclear β-catenin staining was not associated with clinical stage M (P=0.2795). (F) Cytoplasmic 
β-catenin staining was negatively associated with metastasis (p=0.0014). Data represent the mean of five 
random images per case. Unpaired or one-way ANOVA tests were conducted to determine the statistical 
difference for each set of conditions. NP (n=16), PCa (n=80), grade 3 (n=13), grade 4 (n=46), grade 5 (n=18), 
M0 (n= 64) and M1 (n=15).  
Table 4. 2 Nuclear and cytoplasmic β-catenin staining results with clinical data. 
 
In summary, nuclear and cytoplasmic β-catenin staining of the TMA samples was reduced 
significantly in PCa and was negatively associated with increasing primary Gleason grade. 
Cytoplasmic β-catenin staining was also negatively associated with metastasis. 
4.2.2.3 β-catenin immunostaining in the Bath and TMA cohorts: testing 
the hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
in Table 4.3. 
Table 4. 3 The summary of β-catenin results in the Bath and TMA cohorts 
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4.2.3 NDRG1 
NDRG1 IHC was carried out with the TMA prostate tissue samples and, as with the Bath 
cohort, the analysis focused on NDRG1 localisation and staining using IHC.  
4.2.3.1 Immunohistochemical localisation and expression of NDRG1 in 
normal and malignant TMA prostate samples 
The IHC result showed membranous NDRG1 staining in the TMA prostate tissue samples 
with variable levels of staining, ranging from strong (4.3 A, red arrowhead), moderate 
(Figure 4.3 B& C, red arrowheads), weak (Figure 4.3 F, red arrowhead) and negative (Figure 
4.3, G).  Cytoplasmic NDRG1 staining was also observed in normal and malignant prostate 
tissues and the intensity of signal varied widely, ranging from strong (Figure 4.3 E, black 
arrowhead), moderate (Figure 4.3 C, D & F, black arrowheads), weak (Figure 4.3 A, B, black 
arrowheads) and negative (Figure 4.3 G). In addition to membranous and cytoplasmic 
staining, normal and malignant prostate tissue had nuclear NDRG1 staining with variable 
levels of staining, ranging from strong (Figure 4.3 D, arrow), moderate (Figure 4.3 B, arrow), 
weak (Figure 4.3 F, arrow) and negative (Figure 4.3, G). A negative control (no primary 
antibody) showed no significant background staining in prostate tissue (Figure 4.3 H, arrow).  
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4.2.3.2 Association between NDRG1 immunostaining and 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, the membranous, cytoplasmic and nuclear localisation of 
NDRG1 staining was then quantified and compared to the histopathological and clinical data 
available for the TMA cohort. Having scored the localisation, the amount of staining was 
then quantified and the potential association between NDRG1 results and histopathological 
parameters of PCa analysed. 
4.2.3.2.1 NDRG1 localisation 
Three different NDRG1localisations were observed in the TMA prostate tissues using IHC, 
including predominant membranous, predominant nucleocytoplasmic and negative. The 
statistical analysis looked first at the NDRG1 localisation in normal vs. malignant prostate 
tissues. Quantification of the IHC staining showed a significant difference between NDRG1 
localisation in normal vs malignant prostate tissues (p= <0.0001). Decreased membranous 
and increased nucleocytoplasmic NDRG1 staining was observed in PCa tissue compared to 
those with a normal nature (Figure 4.4 A). Membranous NDRG1 staining was predominantly 
localised in  69%  of PCa compared to 35% of NP tissues (Figure 4.4 A). In contrast, 
nucleocytoplasmic NDRG1 localisation was found in 61% of PCa compared to  22% of NP. 
In addition, NDRGI localisation showed significantly associated with primary Gleason grade 
(p=0.0021). The frequency distribution tests showed membranous NDRG1 localisation 
negatively associated with increasing primary Gleason grade, whereas, nucleocytoplasmic 




Figure 4. 3 NDRG1 staining in samples from the TMA cohort.  NDRG1 staining was found heterogeneously 
in both normal and malignant tissues of the prostate. (A) Predominant membranous (Red arrowhead) and 
cytoplasmic (Black arrowhead) NDRG1 staining in NP. (B) Moderate nuclear (Black arrow), membranous 
(Red arrowhead) and weak cytoplasmic (Black arrowhead) NDRG1 staining in NP. (C) Moderate membranous 
(red arrowhead) and cytoplasmic (Black arrowhead) NDRG1 staining in PCa. (D)Strong nuclear (Black arrow) 
with moderate cytoplasmic (Black arrowhead) NDRG1 staining in PCa. (E) Strong cytoplasmic (Black 
arrowhead) NDRG1 staining in PCa. (F) Weak nuclear (Black arrow), membranous (Red arrowhead) and 
moderate cytoplasmic (Black arrowhead) NDRG1 staining in PCa. (G) negative staining for NDRG1 (Black 
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arrow) in PCa. (H) The negative control (no primary antibody) showed no staining (Black arrow) in prostate 
tissue. Scale bars=100µm.  
The membranous NDRG1 localisation was found in 80% of primary Gleason grade 3 and a 
quarter of Gleason grade 5 tissues. In contrast, three-quarters of tissues with a Gleason grade 
5 had nucleocytoplasmic NDRG1 localisation, whereas, NDRG1 was found to be 
predominantly nucleocytoplasmic localised in 20% of PCa with a Gleason grade 3 (Figure 
4.4 B). In contrast, there was no significant difference between NDRG1 localisation and 
clinical stage (TNM) (Figure 4.4 C, D&E). 
 
Figure 4.4 Localisation of NDRG1 in TMA prostate samples. Immunohistochemical staining of NDRG1 
localisation was quantified in the TMA group using the localisation 1 score. (A) Predominant membranous 
NDRG1 staining was higher in NP compared to PCa, whereas, predominant nucleocytoplasmic NDRG1 
staining was higher in PCa compared to NP tissues (P= <0.0001). (B) Reduced membranous and increased 
nucleocytoplasmic NDRG1 localisation was positively associated with increasing primary Gleason grade 
(P=0.0021). (C) There was no clear difference between NDRG1 localisation and stage T (P=0.3770). (D) There 
was no clear difference between NDRG1 localisation and stage N (P=8161). (E) There was no clear difference 
between NDRG1 localisation and stage M (P=0.1392). The mean of five random fields was taken per prostate 
sample. Statistical significance was determined with Chi-square and frequency tests for each set of conditions. 
NP (n=16), PCa (n=80), grade 3 (n=13), grade 4 (n=46), grade 5 (n=18), M0 (n= 64) and M1 (n=15).  
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4.2.3.2.2 NDRG1 staining 
Having quantified the localisation, the amount of nuclear and cytoplasmic NDRG1 staining 
was quantified, as carried out for the Bath cohort, and then compared between normal vs. 
malignant prostate, different primary Gleason grades, clinical stages, using the clinical data 
available for the TMA cohort. The range of nuclear and cytoplasmic NDRG1 scores varied 
between 0-7 (Figure 4.5). 
The first analysis looked at the staining of NDRG1 in the TMA prostate tissues. 
Quantification of the IHC showed nuclear NDRG1 staining increased significantly in PCa 
compared to NP tissues (p=0.0002) (Figure 4.5. A & Table 4.4). In contrast, a significant 
reduction for cytoplasmic NDRG1 staining was observed in PCa compared to NP tissues 
(p=<0.0001) (Figure 4.5 B & Table 4.4). There was a significant difference in nuclear 
NDRG1 scores among different primary Gleason grades (p= 0.0226) (Figure 4.5 C & Table 
4.4). Analysis of the IHC, using Tukey’s multiple comparisons tests showed nuclear NDRG1 
staining significantly decreased in PCa tissues with a primary Gleason grade 3 compared to 
those with a grade 4 (p= 0.0395) or a grade 5 (p= 0.0271) (Figure 4.5 C & Table 4.4), but 
not between a Gleason grade 4 and 5 (p= 0.8083) (Figure 4.5 C & Table 4.4). Cytoplasmic 
NDRG1 staining was observed to a trend toward lower in primary Gleason Grade 5, but the 
results were not significant (p= 0.1742) (Figure 4.5 C & Table 4.4).  
In addition, nuclear NDRG1 staining was increased significantly in advanced PCa stage 
compared to localised PCa (T3-4 vs T1-2) and N (N1 vs N0) (p= 0.0214 & 0.0039 
respectively) (Figure 4.6 A &B &  Table 4.4). However, there was no significant association 
between nuclear NDRG1 staining and PCa metastasis (p= 0.1627) (Figure 4.6 C &  Table 









Figure 4. 5 Quantification of nuclear and cytoplasmic NDRG1 staining in both normal and malignant TMA 
prostate tissues. IHC staining of NDRG1 was quantified in the TMA cohort using the proportion and intensity 
1 score for nuclear and cytoplasmic IHC staining. (A) Nuclear NDRG1 staining was significantly increased in 
PCa compared to NP (p= 0.0002). (B) Cytoplasmic NDRG1 staining was significantly decreased in PCa 
compared to NP (P= < 0.0001). (C) NDRG1 nuclear staining showed a significant difference among primary 
Gleason grades (p= 0.0226) and the multicomparisonTukey’s tests showed nuclear NDRG1 staining lower in 
primary Gleason grade 3 compared to grade 4 (p= 0.0395) or grade 5 (p= 0.0271). (B) Cytoplasmic NDRG1 
staining was not associated significantly with primary Gleason score groups (p= 0.01742). Unpaired or one-
way ANOVA tests were conducted to determine the statistical difference for each set of conditions. NP (n=16), 
PCa (n=80), grade 3 (n=13), grade 4 (n=46), grade 5 (n=18). 
Figure 4. 6 Quantification of nuclear NDRG1 staining in PCa stages. Nuclear NDRG1 staining was quantified 
in the TMA group using the proportion and intensity 1 score. (A) Nuclear NDRG1 staining was significantly 
increased in the advanced stages (T3-4) compared to localised PCa (T1-2) (p= 0.0214). (B) Nuclear NDRG1 
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staining was significantly associated with lymph node status (p= 0.0039). (C) Nuclear NDRG1 was not 
associated significantly with metastasis (P= 0.1627). Unpaired tests were conducted to determine the statistical 
difference for each set of conditions. T1-2 (n=51), T3-4 (n=28), N0 (n= 65), N1 (n= 14), M0 (n= 64) and M1 
(n=15). 
Table 4. 4 Nuclear and cytoplasmic NDRG1 staining results with clinical data 
  
In summary, membranous NDRG1 localisation was lower in PCa compared to NP tissues, 
whereas nucleocytoplasmic localisation was higher. Reduction of membranous and 
increased nucleocytoplasmic NDRG1 staining was positively associated with increasing 
primary Gleason grade, but not with clinical stage. In addition, nuclear NDRG1 staining was 
increased in PCa and was positively associated with increasing primary Gleason grade and 
clinical stage. In contrast, cytoplasmic NDRG1 staining was decreased significantly in PCa 
compared to NP, but not associated with other PCa clinical features.  
4.2.3.3 NDRG1 localisation in the Bath and TMA cohorts: testing the 
hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
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Table 4. 5 The summary of NDRG1 results in the Bath and TMA cohorts. 



















































































































































ABCG2 IHC was carried out with the TMA prostate tissue samples and, as with the Bath 
cohort, the analysis focused on nuclear and cytoplasmic ABCG2 IHC staining. 
4.2.4.1 Immunohistochemical staining of ABCG2 in the normal and 
malignant TMA prostate samples 
Nuclear ABCG2 staining was observed in NP tissues and ranged from strong (Figure 4.7 A, 
arrow) to weak staining or negative (Figure 4.7 B, arrow). Nuclear ABCG2 staining was also 
found in malignant prostate tissues and the intensity of signal varied widely, ranging from 
strong (Figure 4.7 C, arrow), moderate (Figure 4.7 D, arrow), weak (Figure 4.7 E, arrow) 
and negative (Figure 4.7 F&G, arrows). This nuclear staining is not expected for a 
transmembrane protein, as discussed in chapter 3. 
In addition to the nuclear staining, the normal and malignant prostate tissue samples had 
cytoplasmic ABCG2 staining, with a variable level of staining between cases, ranging from 
strong (Figure 4.7 A, arrowhead), moderate ( Figure 4.7 C, D& E, arrowheads), weak (Figure 
4.7 B & F, arrowhead), and negative (Figure 4.7 G, arrow). A negative control (no primary 
antibody) showed no significant background staining in prostate tissue (Figure 4.7 H, arrow).  
4.2.4.2 Association between ABCG2 immunohistochemistry and 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, the nuclear and cytoplasmic ABCG2 staining was 
quantified using the proportion and intensity 1 score, as carried out for the Bath cohort 
samples and then compared between normal vs. malignant prostate tissue, primary Gleason 
grade, clinical stage. The range of nuclear and cytoplasmic ABCG2 scores varied between 
0 to 4 and 0 to 7, respectively (Figure 4.8).   
The potential association between ABCG2 IHC results and histopathological parameters of 
PCa was then analysed and is described below. The first analysis looked at the association 
between nuclear and cytoplasmic ABCG2 staining in normal vs. malignant prostate tissues. 
The IHC quantification showed nuclear ABCG2 staining not associated significantly with  
PCa and other histopathological parameters, including Gleason grade and clinical stage  
(Figure 4.8 A, C & Table 4.6). 
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Figure 4. 7 ABCG2 staining in samples from the TMA cohort. ABCG2 was stained heterogeneously in both 
normal and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and cytoplasmic (Black 
arrowhead) ABCG2 staining in NP. (B) Weak cytoplasmic (Black arrowhead) and negative nuclear (Black 
arrow) ABCG2 staining in NP. (C)  Strong nuclear (Black arrow ) and moderate cytoplasmic (Black arrowhead) 
ABCG2 staining in PCa. (D) Moderate nuclear (Black arrow) and cytoplasmic (Black arrowhead) ABCG2 
staining in PCa. (E) Weak nuclear  (Black arrow) and moderate cytoplasmic (Black arrowhead) ABCG2  in 
PCa. (F) Weak cytoplasmic (Black arrowhead) and negative nuclear (Black arrow) ABCG2 staining in PCa. 
(G) No significant staining for ABCG2 (Black arrow) in PCa. (H) Negative control (no primary antibody 
added) showed no background staining (Black arrow) in PCa. Scale bars=100µm.   
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In contrast, cytoplasmic ABCG2 staining was significantly reduced in PCa compared to NP 
tissues (p= < 0.0001) (Figure 4.8 B & Table 4.6). There was a significant difference between 
cytoplasmic ABCG2 and primary Gleason grade (p= 0.0004) (Figure 4.8 D & Table 4.6). 
Analysis of IHC data using Tukey’s multicomparison tests showed cytoplasmic ABCG2 
staining significantly decreased in primary Gleason grade 5 tissues compared to those with 
a grade 4 (0.0387) or grade 3 (p= 0.0003), and also decreased significantly when comparing 
between PCa tissues with a grade 4 & 3 (p= 0.0.364) (Figure 4.17 D & Table 4.6). 
Cytoplasmic ABCGE staining was not associated significantly with clinical stage TNM 
(Table 4.6).  
Figure 4. 8 Quantification of nuclear and cytoplasmic ABCG2 staining in the glandular region of normal and 
malignant TMA prostate tissues. Immunohistochemical staining of ABCG2 was quantified in TMA group 
using the proportion and intensity 1 score for nuclear and cytoplasmic staining. (A) Nuclear ABCG2 staining 
showed no significant difference between normal and malignant prostate tissues (p= 0.9141). (B) Cytoplasmic 
ABCG2 staining was significantly decreased in PCa compared with NP tissues (p=<0.0001). (C) Nuclear 
ABCG2 nuclear staining was not associated with primary Gleason grade (p= 0.6933).  (B) Cytoplasmic 
ABCG2 staining showed a significant difference among primary Gleason grades (p= 0.0004).  Cytoplasmic 
ABCG2 staining was decreased in Gleason grade 5 compared to grade 4 (p= 0.0387) or grade 3 (p= 0.0003), 
and also a significant reduction when comparing between grade 4 and 3 (p= 0.0364). Unpaired or one-way 
ANOVA tests were conducted to determine the statistical difference for each set of conditions. NP (n=16), PCa 
(n=80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18).  
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Table 4. 6 ABCG2 staining results with clinical data. 
 
In summary, nuclear ABCG2  staining was not associated significantly with PCa and other 
histopathological parameters. This is consistent with the expectation that it should not be in 
the nucleus and this staining is likely to be background.  In contrast, cytoplasmic ABCG2 
staining was decreased significantly in PCa compared to NP and was negatively associated 
with increasing primary Gleason grade, but not associated with clinical stage TNM.  
4.2.4.3 ABCG2 immunostaining in the Bath and TMA cohorts: testing the 
hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
in Table 4.7. 
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4.2.5 ALDH1A1  
ALDH1A1 IHC was carried out with the TMA prostate tissue samples and, as with the Bath 
cohort, the analysis focused on glandular and stromal ALDH1A1 IHC staining. 
4.2.5.1 Immunohistochemical staining of ALDH1A1 in normal and 
malignant TMA prostate samples 
ALDH1A1 staining was observed in the glandular and stromal regions of the TMA prostate 
tissues. Nuclear ALDH1A1 staining was expressed in the glandular regions of the normal 
and malignant prostate tissues with different levels of staining patterns, ranging from strong 
(Figure 4.9 B&E arrows) to weak (Figure 4.9 D, arrow) or negative (Figure 4.9 A& G, 
arrows). Cytoplasmic ALDH1A1 staining was also shown in the glandular regions of normal 
and malignant prostate tissues, ranging from strong (Figure 4.9 F, arrowhead) to weak 
(Figure 4.9 E, arrowhead) or negative (Figure 4.9 G). Interestingly, nuclear and cytoplasmic 
ALDH1A1 staining was found to be restricted in the basal cells of NP, whereas, it was found 
to be expressed in all PCa epithelial cells, which are mainly luminal, with only a few residual 
basal cells. 
In addition to the glandular ALDH1A1 (nuclear and cytoplasmic) staining, the normal and 
malignant tissue samples had stromal ALDH1A1 staining, with different staining levels, 
ranging from strong (Figure 4.9 A & C, arrowheads) to weak (Figure 4.9 G, arrowheads). 






Figure 4. 9 ALDH1A1 was stained heterogeneously in both normal and malignant tissues of the prostate.  (A) 
ALDH1A1 was stained in the stromal region (arrowhead ), but not in the glandular region (arrow) of NP. (B) 
Nuclear AlDH1A1 staining (Black arrow) in the basal cells of NP. (C) Strong stromal (Black arrowhead) with 
negative glandular ALDH1A1staining in PCa. (D) Weak nuclear ALDHIA1 staining (Black arrow) in the 
Glandular region of PCa. (E) Strong nuclear (Black arrow) with weak cytoplasmic (Black arrowhead) 
ALDH1A1 staining in the glandular region of PCa. (F) Strong cytoplasmic ALDH1A1 staining (Black 
arrowhead) in the glandular region of PCa. (G ) Negative ALDH1A1 staining ( Black arrow) with weak stromal 
staining in PCa. (H) The negative control (no primary antibody) showed no staining (Black arrow) in PCa 
tissue. Scale bars=100µm.  
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4.2.5.2 Association between ALDH1A1 immunostaining with 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, nuclear and cytoplasmic ALDH1A1 staining was then 
quantified using the proportion and intensity 3 scores, whereas stromal proportion and 
intensity ALDH1A1  staining were quantified using the proportion 1 and intensity 1 
respectively, as carried out for the Bath cohort samples. The range of nuclear and 
cytoplasmic and proportion and intensity stromal ALDH1A1 staining varied between 0-6, 
0-6, 0-3, and 0-3 respectively (Figure 4.10).  The potential association between ALDH1A1 
IHC and histopathological parameters of PCa was then analysed and is described below.  
The statistical analysis looked at the ALDH1A1 staining in normal vs. malignant prostate 
tissues from the TMA cohort. Nuclear ALDH1A1 staining was expressed in 60% of NP and 
41% of PCa tissues and the IHC analysis showed nuclear ALDH1A1 significantly increased 
significantly in PCa compared to NP tissues (p= 0.0451) (Figure 4.10 A & Table 4.8).  
Cytoplasmic ALDH1A1 staining was also observed in 25% of normal and 41% of malignant 
prostate tissues. Statistically, there was a significant increase in cytoplasmic ALDH1A1 
scores in PCa compared to NP tissues (p= 0.0198) (Figure 4.10 B & Table 4.9). There was 
no significant association between stromal proportion and intensity ALDH1A1 staining in 
normal vs. malignant prostate tissues (p= 0.6832 & 0.4775 respectively) (Table 4.9). Both 
glandular and stromal ALDH1A1 staining was not associated significantly with primary 
Gleason grade (Tables 4.8 & 4.9).   
The statistical analysis showed nuclear and cytoplasmic ALDH1A1 staining significantly 
increased in advanced stage T (T3-4) compared to localised PCa stage T (T1-2) (P= 
0.0011&0.0201 respectively) (Figure 4.10 C&D & Table 4.8). In contrast, nuclear and 
cytoplasmic ALDH1A1 showed no significant difference between N (N0 vs N1) (p= 0.2337 
& 0.9157 respectively) and M (M0 vs M1) (p= 0.0566 & 0.4646 respectively) (Table 4.8). 
There was also no significant association between Stromal ALDH1A1 staining and clinical 
stage TNM (Table 4.9).  
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Figure 4. 10 Quantification of nuclear and cytoplasmic ALDH1A1 staining in the glandular region of normal 
and malignant TMA prostate tissues. IHC staining of ALDH1A1 was quantified in the TMA group using the 
proportion and intensity 3 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear ALDH1A1 staining 
was significantly increased in PCa compared with NP tissues (P= 0.0451). (B) Cytoplasmic ALDH1A1 staining 
was significantly increased in PCa compared with NP tissues (p= 0.0198). (C) Nuclear ALDH1A1 staining 
was significantly increased in advanced prostate cancer stages T (T3-4) compared to localised PCa T (T1-2) 
(p= 0.0011). (B) Cytoplasmic ALDH1A1 staining was also significantly increased in advanced PCa stages T 
(T3-4) compared to localised PCa T (T1-2) (p= 0.0201). Unpaired t-tests were conducted to determine the 
statistical difference for each set of conditions. NP (n=16), PCa (n=80), T1-2 (n=51) and T3-4 (n=28).  
Table 4. 8 Nuclear and cytoplasmic ALDH1A1 staining results with clinical data 
Comparison 
Nuclear ALDH1A1 staining Cytoplasmic ALDH1A1 staining 
 






















Anova test 0.5533 
Grade 4vs. 
Grade 3 
0.9373 Grade 4vs. 
Grade 3 
0.9598 
Grade 5 vs. 
Grade 3 






Table 4. 9 Stromal ALDH1A1 proportion and intensity staining results with clinical data. 
 
In summary, nuclear and cytoplasmic ALDH1A1 staining was increased significantly in PCa 
compared to NP tissues and was positively associated with advanced PCa stages  T (T3-T4 
vs T1-T2), but not with primary Gleason grade or other clinical stages (M&N). Stromal 
ALDH1A1 staining (proportion and intensity) was also not associated with PCa or other 
parameters such as primary Gleason grade and stage.  
4.2.5.3 ALDH1A1 immunostaining in the Bath and TMA cohorts: testing 
the hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
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Grade 4 













No statistically significant 
difference 
0.0566 





No statistically significant 
difference 
0.2337 




ALDH1A1 stromal proportion 
staining 
ALDH1A1 stromal intensity   staining 
 


































Grade 5 vs. 
Grade 3 
0.115 
Grade 5 vs. 
Grade 3 
0.0762 
Grade 5 vs. 
Grade 4 
0.7338 
































Table 4. 10 The summary of ALDH1A1 results in the Bath and TMA cohorts. 



































































































































































































































Not tested N/A N/A 
 
4.2.6 RS1 
RS1 IHC was carried out with the TMA prostate tissue samples and, as with the Bath cohort, 
the analysis focused on nuclear and cytoplasmic RS1 IHC staining. 
4.2.6.1 Immunohistochemical staining of RS1 in the normal and malignant 
TMA prostate samples 
The IHC showed nuclear and cytoplasmic staining for RS1 in the TMA prostate tissues. In 
NP tissues, nuclear RS1 staining was found and ranged from strong (Figure 4.11 A, arrow) 
to weak (Figure 4.11 B, arrow). Nuclear RS1 staining was also observed in PCa tissues and 
the intensity of signal varied widely, from strong (Figure 4.11 C, arrow), moderate (Figure 
4.11 D, arrow), weak and widespread (Figure 4.11 E, arrow) & negative in some cases 
(Figure 4.11 G, arrow).  
In addition to the nuclear staining, the normal and malignant prostate tissues had cytoplasmic 
RS1 staining, with a variable level of staining between cases, ranging from strong (Figure 
4.11 A, B & C, arrowheads), moderate (Figure 4.11 D, arrowhead) and weak (Figure 4.11 
G, arrowheads). A negative control (no primary antibody) showed no significant background 




Figure 4. 11 RS1 staining in samples from the TMA cohort. RS1 was stained heterogeneously in both normal 
and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) 
RS1 staining in NP. (B) Weak nuclear (Black arrow) and strong cytoplasmic (Black arrowhead) RS1 staining 
in NP. (C) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) RS1 staining in PCa. (D) Moderate 
nuclear (Black arrow) and cytoplasmic (Black arrowhead) RS1 staining in PCa. (E) Weak nuclear (Black 
arrow) RS1 in PCa. (F) Weak cytoplasmic (Black arrowhead) and negative nuclear RS1 staining in PCa. (G) 
Negative nuclear (Black arrow) with weak cytoplasmic (Black arrowhead) RS1 staining in PCa. (H) Negative 
control (no primary antibody added) showed no background staining (Black arrow) in PCa. Scale bars=100µm.   
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4.2.6.2    Association between RS1 immunostaining and histopathological 
parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, nuclear and cytoplasmic RS1 staining was then quantified 
using the proportion and intensity scoring 1 and then compared to histopathological 
parameters of PCa using the clinical data available for the TMA cohorts. The scoring system 
for RS1 here is different from the RS1 scoring system used in Chapter 3 because the H score 
system requires a long time to finish and the signal may be background as a secreted protein 
RS1 would not be expected to be in the nucleus. For these reasons, our collaborating 
histopathologist (Dr John Mitchard) suggested using a proportion and intensity score instead 
(See Chapter 2.3.2). Cytoplasmic staining was also quantified using the same proportion and 
intensity scoring system. The range of nuclear and cytoplasmic RS1 scores varied between 
0-7 (Figure 4.12). The potential association between RS1 IHC results and histopathological 
parameters of PCa was then analysed and is described below. 
The first analysis looked at the RS staining in normal vs. malignant prostate tissues. 
Quantification of the IHC showed no significant difference between nuclear RS1 staining in 
normal vs. malignant prostate tissues (p=0.4453) (Figure 4.12 A& Table 4.11). In contrast, 
cytoplasmic RS1 staining was reduced significantly in PCa compared to NP tissues (p= 
0.0088) ( Figure 4.12 B& Table 4.11). Nuclear RS1 staining showed a significant difference 
among primary Gleason grades (p=0.0277) (Figure 4.12 C &Table 4.11). Analysis of the 
IHC data using Tukey’s multicomparison tests showed  nuclear RS1 staining increased 
significantly in primary Gleason grade 5 tissues  compared to those with a  grade 3 (p= 
0.021) (Figure 4.12 A & Table 4.11), whereas, there was no significant difference between 
nuclear RS1 scores when comparing a primary Gleason grade 4 to grade 3 (p= 0.2184) or 
grade 5 (p=0.2242) (Figure 4.12 & Table 4.11). Cytoplasmic RS1 showed no significant 
difference between primary Gleason grade groups (p=0.4295) (Figure 4.12 D & Table 4.11). 
Nuclear RS1 staining was not associated significantly with the clinical stage (TNM) (Figure 
4.12 & Table 4.11). Cytoplasmic RS1 was also associated significantly with lymph node 
status (N1 vs N0) (P=0.004) (Figure 4.12& Table 4.11), but not with stage T (T1-2 vs T3-4) 





Figure 4. 12 Quantification of nuclear and cytoplasmic RS1 staining in both normal and malignant prostate 
tissues.  Immunohistochemical staining was quantified in the TMA cohort using the proportion and intensity 1 
score. (A) Nuclear RS1 showed no significant difference between normal and malignant prostate tissues (p= 
0.4453). (B) Cytoplasmic RS1 staining was decreased significantly in PCa compared to NP tissues (p=0.0088). 
(C) Nuclear RS1 showed a significant difference among primary Gleason grade groups (p= 0.0277). Tukey’s 
multicomparison test showed that nuclear RS1 was significantly associated with increasing primary Gleason 
grade. (D) Cytoplasmic RS1 staining was not associated with primary Gleason score (p=0.0646). (E) Nuclear 
ALDH1A1 staining showed no significant difference with stage T (T1-2 ns T3-4) (p= 0.03669). (F) 
Cytoplasmic RS1 staining was decreased significantly in stage NI compared to N0 cases (p= 0.0004). Unpaired 
or one-way ANOVA tests were conducted to determine the statistical difference for each set of conditions.NP 
(n=16), PCa (n=80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18), N0 (n= 65) and N1 (n=14). 
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 Table 4. 11 RS1 staining results with clinical data. 
 
In summary, nuclear RS1 staining showed no significant association between normal vs 
malignant prostate or different primary Gleason grade and stage. In contrast,  cytoplasmic 
RS1 staining was reduced significantly in PCa compared to NP tissues and was negatively 
associated with lymph node status, but not with primary Gleason grade and clinical stage  
T&M.  
4.2.6.3 RS1 immunostaining in the Bath and TMA cohorts: testing the 
hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
in Table 4.12. 
Table 4. 12 The summary of RS1 results in the Bath and TMA cohorts. 











































Rs1 nuclear staining Rs1 cytoplasmic staining 
 
Results p. value Results p. value 
 
Normal vs malignant 
No statistically significant 
difference 
0. 4453 





















Grade 5 vs. 
Grade 3 
0.021 
Grade 5 vs. 
Grade 3 
0.7406 
Grade 5 vs. 
Grade 4 
0.2242 




No statistically significant 
difference 
0.3669 




No statistically significant 
difference 
0.8995 




No statistically significant 
difference 
0.0568 Lower in N1 0.0004 
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Nuclear N/A No 
significant 
difference 
Not tested N/A N/A 





Not tested N/A NO 
 
4.3 Discussion  
4.3.1 Summary of the confirmed results 
Results presented in this chapter quantify the IHC staining levels of five candidate 
biomarkers, β-catenin, NDRG1, ABCG2, ALDH1A1 and RS1 in normal vs. malignant 
prostate tissue, different primary Gleason grades and stages. Previous work presented in 
Chapter 3 looked at the expression of the same makers in an independent cohort of patients, 
the Bath cohort. Patterns of expression were accepted as having been confirmed if they were 
found in both cohorts of patients or were shown in the larger TMA cohort and in the Bath 
cohort as not significant, but have some trend. These results are summarised in Table 4.13. 
In this discussion, I will consider how the staining patterns of these candidate biomarkers 
compare to previous reports and then describe what the patterns of expression suggest about 







Table 4. 13 Confirmed patterns of expression for the candidate biomarkers. 
Biomarkers Confirmed patterns of expression  
β -catenin  Nuclear and cytoplasmic β -catenin staining was decreased in PCa and was negatively 





 The frequency of membranous localisation was reduced in PCa and was negatively 
associated with increasing primary Gleason grade. In contrast, nucleocytoplasmic 
localisation was increased in PCa and high Gleason grade, but not stage and relapse.  
  Cytoplasmic   NDRG1 staining was reduced in PCa, but not with grade, stage and relapse. 
 Nuclear NDRG1 staining increased in PCa and was positively associated with increasing 
grade and stages, but not with relapse.  
ABCG2 
 
 Cytoplasmic ABCG2 staining was reduced in PCa and was negatively associated with 
primary Gleason grade and relapse, but not with the stage. 
 
ALDH1A1 
 Nuclear and cytoplasmic ALDH1A1 staining was increased in PCa and was positively 
associated with stage T (T1-2 vs T3-4).  
 Stromal ALDH1A1 staining was negatively associated with relapse but not normal vs 
malignant, grades and stages.   
RS1  Changes in nuclear and cytoplasmic RS1 staining was not associated with clinical 
features of PCa.  
 
4.3.2 β-catenin is decreased significantly in prostate cancer and 
is negatively associated with increasing primary Gleason grades 
Previous studies have reported contradictory β-catenin results in prostate tissue samples. In 
the current study, a reduction of nuclear β-catenin staining was observed in PCa compared 
to NP tissues from both cohorts. This data is supported by previous studies with a large 
cohort (Horvath et al., 2005; Whitaker et al., 2008), but was inconsistent with Ipekci, et al 
data which is reported increased nuclear β-catenin staining in PCa compared to BPH (Ipekci 
et al., 2015). In addition, cytoplasmic β-catenin staining was decreased in PCa compared to 
NP tissues, but this reduction was not significant, perhaps due to the small sample size of 
this cohort. The cytoplasmic data was consistent with a previous finding (Ipekci et al., 2015), 
but was not supported by other previous literature (Chen et al., 2004; Horvath et al., 2005). 
The different outcome of the literature may become due to using different antibodies and/or 
different scoring systems. Taken together, the results suggest that loss β-catenin (nuclear and 
cytoplasmic) might be an early event in PCa formation. 
Nuclear and cytoplasmic β-catenin staining was negatively associated with increasing 
primary Gleason grade in both cohorts. This data largely agreed with the previous findings 
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(Aaltomaa et al., 2005; Jaggi et al., 2005; Kallakury et al., 2001b; Whitaker et al., 2008). In 
contrast, this was not supported by other data (Horvath et al., 2005; Ipekci et al., 2015) which 
showed no significant association between β-catenin staining and Gleason grade. The use of 
different scoring systems may explain this difference. The nuclear data is not supported by 
Jaggi et al. study which demonstrated increased nuclear β-catenin localisation with 
increasing Gleason grade (Jaggi et al., 2005). However, Jaggi et al. study had a  small 
number of PCa cases (17 ) as well as used a different scoring system. Taken together, our 
results and previous studies suggest that β-catenin may play a role in PCa progression and 
downregulation of β-catenin may be considered to be a worse indicator for PCa 
aggressiveness.  
In this study, nuclear and cytoplasmic β-catenin staining was not associated with clinical 
stage except that there was a negative association between cytoplasmic staining and PCa 
metastasis in the TMA cohort. The association between cytoplasmic β-catenin and 
metastasis was consistent with (Horvath et al., 2005; Jaggi et al., 2005), but inconsistent 
with other previous studies (Aaltomaa et al., 2005; Ipekci et al., 2015). In summary, some 
of the current data suggest that β-catenin reduction may play a role in metastasis, while other 
studies contradict this conclusion.  
There was also no association between β-catenin staining and risk of biochemical recurrence 
in the Bath cohort data. This was consistent with some previous reports (Kallakury et al., 
2001b; Jaggi et al., 2005; Whitaker et al., 2008), but inconsistent with the Horvath et al  
report that found PCa patients with  less than 10% positive nuclear β-catenin staining had 
decreased biochemical relapse-free survival (Horvath et al., 2005). Therefore, the majority 
of evidence suggests there is not an association between β-catenin staining and risk of 
biochemical recurrence.   
Previous studies have proposed different functional roles for β-catenin in cancer, including 
PCa (Miyabayashi et al., 2007; Miki et al., 2011). However, this section will focus on a 
couple of possible mechanisms for β-catenin which would be consistent with its role in PCa 
based on the expression data described above. Increased β-catenin levels can induce 
apoptosis in both normal and malignant cells independently of TCF transcriptional activity 
and/ or cell cycle/apoptosis regulators, including p53 and transcription factor E2F1( 
alternatively named retinoblastoma-associated protein 1 or retinoblastoma-binding protein 
3) (Kim et al., 2000), suggesting that β-catenin might interact with other proteins through a 
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potential death domain to induce apoptosis. Decreased β-catenin might then protect cells 
from apoptosis. Other studies have reported that β-catenin can bind to the transcription factor 
TCF/LEF, which is located in the nucleus,  and/or p300 (Histone acetyltransferase p300) to 
form a β-catenin/TCF/ P300 complex which plays a role to induce differentiation (Miki et 
al., 2011; Miyabayashi et al., 2007), suggesting reduction of β-catenin in cells may lead to 
reduced differentiation and promotion of PCa.  
Taken together, it appears that reduced β-catenin signalling is involved in PCa tumorigenesis 
and decreased β-catenin levels may be a promising marker of a worse prognosis in localised 
PCa. However, further study is needed to confirm the staining patterns of β-catenin in 
prostate tissue samples, using either a second independent antibody and/or mRNA probe 
(RNAscope®) which can detect the mRNA level in prostate tissues from both cohorts. 
Finally, it will be very interesting to address the functional role of β-catenin in PCa formation 
and progression, using tissue culture (see Chapter 8 for more details). 
4.3.3 Nuclear NDRG1 is increased in prostate cancer and is 
positively associated with increasing grade and stage, while 
membranous and cytoplasmic NDRG1 staining is decreased in 
prostate cancer 
There are a number of studies focused on either NDRG1 localisation or staining in normal 
and malignant prostate. However, these studies come with contradictory results. IHC results 
in both cohorts showed that decreased membranous localisation of NDRG1 was observed in 
PCa compared to NP and was positively associated with increasing primary Gleason grade, 
but not with stage and replace. In contrast, nucleocytoplasmic localisation was increased 
significantly in PCa and was positively associated with increasing primary Gleason grade, 
but not with stage and relapse. The association between  NDRG1 localisation and Gleason 
grade in the Bath cohort was not significant, which may be because of the small sample size. 
However, this data is consistent with the previous findings (Caruso et al., 2004; Song et al., 
2010; Symes et al., 2013), suggesting that the change in NDRG1 localisation might play a 
role in PCa formation and differentiation. 
In addition, this study is the first to quantify nuclear NDRG1 staining and shows an 
association between nuclear NDRG1 staining in normal vs malignant, different primary 
Gleason grades, clinical stages and relapse. The IHC data from the TMA cohort shows that 
nuclear NDRG1 staining was increased significantly in PCa compared to NP tissues and was 
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positively associated with increasing primary Gleason grade and clinical stage. However, 
the nuclear NDRG1 staining in the Bath cohort was not significant, perhaps due to the small 
sample size in this cohort. However, our data was supported by Song et al. who reported that 
nuclear NDRG1 expression was increased in colorectal carcinoma compared to normal 
tissues (Song et al., 2013) as well by Hosoya et al. who reported increased nuclear NDRG1 
was positively associated with grade and stage of renal cell carcinoma (Hosoya et al., 2013), 
suggesting that increased nuclear NDRG1 expression plays an important role in PCa 
formation and progression and could be a predictive marker for a poor prognosis.  
Cytoplasmic NDRG1 staining was decreased in malignant prostate tissues compared to NP 
tissues from the TMA cohort, but not the Bath cohort. This result was largely agreed with a 
previous finding (Li et al., 2015b), suggesting that reduction cytoplasmic NDRG1 staining 
might play a role in PCa formation. However, this data was contradictory with (Symes et al., 
2013; Song et al., 2010). Cytoplasmic NDRG1 staining was not associated significantly with 
primary Gleason grade, stage and relapse. This data is consistent with a previous prostate 
report (Symes et al., 2013), but not with the other data (Bandyopadhyay et al., 2003; Song 
et al., 2010). This difference between the literature could be because of the sample size, the 
use of different antibodies and/or the use of different methods. Taken together, a reduction 
in cytoplasmic NDRG1 level, in addition to the increase in nuclear NDRG1 described above, 
could play a role in PCa formation and progression. 
What role might NDRG1 play in cancer formation?  Previous studies have been found either 
an oncogenic or tumour suppressor role of NDRG1 in cancer.  However, the majority of the 
studies have reported a tumour suppressor role, including for PCa (Bae et al., 2013; Song et 
al., 2010). There are many different possible mechanisms to explain this role in cancer. First, 
NDRG1 upregulates frequently rearranged in advanced T cell protein (FRAT1) which plays 
an important role in preventing binding of Glycogen synthase kinase 3 beta (GSK3B) with 
the distraction complex, that subsequently prevents phosphorylation of β-catenin and then 
prevents nuclear translocation of phosphorylated β-catenin (Jin et al., 2014). This study also 
found that blocking nuclear β-catenin translocation may occur through NDRG1’s role to 
inactivate P21- activated kinase 4 (PAK4) protein, which plays a transporter role for β-
catenin. Therefore, loss of cytoplasmic NDRG1 could increase Wnt signalling (Jin et al., 
2014), which is consistent with the β-catenin data described above. In addition, a previous 
study found that increased NDRG1 in pancreatic cancer cell lines inhibits PI3K and Ras 
signalling pathways through increasing PTEN and SMAD4 which inhibit tumour 
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progression (Kovacevic et al., 2013), providing another mechanism to explain its tumour 
suppressor role. 
In addition to a tumour suppressor role, previous literature has reported an oncogenic role 
for NDRG1. Increased NDRG1 may promote the growth of tumours through its role in 
promoting metastasis and angiogenesis, as well as protecting cells from apoptosis (Wei et 
al., 2013). A study done by Ai et al reported that increased NDRG1 expression may promote 
oesophagal squamous cell carcinoma progression through modulating Wnt signalling 
pathway by affecting transducin-like enhancer of split 2 (TLE2) and β-catenin (Ai et al., 
2016). This is confirmed by our data which found a moderate negative correlation between 
nuclear staining of β-catenin and nuclear NDRG1 (R=-0.56) (data are not shown), suggesting 
that increased nuclear NDRG1 reduces nuclear β-catenin levels. In colorectal carcinoma, 
NDRG1 translocation from the membrane to the nucleus of cells may play a role in lymph 
node metastasis by regulation of E-Cadherin expression (Song et al., 2013). This is 
confirmed by our data which found increased nuclear NDRG1 significantly associated with 
lymph node metastasis in the TMA cohort.    
Taken together, this study suggests that decreased membranous and cytoplasmic NDRG1 
levels in PCa cells may downregulate  PTEN and activate  PI3K signalling pathways which 
lead to increased proliferation and inhibit apoptosis. Whereas increased nuclear localisation 
of NDRG1 may lead to a decrease in nuclear β-catenin transcriptional activity, however, this 
is complicated as a reduction in cytoplasmic may have the opposite effect. The change of  
NDRG1 localisation and/or increased nuclear NDRG1 level could be a poor indicator for 
PCa prognosis and it could be a useful prognostic biomarker for PCa. Further studies are 
needed to confirm the staining patterns of NDRG1 using either IHC with a second 
independent antibody or RNAscope to detect the mRNA level of NRGG1 in prostate tissue 
from both cohorts. In addition,  It would be very interesting to be to use a large cohort with 
clinical data about a risk of relapse to confirm if there is an association between NDRG1 
staining and biochemical relapse. Future research is also needed to determine if there is an 
association between NDRG1 localisation and PTEN level in PCa. Finally, it would also be 
interesting to investigate NDRG1 functional roles in PCa using an in vitro cell culture 
approach (see final discussion for more details).  
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 4.3.4 Cytoplasmic ABCG2 expression is reduced in prostate 
cancer and is negatively associated with increasing Gleason 
grades and relapse  
Cytoplasmic ABCG2 staining was reduced significantly in PCa compared to NP tissues. 
This data was supported by the literature (Thompson et al., 2008) and taken together suggests 
that decreased cytoplasmic ABCG2 may play an important role in PCa formation. However, 
this data disagrees with the previous ABCG2 mRNA data that showed there was no 
significant association in ABCG2 mRNA level between normal and malignant using real-
time PCR (Guzel et al., 2014), suggesting there might be differences between mRNA and 
protein expression. It might also be that the difference is caused by using different methods 
for detection. Cytoplasmic ABCG2 staining was significantly reduced with increasing 
primary Gleason grade. This data is supported by Castellon et al data who reported that PCa 
tissues with a medium Gleason grade showed increased ABCG2 staining compared to those 
with a high Gleason grade (Castellon et al., 2012). Cytoplasmic ABCG2 staining was not 
associated with clinical stage, which is consistent with a previous finding on breast cancer 
(Xiang et al., 2011). Data from the Bath cohort showed a significant reduction of 
cytoplasmic ABCG2 staining in relapsed tissues compared to those with non-relapsed, 
suggesting ABCG2 may play a role to prevent PCa relapse. This result is also contradictory 
with previous ABCG2 mRNA data (Guzel et al., 2014; Pfeiffer et al., 2011).  
This study showed nuclear ABCG2 staining in prostate samples for the first time. The 
statistical analysis showed that there was no significant difference between nuclear ABCG2 
staining when comparing NP tissues to those with malignancies. The Bath data shows that 
there was a positive association between nuclear ABCG2 staining and Gleason grade or 
clinical stage, but not with relapse. In contrast, the TMA data shows that nuclear ABCG2 
was not associated with primary Gleason grade and clinical stage. ABCG2 as a 
transmembranous transporter protein is not expected to be expressed in the nuclei of cells, 
but two different studies have reported the nuclear localisation of ABCG2 in glioblastoma 
multiform cells (Bhatia et al., 2012) and lung cancer cells (Liang et al., 2015) using different 
IHC and immunofluorescence. This might suggest a role for ABCG2 in the nucleus, but 
another possibility is that the nuclear ABCG2 staining is non-specific. Further study is 
needed to confirm if there is nuclear localisation of ABCG2 in prostate tissues.   
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Previous studies have proposed different roles for ABCG2 in human tissues, including 
cancer. The ABC transporter superfamily proteins use ATP hydrolysis to transport different 
molecules through the plasma membrane, including drugs (Fetsch et al., 2006). ABCG2 is 
found to play a role in transporting cytotoxic anti-cancer agents, as well as endogenous 
materials out of cells (Gottesman et al., 2002). A previous ABCG2 review reported that by 
active efflux of anticancer medicine, the expression of ABCG2 may directly cause multidrug 
resistance (Nakanishi and Ross, 2012). However, ABCG2 may also play additional roles in 
promoting proliferation and maintaining the undifferentiated phenotype of SCs (Ding et al., 
2010). A more recent study done by Sabnis et al. reported that ABCG2 has a role in the 
maintenance of PSCs as well as in providing a rationale for targeting ABCG2 for 
differentiation therapy in PCa, using cancerous and non-cancerous prostate cell lines (Sabnis 
et al., 2017). This role might occur because inhibiting ABCG2-mediated androgen efflux 
with ABCG2 inhibitor (Ko143) increases the nuclear translocation of AR (Sabnis et al., 
2017). A third study has identified that androgen-independent PCa patients with the Q141K 
variant have a shorter overall survival time than patients without the single nucleotide 
polymorphism (SNP) (Gardner et al., 2008), suggesting that the reduced function of the 
variant ABCG2 protein helps to increase the intracellular concentration of androgen which 
may play a role in  driving the proliferation of the cells. This last study appears most 
consistent with the loss of expression described here.  
Data presented here suggest that downregulation of ABCG2 may play an important role in 
cancer formation and progression as well as increasing the risk of relapse. ABCG2 in the 
nucleus may have another role, but this role is still unclear. Further study is needed to 
confirm the nuclear localisation of ABCG2, perhaps using immunofluorescence or nuclear 
fractionation. In addition,  it will very important to confirm the cytoplasmic staining patterns 
of ABCG2 in prostate tissues, using a second independent antibody  (IHC) or mRNA probe 
(RNAscope®) in normal and malignant prostate tissues from both cohorts. The future work 
could be carried out with a large cohort, which has clinical information about a risk of 
biochemical recurrence of PCa to assess the role of ABCG2 in risk of recurrence. Finally, it 
would also be interesting to investigate NDRG1 functional roles in PCa using an in vitro cell 
culture approach (see final discussion for more details).  
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4.3.5 Glandular ALDH1A1 is increased in prostate cancer and 
is positively associated with tumour size, whereas, stromal 
ALDH1A1 is negatively associated with relapse  
IHC demonstrated glandular and stromal staining for ALDH1A1 in both normal and 
malignant prostate tissues from the Bath cohort. This was consistent with a previous finding 
(Deng et al., 2010; Matsika et al., 2015). ALDH1A1 staining was found to be restricted to 
basal cells of NP tissues, but was expressed all epithelial cells of PCa tissues.  
Nuclear and cytoplasmic ALDH1A1 staining was increased significantly in PCa compared 
to NP and was positively associated with clinical stage T in the TMA cohort. The results 
largely agreed with (Ting et al., 2009; Kalantari et al., 2017; Matsika et al., 2015), suggesting 
increased ALDH1A1 may play a role in PCa formation and progression. The results were 
inconsistent with the Bath data, but this may be because of the sample size. Nuclear and 
cytoplasmic ALDH1A1 staining was not associated significantly with primary Gleason 
grade and metastasis in both cohorts. This results are consistent with a previous gastric 
cancer study (Li et al., 2014), but was inconsistent with other PCa studies (Ting et al., 2009; 
Kalantari et al., 2017). The cause of this difference is not known, but might be explained as 
the previous prostate studies (Ting et al., 2009; Kalantari et al., 2017) used different antibody 
concentrations and IHC staining protocols. It might also be that the difference is caused by 
differences in the patient populations. The current study shows for the first time that the 
stromal ALDH1A1 staining was not associated significantly with PCa and other 
histopathological parameters, including primary Gleason grade and clinical stage. The Bath 
data, however, shows for the first time that stromal ALDH1A1 was negatively associated 
with biochemical relapse, suggesting loss of stromal staining of ALDH1A1 might play a role 
in relapse.   
ALDHIA1 has been linked to the SC population and is thought to be a marker of SCs and 
CSCs (Tomita et al., 2016). Other work reported that ALDH1A1 plays an important role in 
catalyzing the oxidation of retinal to retinoic acid (RA) that is linked to differentiation during 
development of cells (Tomita et al., 2016; Ting et al., 2009). Increased ALDH1A1 in cells 
could cause RA to accumulate in the nucleus and then either bind with RA receptor RAR 
and/ or retinoid X receptors (RXRS) to increase RARβ genes. These play a role in 
differentiation, apoptosis and growth inhibition and/ or increases c-Myc and Cyclin D1 
transcription which can promote cell proliferation, anti-apoptosis and tumour growth in 
CSCs (Tomita et al., 2016). Therefore, increased ALDH1A1 could lead to increased cell 
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proliferation and tumour growth through its role in increasing RA levels. Further study is 
needed to confirm the staining patterns of ALDH1A1 in prostate tissues, using a second 
independent antibody in normal and malignant prostate tissues from both cohorts. The future 
work could be carried out with a large cohort, which has clinical information about a risk of 
biochemical recurrence of PCa to assess the role of ALDH1A1 in risk of recurrence. 
4.3.6 Changes in nuclear and cytoplasmic RS1 staining was not 
associated with clinical features of prostate cancer  
IHC data showed nuclear staining was not associated with the clinical feature of PCa in both 
cohorts. This result was consistent with the previous finding (Sharpe, 2016). RS1 is an 
extracellular protein and is not expected to be in the nucleus of prostate gland cells. This 
staining could be non-specific. 
Cytoplasmic  RS1 was decreased significantly in PCa compared to NP tissues from the 
TMA, whereas, there was no association in cytoplasmic RS1 staining between normal vs 
malignant prostate tissues from the Bath cohort. This difference may be because of the 
sample size or using different scoring systems. There was no significant association between 
cytoplasmic RS1 staining and primary Gleason grade, clinical stage and relapse. This result 
was consistent with previous findings from our laboratory (Sharpe, 2016). The TMA data 
showed that cytoplasmic RS1 was negatively associated with clinical stage (N). This data, 
however, was inconsistent with previous bioinformatic data, cBioportal 
(http://www.cbioportal.org/) that found RS1 amplification was observed more frequently in 
a subset of metastatic and castration-resistant prostate carcinomas, using 10 large prostate 
cancer microarray datasets. 
In summary, there is little evidence to suggest a link between expression of RS1 and PCa 
formation or progression, although there remains a possible role for cytoplasmic expression 
that could be studied further.  
4.3.7 Conclusion  
In conclusion, decreased β-catenin, ABCG2, membranous and cytoplasmic NDRG1 staining 
is observed in PCa compared to NP tissues, whereas, nuclear NDRG1 and glandular 
ALDH1A1 staining is increased in PCa compared to NP.  β-catenin and cytoplasmic ABCG2 
staining are negatively associated with increasing Gleason grade, whereas nuclear NDRG1 
staining is positively associated with increasing primary Gleason grade. In addition, 
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increased nuclear NDRG1 staining is positively associated with clinical stage and increased 
ALH1A1 staining was only associated with stage T. In contrast, decreased cytoplasmic β-
catenin and RS1 staining is associated with a lymph node metastasis. ABCG2 and stromal 
ALDH1A1 staining is only negatively associated with biochemical relapse.  
 β-catenin, ABCG2 and NDRG1 might play a role in PCa formation and progression and 
could be prognostic biomarkers for PCa. ABCG2 and stromal ALDH1A1 may have a role 
to reduce the risk of relapse. However, further studies are needed to confirm the staining 
patterns of the candidate biomarkers using either a second independent antibody or 
RNAscope to detect the mRNA levels in prostate tissues from both cohorts. In addition, it 
would be very interesting to use an academic TMA cohort (Rubin et al., 2002; Nariculam et 
al., 2009; Symes et al., 2013) with clinical information to determine if there is an association 
between these biomarkers staining and biochemical relapse. Additional future work is 



































ASSESSMENT OF SOX7 
EXPRESSION IN PROSTATE 




5. Identification and Assessment of Sox7 expression 
in prostate tissues from the Bath and TMA cohorts 
5.1 Introduction 
Sex-determining region Y box 7 (Sox7) is one of the candidate biomarkers that was 
identified for analysis. This chapter focuses on Sox7 and describes why the protein was 
selected for analysis and presents all the experimental data that was collected for the protein.  
5.1.1 Identification of Sox7 using literature searching 
Sox7 is a transcription factor that plays an essential role in regulating different biological 
processes, including haematopoiesis, vasculogenesis and cardiogenesis through embryonic 
development (Stovall et al., 2014). It is also thought to have a tumour suppressor role in a 
range of cancers (Cui et al., 2014). Interestingly for this study, reduction of Sox7 levels has 
been suggested to play a role in PCa formation, progression and relapse (described below 
and summarised in Table 5.1). 
There are several publications that have studied the expression levels of Sox7 in both normal 
and malignant tissues. Generally, most of these studies reported that nuclear and cytoplasmic 
Sox7 expression is significantly reduced in cancer tissues compared to normal tissues, 
including breast (Liu et al., 2016), ovarian (Liu et al., 2014), liver (Wang et al., 2014a; Wang 
et al., 2017), pancreas (Wang et al., 2017) and prostate (Guo et al., 2008; Zhong et al., 2012). 
Therefore,  these previous studies, especially (Guo et al., 2008; Zhong et al., 2012) provide 
significant evidence to suggest that the reduction of Sox7 expression may be linked to PCa 
formation.  
In terms of an association between Sox7 expression and histopathological parameters of 
cancer including grades and stages, previous studies have found that there was no association 
between Sox7 mRNA and/ or protein expressions and cancer grades in  ovarian (Liu et al., 
2014), liver (Wang et al., 2014a; Wang et al., 2017) and prostate (Zhong et al., 2012). In 
contrast, more recent studies showed that Sox7 was significantly reduced with increasing 
grades of the breast (Liu et al., 2016) and pancreatic cancers (Wang et al., 2017).  
Several studies have shown a significant association between Sox7 expression and cancer 
stages. For example, Sox7 was significantly reduced in an advanced stage of tumours such 
as ovarian (Liu et al., 2014), liver (Wang et al., 2017) and breast cancers (Liu et al., 2016). 
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Another IHC study showed that Sox7 mRNA level in PCa patients with a low serum level 
of PSA and no-metastasis was significantly higher than those with a high serum PSA level 
and metastasis (Zhong et al., 2012). In contrast, Sox7 expression was not found to be 
associated with a stage of liver cancer (Wang et al., 2017). Therefore, the more recent studies 
on the breast (Liu et al., 2016) and pancreatic cancer tissues (Wang et al., 2017) provide 
significant evidence to suggest that reduction of Sox7 expression is linked to PCa grades and 
stages.  
In terms of a link to PCa relapse, one study has reported that reduction of Sox7 at mRNA 
level is significantly associated with PCa recurrence (Zhong et al., 2012).  However, a link 
between Sox7 protein level and PCa relapse using IHC has not been described before. 
Therefore, the association between mRNA Sox7 level and PCa provides evidence to suggest 
that alterations in Sox7 protein expression could be linked to PCa relapse, but further 
analysis is required to establish if such a relationship exists. 
Given the conflicting evidence, described above, it was decided that it would be worthwhile 
to re-examine the expression of Sox7 in PCa. Specifically, to examine nuclear and 
cytoplasmic Sox7 expression in normal and malignant prostate tissues, primary Gleason 
grade, clinical stage and biochemical recurrence. This would increase our understanding of 
Sox7 expression and its relationship to PCa formation and clinical parameters, including 
grades and stages. It would also be the first study to look at the relationship between Sox7 
protein expression and relapse using IHC. The hypothesis used predicted that nuclear and 
cytoplasmic Sox7 expressions will be negatively associated with PCa, primary Gleason 
grade, clinical stages and biochemical recurrence.  
Table 5. 1 Summary of Sox7 key findings and hypothesis 
Name & type 
of Protein 




 Sox7 protein and mRNA levels were significantly decreased in 
PCa compared to NP tissues (Guo et al., 2008; Zhong et al., 2012). 
The reduction in metastatic PCa cases was significantly higher than 
in non-metastatic cases and was associated with biochemical relapse. 
Sox7 mRNA level was not associated significantly with Gleason 
grades (Zhong et al., 2012).  
 
 A significant reduction of Sox7 expression has been shown in 
ovarian cancer compared to the normal ovary and this reduction was 
significantly associated with advanced stages, but not with grades 
(Liu et al., 2014). 
 
 Nuclear and 
cytoplasmic Sox7 
staining will be 
reduced in PCa 
compared to NP 
tissues. 
 Nuclear and 
cytoplasmic Sox7 







 Nuclear and cytoplasmic Sox7 expression was reduced in breast 
cancer compared to normal breast tissues and was negatively 
associated with grades and stages (Liu et al., 2016).  
 
 Sox7 was decreased significantly in liver and pancreatic cancers 
compared to benign tissues. In liver cancer, this reduction was 
significantly associated with advanced stages, but not associated 
with grades. In contrast, this reduction in pancreatic cancer was 
significantly associated with increasing grades, but not with stages 





5.1.2 Aims  
1. To determine the expression patterns of Sox7 in normal and malignant prostate 
tissues from the Bath and the TMA cohort patients. 
2. To establish if Sox7 expression correlates with clinical features of PCa, including 
primary Gleason grade, clinical stage and biochemical recurrence. 
3. To confirm the specificity of Sox7 staining pattern and IHC results by repeating the 
experiments with a second independent antibody. 
5.2 Results 
5.2.1 Testing of antigen retrieval methods 
Having chosen Sox7 as a candidate biomarker, the next step was to assess its expression 
using IHC. Before this could be carried out, different types of antigen retrieval such as citrate 
or Tris/EDTA buffers were tested to establish which give the best staining for Sox7. The 
staining was carried out with an anti-Sox7 antibody from Abcam that is referred to here as 
the anti-Sox7 A antibody. IHC staining with citrate and Tris/ EDTA buffers showed nuclear 
and cytoplasmic anti-Sox7 A staining in prostate tissues from the Bath cohort. However, this 
study chose citrate buffer as antigen retrieval for Sox7 because the nuclear and cytoplasmic 
anti-Sox7 A staining patterns in the citrate buffer (Figure 5.1 A) was clearer than in 





Figure 5. 1 Expression of Sox7 after different antigen retrieval methods. (A) Strong nuclear (Black arrow) and 
weak cytoplasmic anti-Sox7 A staining was observed in prostate tissues from the Bath cohort, using citrate 
buffer (B) Strong nuclear (Black arrow) and cytoplasmic anti-Sox7 A staining was observed in prostate tissue, 
using Tris/EDTA buffer. Sox7 showed a clearer nuclear and cytoplasmic staining with citrate compared to 
Tris/ EDTA buffers. Scale bars=100µm with inserts at 2x zoom.   
 5.2.2 Expression of Sox7 in the Bath cohort using the anti-Sox7 
A antibody  
To test the hypothesis, that nuclear and cytoplasmic Sox7 staining will be decreased in PCa 
and will be negatively associated with primary Gleason grade, clinical stage and biochemical 
recurrence. IHC was carried out with the Bath cohort prostate tissue samples using the anti-
Sox7 A antibody. 
5.2.2.1 Immunohistochemical expression of anti-Sox7 A in the normal and 
malignant Bath prostate samples 
In NP tissues, nuclear anti-Sox7 A staining was found and ranged from strong (Figure 5.2 
A, arrow) to weak (Figure 5.2 B, arrow). Nuclear anti-Sox7 A staining was also observed in 
PCa tissues and the intensity of signal varied widely, from a strong and widespread (Figure 
5.2 C, arrow) to a weak and scattered (Figure 5.2 E, arrow) or a negative (Figure 5.2 F, 
arrow).  
In addition to the nuclear staining, cytoplasmic anti-Sox7 A was also observed in the 
glandular regions of the Bath prostate tissues with variable staining levels, ranging from 
strong (Figure 5.2 D, arrowhead), weak (Figure 5.2 A& E, arrowheads) and negative (Figure 
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5.2 F, arrow). Sox7 is expressed in the cytoplasm of normal liver tissues (Wang et al., 2017) 
and so this study used normal liver tissue as a positive control for Sox7 expression and as 
expected IHC staining showed cytoplasmic anti-Sox7 A staining in normal liver tissue 
(Figure 5.2 G, arrowhead). A negative control showed no significant background staining in 
prostate tissue (Figure 5.2 H, arrow).  
Figure 5. 2 Sox7 staining in samples from the Bath cohort. Sox7 was expressed heterogeneously in both normal 
and malignant tissues of the prostate, using anti-Sox7 A antibody. (A) Strong nuclear (Black arrow) and weak 
cytoplasmic (Black arrowhead) anti-Sox7 A staining in NP. (B) Weak nuclear (Black arrow) anti-Sox7 A 
staining in NP. (C) Strong nuclear (Black arrow) anti-Sox7 A staining in PCa. (D) Strong cytoplasmic anti-
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Sox7 A staining (Black arrowhead) in PCa. (E) Weak nuclear (Black arrow) and cytoplasmic (Black 
arrowhead) anti-Sox7 A staining in PCa. (F) PCa showed no detectable staining for Anti-Sox7 A (Blackarrow). 
(G) Positive control: Strong cytoplasmic  anti-Sox7 A staining (Black arrowhead) in normal liver tissue. (H) 
Negative control (no primary antibody added) showed no detectable background staining ( Black arrow) in 
PCa. Scale bars=100µm with inserts at 2x zoom.   
5.2.1.2 Association between anti-Sox7 immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort 
Having carried out IHC staining on the TMA prostate tissue samples, using anti-Sox7 A 
antibody, the nuclear and cytoplasmic anti-Sox7 A staining was assessed using the 
proportion and intensity 2 scores (Described in Chapter 2.3.2) and then compared  between 
normal vs malignant prostate tissues, different primary Gleason grades, clinical stages and 
biochemical recurrence, using the clinical data available for the Bath cohort. The range of 
nuclear and cytoplasmic anti-Sox7 A scores varied between 0– 5.8 and 0-5.2, respectively  
(Figure 5.3). The potential association between anti-Sox7 A IHC results and PCa 
histopathological parameters was then analysed and is described below.  
The statistical analysis looked first at the expression of anti-Sox7 A in normal and malignant 
prostate tissues. Quantification of the IHC staining showed nuclear and cytoplasmic anti-
Sox7 A staining reduced significantly in PCa compared to NP tissues (p=0.0152, 0.0205 
respectively) (Figure 5.3 (A&B) & Table 5.2). Nuclear and cytoplasmic anti-Sox7 A staining 
was also reduced significantly in PCa patients with a primary Gleason grade 4 compared to 
those with a primary Gleason grade 3 (p= 0.0073, 0.0405, respectively) (Figure 5.3 (C&D) 
& Table 5.2). In contrast, nuclear and cytoplasmic anti-Sox7 A staining was not associated 
significantly with PCa primary tumour stage T (T1-2 vs T3-4) (p=0.9732 & 0.4676, 
respectively) (Figure 5.3 E&F & Table 5.2). Finally, nuclear and cytoplasmic anti-Sox7 A 
staining showed a slight significant reduction in recurrent PCa patients compared to those 




Figure 5. 3 Quantification of nuclear and cytoplasmic anti-Sox7 A staining in both normal and malignant Bath 
prostate tissues. Immunohistochemical staining of anti-Sox7 A was quantified using proportion and intensity 
2 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear anti-Sox7 A staining was significantly reduced 
in PCa compared to NP (p=0.0152). (B) Cytoplasmic anti-Sox7 A staining was also significantly reduced in 
PCa compared to NP (p=0.0205). (C) Nuclear anti-Sox7 A staining was significantly reduced in primary 
Gleason grade 4 compared to grade 3 (p=0.0073). (D) Cytoplasmic anti-Sox7 A staining was significantly 
reduced in primary Gleason grade 4 compared to grade 3 (p= 0.0405). (E) Nuclear anti-Sox7 A staining was 
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not associated significantly with PCa clinical stage T (p=0.9732). (F) Cytoplasmic anti-Sox7 A staining was 
not associated significantly with PCa clinical stage T (p=0. 4676). (G) Nuclear anti-Sox7 A staining was 
reduced significantly in a patient with recurrent PCa compared to those with a non-recurrent (p= 0.0424). (H) 
Cytoplasmic anti-Sox7 A staining was also reduced significantly in a patient with a recurrent PCa compared 
to those with a non- recurrent (p=0.0479). The mean of five random fields was taken per prostate sample. 
Statistical significance was determined with unpaired t-test for each set of conditions. NP(n=5) PCa (n=28), 
grade 3 (n=12), grade 4 (n=14), recurrent PCa (n=14) and non- recurrent PCa (n=11). 
Table 5. 2 Nuclear and cytoplasmic anti-Sox7 A staining results with clinical data of the Bath cohort 
 
In summary, nuclear and cytoplasmic anti-Sox7 A staining was reduced significantly in PCa 
compared to NP tissues and was also negatively associated with increasing primary Gleason 
grade and biochemical recurrence, but not with the clinical stage (T). These results 
confirmed our hypothesis about Sox7 expression in PCa and its association with 
histopathological parameters, including primary Gleason grade and biochemical relapse. 
However, the results should be treated as preliminary data because of the small sample size, 
so the staining was repeated using the tissue microarray with a larger sample size.   
5.2.3 Expression of Sox7 in the TMA cohort, using anti-Sox7 A 
antibody  
5.2.3.1 Immunohistochemical expression of anti-Sox7 A in the normal and 
malignant TMA prostate samples. 
IHC staining of samples from the TMA showed nuclear anti-Sox7 A staining in the glandular 
regions of all NP tissues (16/16, 100%) with variable levels of staining, ranging from strong 
(Figure 5.4 A, arrow) to weak staining (Figure 5.4 B, arrow). Nuclear anti-Sox7 A staining 
was also observed in PCa tissues and the intensity of signal varied widely, ranging from a 
strong and widespread (Figure 5.4 C&D, arrows), weak and scattered (Figure 5.4 E, arrow) 
or negative (Figure 5.4 F).  
Comparison 
Nuclear   anti- Sox7 A staining Cytoplasmic    anti-Sox7 A staining 
Results p. value Results p. value 
 
Normal vs malignant Lower in malignant 0.0152 Lower in malignant 0.0205 
Primary Gleason grades (3 & 4) Lower in high grade 0.0073 Lower in high grade 0.0405 
Clinical Stage (T) 
No statistically significant 
difference 
0.9732 
No statistically significant 
difference 
0.4676 
5 years Biochemical recurrence Slightly lower in recurrent 0.0424 Slightly lower in recurrent 0.0479 
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In addition to the nuclear staining, the TMA prostate tissue samples had cytoplasmic anti-
Sox7 A staining, with different levels of staining pattern between cases, ranging from strong 
(Figure 5.4 D arrowheads), moderate (Figure 5.4 A, arrowhead), weak (Figure 5.4 B & F, 
arrowheads), and negative (Figure 5.4 G). A negative control (no primary antibody) showed 
no detectable background staining (Figure 5.4 H, arrow). The IHC of the TMA prostate 
sample result was consistent with the Bath cohort results.  
5.2.3.2 Association between anti-Sox7 A immunostaining and 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, the nuclear and cytoplasmic anti-Sox7 A staining was then 
quantified using the proportion and intensity 2 score, as carried out for the Bath cohort 
samples. The range of nuclear and cytoplasmic anti-Sox7 A scores varied between 0-6 
(Figure 5.5). The potential association between anti-Sox7 A IHC results and PCa 
histopathological parameters was then analysed and is described below (Figure 5.5 and Table 
5.3).  
The statistical analysis looked at the expression of anti-Sox7 A in cancerous and non-
cancerous prostate tissue samples. Quantification of the IHC staining showed a significant 
reduction of nuclear and cytoplasmic anti-Sox7 A staining in PCa compared to NP tissues 
(p= < 0.0001) (Figure 5.5 (A&B) & Table 5.3). Nuclear and cytoplasmic Anti-Sox7 A 
staining showed a significant difference among different primary Gleason grade groups (p= 
0.0084 & 0.0488, respectively) (Figure 5.5 (C&D), Table 5.3). The multi-comparison 
Tukey’s tests showed reduced nuclear and cytoplasmic anti-Sox7 A staining significantly 
within increasing primary Gleason grade. This significant reduction was only shown 
between nuclear and cytoplasmic anti-Sox7 A when comparing PCa patients with a primary 
grade 5 to those with a grade 3 (p= 0.0061 & 0.0429, respectively) (Figure 5.5 (C&D) 
&Table 5.3). In contrast, nuclear and cytoplasmic anti-Sox7 A staining showed no 
significant difference when comparing PCa patients with a primary Gleason grade 4 to those 
with a grade 3 (p= 0.1454 & 0.1046, respectively) or a grade 5 (p= 0.1247&0.67, 
respectively) (Figure 5.5 (C&D) &Table 5.3). Nuclear and cytoplasmic anti-Sox7 A staining 
data was then examined in samples from different clinical stages,  including primary tumour 
stages (T1-2 vs T3-4), regional lymph node (N0 vs N1) and distant metastasis (M0 vs M1), 
using the clinical data available for the TMA cohort. There was no statistical difference 
between nuclear and cytoplasmic anti-Sox7 A staining and PCa stage (Table 5.3).  
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Figure 5. 4 Anti-Sox7 staining in samples from the TMA cohort. Anti-Sox7 A was expressed heterogeneously 
in both normal and malignant tissues of the prostate. (A) Strong nuclear (Black arrow) and moderate 
cytoplasmic (Black arrowhead) anti-Sox7 A staining in NP. (B) Weak nuclear (Black arrow) and cytoplasmic 
(Black arrowhead) anti-Sox7 staining in NP. (C) Strong nuclear (Black arrow) anti-Sox7 A staining in PCa. 
(D) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Sox7 A staining in PCa. (E) Weak 
nuclear (Black arrowhead)  anti-Sox7 A staining in PCa. (F) Weak cytoplasmic (Black arrowhead) anti-Sox7 
A staining in PCa. (G) Negative anti-Sox7 A staining  (Black arrow) in PCa. (H) Negative control (no primary 
antibody added) shows no background staining (Black arrow) in PCa. Scale bars=100µm with inserts at 2x 
zoom.   
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Figure 5. 5 Quantification of nuclear and cytoplasmic anti-Sox7 A staining in both normal and malignant TMA 
prostate tissues, Immunohistochemical staining of anti-Sox7 A was quantified in TMA group using the 
proportion and intensity 2 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear anti-Sox7 A staining 
was significantly reduced in PCa compared to NP tissues (p= < 0.0001). (B) A significant reduction of 
cytoplasmic anti-Sox7 A staining was in PCa compared with NP (P= < 0.0001). (C) Nuclear anti-Sox7 A 
staining showed a significant difference among different primary Gleason grade (p= 0.0084) and multiple 
comparison tests (Tukey) showed a negative association with increasing primary Gleason grades. This 
reduction was only statistically significant between primary Gleason grade 5 & 3 (p= 0.0061). (D) Cytoplasmic 
anti-Sox7 A staining showed a significant difference among different primary Gleason scores (P= 0.0088). 
Cytoplasmic anti-SOX7 staining was negatively associated with increasing grade, using multiple comparison 
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tests (Tukey). This reduction of cytoplasmic anti-Sox7 A was observed only between primary Gleason grade 
5 and 3 (p= 0.0429). Data represent the mean of five random images per case. Unpaired or one-way ANOVA 
tests were conducted to determine the statistical difference for each set of conditions. NP (n=16), PCa (n=80), 
grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 5. 3 Summary of nuclear and cytoplasmic anti-Sox7 A staining results with clinical data in the TMA 
cohort. 
 
In summary, nuclear and cytoplasmic anti-Sox7 A staining was reduced significantly in PCa 
and was negatively associated with increasing Gleason grades, but not with stage (TNM). 
This result largely agreed with the Bath cohort results. 
5.2.4 Expression of Sox7 in the Bath cohort using the anti-Sox7 
B antibody 
In order to increase confidence in the results showing a reduction in Sox7 expression, it was 
important to confirm them using a second antibody, independent from the anti- Sox7 rabbit 
polyclonal antibody from Sigma. This helps confirm that the staining is specific for Sox7 
and not cross-reactive with other proteins. A second antibody was identified which was 
raised against a different immunogenic part of Sox7 (Figure 5.6) and is referred to here as 
the anti-Sox7 B antibody.  
Comparison 
Nuclear anti-Sox7 A staining   Cytoplasmic anti-Sox7 A staining 
 




Lower in malignant < 0.0001 
 





































































Figure 5. 6 Sox7 protein sequence with the immunogenic part of the two different antibodies highlighted. Sox7 
protein consists of 388 amino acids and the immunogen for each antibody was in a different region of the 
protein. The immunogenic part of the anti-Sox7 A antibody was in the N terminal amino acids 37-86 (Green 
highlighted). The anti-Sox7 B antibody was raised against an immunogen at the C terminal of Sox7 (Yellow 
highlighted).  
5.2.4.1 Immunohistochemical staining patterns of the two Sox7 antibodies  
In order to confirm that the two independent Sox7 antibodies were producing a similar 
staining pattern, IHC was carried out using sections from similar regions of prostate and 
liver tissue samples from the Bath cohort. The IHC showed that both Sox7 antibodies had a 
very similar staining pattern in prostate and liver tissues (Figure 5.7). In prostate tissue, anti-
Sox7 A& B staining was found in the glandular (Figure 5.7 A&B arrows) and stromal 
regions (Figure 5.7 A&B arrowheads). A moderate nuclear Sox7 staining was also observed 
in prostate tissues, using anti-Sox7 A & B (Figure 5.7 C&D arrows, respectively). In addition 
to its expression in prostate tissue, cytoplasmic Sox7 staining was also observed in normal 
liver tissue, using the two different antibodies (Figure 5.7 E & F arrowheads).  
The two different Sox7 antibodies had the same staining pattern in prostate and liver tissues 
samples so it was decided to carry out IHC staining of the prostate samples from the Bath 




 Figure 5. 7 Two distinct Sox7 antibodies show the expected patterns of Sox7 expression in the Bath prostate 
and liver tissue samples. (A) Moderate glandular (Black arrow) and strong stromal (Black arrowhead) anti-
Sox7 A staining in prostate tissue. (B) Moderate glandular (Black arrow) and strong stromal (Black arrowhead) 
anti-Sox7 B staining in prostate tissue. (C) Moderate nuclear anti-Sox7 A staining in prostate tissues. (D) 
Moderate nuclear anti-Sox7 B staining in prostate tissues. (E) Weak cytoplasmic staining (Black arrowhead) 
anti-Sox7 A staining in liver tissue.  (F) Weak cytoplasmic staining (Black arrowhead) anti-Sox7 B staining in 
liver tissue. Both Sox7 antibodies showed very similar staining patterns in prostate and liver tissues. Scale 




5.2.5 Expression of Sox7 in the Bath cohort, using anti-Sox7 B 
antibody 
5.2.5.1 Anti-Sox7 B staining in the normal and malignant Bath prostate 
samples 
IHC was carried out on normal and malignant prostate tissues from the Bath cohort, using 
anti-Sox7 B antibody. The IHC staining showed nuclear anti-Sox7 B staining in NP tissues 
and ranged from strong (Figure 5.8 A, arrow) to weak (Figure 5.8 B, arrow). Nuclear anti-
Sox7 B staining was also detected in PCa tissues and the intensity of signal varied widely, 
from strong (Figure 5.8 C, arrow), moderate (Figure 5.8 D, arrow), weak (Figure 5.8 E, 
arrow) and negative (Figure 5.8 F, arrow).  
In addition to the nuclear staining, Sox7 was also expressed in the cytoplasm of the glandular 
epithelial cells of both normal and malignant prostate tissues from the Bath cohort, using 
anti-Sox7 B antibody. The staining patterns of anti-Sox7 B varied between cases, ranging 
from strong (Figure 5.8 A& C, arrowheads), moderate (Figure 5.8 D, arrowhead), weak 
(Figure 5.8 E, arrowhead) and negative (Figure 5.8 F, arrow). The IHC data showed 
cytoplasmic anti- Sox7 B staining in the positive control liver tissues (Figure 5.8 G, 
arrowhead). A negative control showed no significant background staining in prostate tissue 
(Figure 5.8 H, arrow). This result appeared very similar to that obtained using the anti-Sox7A 
antibody. 
5.2.5.2 Association between anti-Sox7 B immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort 
Having carried out IHC staining, the nuclear and cytoplasmic anti-Sox7 B staining was then 
quantified using the proportion and intensity 2 scores, respectively (Described in Chapter 
2.3.2) and then compared between normal vs. malignant prostate tissues, primary Gleason 
grades, clinical stages. The range of nuclear and cytoplasmic anti-Sox7 B scores varied 
between 0– 5.8 (Figure 5.9). Since this analysis was carried out later in the project and the 
number of samples still available from the Bath cohort was reduced, for example, 3 NP vs. 
17 PCa, statistical tests were not carried out. 
Quantification of the IHC showed that PCa tissues had lower nuclear and cytoplasmic anti- 
Sox7 B scores compared to NP tissues (Figure 5.9 (A&B) & Table 5.4). Nuclear and 
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cytoplasmic anti-Sox7 B staining was also reduced in PCa tissues with a primary Gleason 
grade 4 compared to those with a grade 3 (Figure 5.9 (C&D) & Table 5.4). 
Figure 5. 8 Sox7 staining in samples from the Bath cohort. Sox7 was expressed heterogeneously in both normal 
and malignant tissues of the prostate, using anti-Sox7 B antibody. (A) Strong nuclear (Black arrow) and 
cytoplasmic (Black arrowhead) anti-Sox7 B staining in NP. (B) Weak nuclear (Black arrow) anti-Sox7 B 
staining in NP. (C) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Sox7 B staining in 
PCa. (D) Moderate nuclear (Black arrow) and cytoplasmic anti-Sox7 B staining (Black arrowhead) in PCa. (E) 
Weak nuclear ( Black arrow) and cytoplasmic (Black arrowhead) anti- Sox7 B staining in PCa. (F) PCa tissue 
had negative staining for anti-Sox7 B (Black arrow). (G) Positive control: Cytoplasmic  anti-Sox7 B staining 
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(Black arrowhead) in normal liver tissue. (H) Negative control (no primary antibody added) showed no 
background staining (Black arrow) in PCa. Scale bars=100µm with inserts at 2x zoom. 
Nuclear and cytoplasmic Sox7 staining trended to be lower in PCa patients with clinical 
stage T3-4 compared to those with a T1-2 (Figure 5.9 (E&F) & Table 5.4). In contrast, IHC 
quantification showed nuclear and cytoplasmic anti-Sox7 B scores trended to be lower in 
recurrence compared to non-recurrence (Figure 5.9 (G&H) & Table 5.4). This result largely 
agreed with anti-Sox7 A IHC results in the Bath cohorts.  
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Figure 5. 9 Quantification of nuclear and cytoplasmic anti-Sox7 B staining in both normal and malignant Bath 
prostate tissues, using anti-Sox7 B antibody. IHC staining of anti-Sox7 B was quantified in the Bath cohort the 
proportion and intensity 2 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear anti-Sox7 B staining 
was reduced in PCa compared to NP. (B) Cytoplasmic anti-Sox7 B staining was reduced in PCa compared to 
NP. (C) Nuclear anti-Sox7 B staining was reduced in Gleason grade 4 compared to Gleason grade 3. (D) 
Cytoplasmic anti-Sox7 B staining was reduced in Gleason grade 4 compared to Gleason grade 3. (E) Nuclear 
anti-Sox7 B staining trended to be lower in advanced stage T3-4 (F) Cytoplasmic anti-Sox7 B staining trended 
to be lower in advanced stage T3-4. (G) Nuclear anti-Sox7 B staining trended to be lower recurrent PCa 
compared to a non-recurrent. (H) Cytoplasmic anti-Sox7 B staining trended to be lower recurrent PCa 
compared to a non-recurrent. NP (n=3) PCa (n=17), grade 3 (n=6), grade 4 (8), T1-T2 (n= 9), T3-T4 (n= 7), 
non-recurrent (n= 6) and recurrent (n=8). 
Table 5. 4 Summary of nuclear and cytoplasmic Sox7 B staining results with clinical data in the Bath cohort. 
The small sample size meant that statistical analysis was not carried out. 
In summary, nuclear and cytoplasmic anti-Sox7 B staining was reduced in PCa compared to 
NP tissues and was negatively associated with increasing Gleason grade, clinical stage and 
biochemical relapse. The results were agreed with anti-Sox7 A results in both cohorts. 
However, the staining should be treated as preliminary data because of the small sample size, 
so the staining was repeated using a tissue microarray with a larger sample size.    
5.2.6 Expression of Sox7 in the TMA cohort, using anti-Sox7 B 
antibody 
5.2.6.1 Immunohistochemical expression of anti-Sox7 B in the normal and 
malignant TMA prostate samples 
Expression of Sox7 was investigated by IHC on the TMA prostate tissue samples, using anti-
Sox7 B antibody. IHC results showed that NP tissues had nuclear anti-Sox7 B staining that 
ranged from strong (Figure 5.10, A, arrow) to weak (Figure 5.10 B, arrow). Nuclear anti-
Sox7 B staining was also observed in PCa tissues and the intensity of signal varied widely, 
from strong (Figure 5.10 C, arrow), moderate (Figure 5.10 D&E, arrows) and weak (Figure 
5.10 F&G, arrows).  
In addition to the nuclear staining, both normal and malignant prostate tissues showed 
cytoplasmic anti-Sox7 B staining with variable staining levels, ranging from moderate 
(Figure 5.10 C, arrowhead), weak (Figure 5.10 B, D &F, arrowheads) and negative (Figure 
Comparison Nuclear anti- Sox7 B staining  Cytoplasmic    anti-Sox7 B staining 
Results Results 
Normal vs malignant Lower in malignant Lower in malignant  
Primary Gleason grades (3 &4)  Lower in high grade Lower in high grade 
Clinical Stage (T) Trend to be lower in T3-4 Trend to be lower in T3-4 
5 years Biochemical recurrence  Trend to be lower in recurrence Trend to be lower in recurrence 
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5.10 F). A negative control showed no significant background staining in prostate tissue 
(Figure 5.10 H, arrow).  This result largely agreed with anti-sox7 A results in both cohorts. 
Figure 5.10 Anti-Sox7 B staining in samples from the TMA cohort. Anti-Sox7 B was expressed 
heterogeneously in both normal and malignant tissues of the prostate.  (A) Strong nuclear (Black arrow) anti-
Sox7 B staining in NP. (B) Weak nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Sox7 B 
staining in NP. (C) Strong nuclear (Black arrow) and moderate cytoplasmic (Black arrowhead) anti-Sox7 B 
staining in PCa. (D) Moderate nuclear (Black arrow) and weak cytoplasmic (Black arrowhead) anti-Sox7 B 
staining in PCa. (E) Moderate nuclear ( Black arrow) anti-Sox7 B staining in PCa. (F) Weak nuclear (Black 
arrow) and cytoplasmic (Black arrowhead) anti-Sox7 B staining in PCa. (G) Weak nuclear (Black arrow) anti-
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Sox7 B staining in PCa.  (H) Negative control (no primary antibody added) showed no detectable background 
staining ( Black arrow) in PCa. Scale bars=100µm with inserts at 2x zoom.   
5.2.6.2 Association between anti-Sox7 B immunostaining and 
histopathological parameters of prostate cancer in the TMA cohort 
Having carried out IHC staining, the nuclear and cytoplasmic anti-Sox7 B staining was then 
quantified using the proportion and intensity 2 scores (Described in Chapter 2.3.2). The 
range of nuclear and cytoplasmic anti-Sox7 B scores varied between 0 – 6 (Figure 5.11). The 
potential association between anti-Sox7 B IHC results and histopathological parameters of 
PCa was then analysed and is described below.  
The analysis looked first at the expression of Sox7 in cancerous vs. non-cancerous prostate 
tissue, using anti-Sox7 B antibody. Quantification of the IHC showed reduced nuclear and 
cytoplasmic anti-Sox7 B staining significantly in PCa compared to NP tissues (p= < 0.0001) 
(Figure 5.11 (A&B) & Table 5.5). Nuclear and cytoplasmic anti-Sox7 B staining showed a 
significant difference among different Gleason grade groups (p= < 0.0001, respectively) 
(Figure 5.11 (C&D)& Table 5.5). Detailed analysis, using multi-comparison (Tukey) tests 
showed that nuclear and cytoplasmic anti-Sox7 B  staining was negatively associated with 
increasing primary Gleason grades. Nuclear and cytoplasmic anti-Sox7 A staining was 
significantly reduced when comparing PCa patients with a grade 5 to those with a grade 3 
(p= < 0.0001) or a grade 4 (p= < 0.0001) (Figure 5.9 (C&D)& Table 5.4). Cytoplasmic anti-
Sox7 B staining was also reduced significantly in a Gleason grade 4 compared to Gleason 
grade 3 (p=<0.0001) (Figure 5.11 D & Table 5.5). 
There was no statistical association between nuclear anti-Sox7 B staining and PCa stage 
(Table 5.5). In contrast, cytoplasmic anti-Sox7 B staining was negatively associated with 
clinical stage T (P= 0.0085) (Figure 5.11 F & Table 5.5), but not associated with other 
clinical stages, including N (N0 vs N1) (P= 0.0098) and M (M0 vs M1) (P= 0.136) (Table 




Figure 5. 11 Quantification of nuclear and cytoplasmic Sox7 staining in both normal and malignant TMA 
prostate tissues, using anti-Sox7 antibody. Immunohistochemical staining of anti-Sox7 B was quantified in the 
TMA group using the proportion and intensity 2 scores for nuclear and cytoplasmic IHC staining. (A) Nuclear 
anti-Sox7 B staining was significantly decreased in PCa compared to NP tissues (p= < 0.0001). (B) A 
significant reduction of cytoplasmic anti-Sox7 B staining was in PCa compared to NP tissues (p= < 0.0001). 
(C) Nuclear anti-Sox7 B staining showed a significant difference among different Gleason grades (p= <0.0001) 
and multiple comparison tests (Tukey) showed a significant reducing with increasing primary Gleason grades. 
This reduction was statistically significant when comparing PCa patient with a Gleason grade 5 to grade 3 (p= 
<0.0001) or grade 4 (p=<0.0001) only. (D) Cytoplasmic anti-Sox7 B staining showed a significant difference 
among different primary Gleason grades (p= <0.0001). Multiple comparison tests (Tukey) showed that this 
reduction was statistically significant when comparing PCa patient with a primary Gleason grade 5 to grade 3 
(p= <0.0001) or grade 4 (p=<0.0001) and when comparing grade 4 tissues to those with grade 3 (p=<0.0001). 
(E) Nuclear anti-Sox7 B staining was not associated with primary tumour volume (p=0.6656).  (F) Cytoplasmic 
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anti-Sox7 B was negatively associated with clinical stage T (p= 0.0085). Unpaired or one-way ANOVA tests 
were conducted to determine the statistical difference for each set of conditions.  PCa (n=80) and NP (n=16), 
grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18), T1-2 (n= 51) and T3-4 (n= 28). 
Table 5. 5 Summary of nuclear and cytoplasmic anti-Sox7 B staining results with the TMA clinical data 
In summary, nuclear and cytoplasmic anti-Sox7 B staining was reduced significantly in PCa 
compared to NP tissues and was negatively associated with increasing primary Gleason 
grades. There was no association with stage, except for the cytoplasmic anti-Sox7 B staining 
which was negatively associated with clinical stage T. This result largely agreed with the 
Bath cohort and the anti-Sox7 A result in both cohorts.   
2.5.7 Sox7 immunostaining in the Bath and TMA cohorts: 
testing the hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
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Table 5. 6 The summary of Sox7 results in the Bath and TMA cohorts  









































































































































































































































































This study used IHC to investigate the expression of Sox7 in normal and malignant prostate 
tissues from the Bath and TMA cohorts and to determine if there was an association between 
Sox7 immunostaining and PCa clinical and histopathological parameters, including primary 
Gleason grade, clinical stage and biochemical relapse, using two different anti-Sox7 
antibodies. The staining patterns of anti-Sox7 A& B were very similar and data from both 
antibodies showed that nuclear and cytoplasmic Sox7 staining was significantly reduced in 
PCa and was also negatively associated with increasing primary Gleason grade and risk of 
biochemical relapse. Sox7 staining did not show a clear association with other clinical 
parameters. 
5.3.2 Sox7 is reduced significantly in prostate cancer and 
negatively associated with increasing grade and relapse  
The IHC data in this study found reduced nuclear and cytoplasmic Sox7 staining 
significantly in PCa tissues compared to NP tissues from the two independent cohorts, using 
two different antibodies. This result largely agreed with previous findings for breast, liver, 
pancreatic, ovarian, gastric and prostate tumours (Guo et al., 2008; Zhong et al., 2012; Liu 
et al., 2014; Liu et al., 2016; Wang et al., 2017). In particular, the PCa study in China by 
Zhong, et al.  reported downregulation of Sox7 immunostaining in 147 PCa tissues compared 
to  28 NP tissues (Zhong et al., 2012). Combining the Zhong et al data with the results 
presented in this thesis means that Sox7 has been shown to be downregulated in three 
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independent cohorts of PCa patients, suggesting its loss is a widespread phenomenon and 
not restricted to one particular patient cohort.  
In the present study, Sox7 staining was negatively associated with increasing primary 
Gleason grade in both cohorts, using two different antibodies. This significant association 
has been previously reported for pancreatic and gastric tumours (Liu et al., 2016; Wang et 
al., 2017). In PCa, to our knowledge, there is only one study that has investigated the 
association between Sox7 expression and Gleason score and reported that there was no a 
significant association between them (Zhong et al., 2012). The cause of this difference is not 
known, but might be explained as the previous prostate study in China used a different 
antibody. It might also be that the difference is caused by differences in the patient 
populations. 
Our data showed that cytoplasmic anti-Sox7 B staining was reduced significantly in T3-4 
compared to T1-2. However, overall, there was no clear biological association between Sox7 
immunostaining and PCa clinical stage in both cohorts. These results are consistent with 
previous findings for pancreatic, breast and prostate carcinomas (Guo et al., 2008; Liu et al., 
2016; Wang et al., 2017), suggesting that Sox7 expression is unable to distinguish between 
PCa patients with different clinical stages, such as invasion and metastasis. However, 
another PCa study reported that Sox7 immunostaining in metastatic PCa tissues is higher 
than in non-metastatic tissues (Zhong et al., 2012) and there was a negative association 
between Sox7 immunostaining and clinical stage of the liver cancer (Wang et al., 2017). 
Multiple reasons could explain the differences between the Sox7 results, including sample 
collection, antibodies used, as well as cancer type.  
To our knowledge, this study is the first IHC study that showed an association between 
nuclear and cytoplasmic Sox7 staining and the risk of relapse, using IHC. However, this 
result is supported by a previous prostate study by Zhong, et al. that reported that Sox7 
mRNA  and protein levels were decreased in castration-resistant regrowth tumour mouse 
models (CR) compared to castration-induced regression nadir (ND) and androgen-dependent 
growth (AD) tumours, using RT-PCR and western blot analysis (Zhong et al., 2012). They 
proposed that downregulation of Sox7 might play a potential role in increasing risk of 
biochemical relapse.  
Further work could be carried out to extend the analysis of Sox7 expression reported in this 
thesis. Another method, such as RNAscope® (described in Chapter 2), might be used to 
determine the Sox7 mRNA level in both normal and malignant prostate tissue samples from 
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both cohorts. This would provide an independent method to confirm the IHC findings.  In 
addition, the present study suggests that there is a negative association between Sox7 
immunostaining and risk of biochemical relapse. However, there are still many unanswered 
questions about this association, because the sample size of the Bath cohort is small and the 
TMA cohort does not have clinical data regarding the PCa relapse and non- relapse. It would 
be very interesting to assess the expression of Sox7 at protein and mRNA levels, using IHC 
and RNAscope in a large TMA cohort which has clinical information about a risk of PCa 
biochemical relapse (see Chapter 8 for more details). 
5.3.3 The regulation of Sox7 expression in prostate cancer 
There are different mechanisms, including promoter hypermethylation and allelic deletion, 
that have been suggested to suppress the expression of Sox7 in PCa (Guo et al., 2008). A 
previous report demonstrated that a frequently methylated CPG island, which is located in 
the promoter region of Sox7, plays an important role in regulating the expression of Sox7 
(Stovall et al., 2014). As a result of a tumour specific promoter hypermethylation which is 
detected in 48% of PCa and 44% of PCa cell lines, Sox7 level was reduced significantly in 
PCa and PCa cell lines compared to NP and NP cell lines, respectively using methylation-
specific PCR (MSP) (Guo et al., 2008). Furthermore, another study has identified that 
reduction of Sox7 mRNA and protein levels in breast cancer cell lines compared to normal 
breast cell lines was found to be due to Sox7 promoter hypermethylation which was higher 
in breast cancer cell lines compared to normal breast cell lines (Stovall et al., 2013).  
In addition to the promoter hypermethylation, Sox7 gene deletion is another mechanism for 
Sox7 loss in cancers, including PCa. Previous studies have been indicated that the Sox7 gene 
is located in a short arm of chromosome 8 that is a frequently deleted in a number of cancers, 
including PCa (Oba et al., 2001; Stovall et al., 2014). Sox7 deletion has also been reported 
in multiple non – small cell lung cancer (NSCLC) cell lines (Hayano et al., 2013). Another 
study reported that allelic loss was found in 18 PCa samples (61%) and also found that 64% 
of PCa (7/11) had a combination of promoter methylation and allelic loss (Guo et al., 2008).  
 Therefore, the downregulation of Sox7 seen in this study is likely to be due to a combination 
of promoter hypermethylation and allelic loss.  
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5.3.4 The function of Sox7 in prostate cancer 
Sox7 is a transcription factor that has been proposed to be a tumour suppressor in multiple 
cancers, including PCa and previous studies have been suggested that Sox7 expression might 
inhibit cell proliferation, migration, invasion and colony formation in PCa and breast cancer  
(Guo et al., 2008).  
The Sox7 protein consists of  338 amino acids and has a β-catenin interaction site on its C-
terminal domain (Takash et al., 2001; Guo et al., 2008; Stovall et al., 2014).  It has been 
reported that Sox7 can inhibit β-catenin /T cell factor (TCF) regulated transcription (CRT) 
(Takash et al., 2001). Another study showed that  Sox7 can physically interact through its β-
catenin binding motif with β-catenin protein and then inhibits its activity (Guo et al., 2008; 
Chang et al., 2013; Liu et al., 2016), suggesting Sox7 negatively regulates active β-catenin. 
There was a significant reduction in active β-catenin in transfected cells with Sox7, but 
transfected cells were found to have the same expression level of β-catenin (Guo et al., 
2008), suggesting Sox7 depletes active, but not total β-catenin. This argues that a reduction 
in Sox7 might cause an increase in active β-catenin that would counteract some of the loss 
of total β-catenin expression seen in PCa (see Chapter 3) and so contribute to tumour 
formation and progression.     
 Interestingly, a study on breast cancer demonstrated that Sox7 and Axin-2 (Axin inhibition 
protein-2) expression is reduced in breast cancer, compared to the normal breast and they 
have a cooperative role in regulating Wnt/ β-catenin signalling pathway (Liu et al., 2016). 
For future work, it would be very interesting to investigate Axin 2 expression in normal and 
malignant prostate tissues and to determine if there is an association between Axin 2 and 
histopathological and clinical parameters of PCa, including primary Gleason grade, clinical 
stage and biochemical relapse. 
5.3.5 Conclusion  
In conclusion, Sox7 was found to be downregulated in PCa and its expression negatively 
associated with primary Gleason grade and biochemical recurrence. Sox7 downregulation 
may be a potential indicator for aggressive PCa progression and risk of relapse. Further 
studies, however, are needed to confirm the role of Sox7 in risk of the biochemical relapse 
and elucidate its molecular function in normal and cancerous prostate tissues. Additional 
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6. Identification and Assessment of Sall4 expression 
in prostate tissues from the Bath and TMA cohorts 
6.1 Introduction  
One of the candidate biomarkers that has been identified for analysis was Sall4. This chapter 
focuses on Sall4 and describes why the protein was selected for analysis, describes the 
possible role of RNAscope® in cancer and presents all the experimental data that was 
collected for the protein. 
6.1.1 Identification of Sall4 using literature searching  
Sall4 is a zinc transcription factor found to be expressed in ESCs and during the development 
of embryos, but its expression level after birth is observed to be decreased in most of normal 
human adult tissues. Sall4, however, is found to be reactivated in a number of cancers (Zhang 
et al., 2015; Tatetsu et al., 2016). Of particular importance for this study, altered Sall4 levels 
have been suggested to play a role in PCa progression and relapse (described below and 
summarised in Table 6.1).  
A previous IHC study showed nuclear Sall4 staining in a subset of non-small lung carcinoma 
(33.8%) and only 10% of normal lung tissues (1/10 cases) (Rodriguez et al., 2014). In 
colorectal carcinoma, Sall4 mRNA was found to be expressed two times higher than in 
normal colon tissues, using real-time PCR (Forghanifard et al., 2013). In contrast,  another 
study showed a reduction of nuclear and cytoplasmic Sall4 staining in colorectal carcinoma 
compared to normal colon tissues (Hao et al., 2016). In PCa, according to our knowledge, 
the association between Sall4 staining in normal and malignant prostate tissue has not been 
extensively investigated, however a couple of studies on other cancers have included small 
numbers of prostate tissue samples. For example, a previous study on non- small cell lung 
carcinomas used a TMA with 112 normal tissues as controls, including 7 NP tissues and 
showed a weak nuclear Sall4 staining in 57% of NP tissues (4/7) (Rodriguez et al., 2014). 
Another study on metastatic germ & non-germ cell tumours showed negative Sall4 staining 
in all metastatic PCa samples (12 cases only) (Cao et al., 2009). Therefore, most of the 
studies on other tumours, and the limited evidence relating to PCa suggest that increased 
nuclear Sall4 staining might be associated with PCa. 
In terms of a link with PCa histopathological features, including primary Gleason grade, 
clinical stage and biochemical relapse, according to our knowledge, there is no specific study 
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that investigates a link between Sall4 expression and PCa histopathological parameters.  
However, Sall4 association with the histopathological parameters has been studied in other 
types of cancer tissues, including lung and colorectal carcinomas (Rodriguez et al., 2014; 
Hao et al., 2016).  An IHC study on non-small cell lung carcinoma reported that nuclear 
Sall4 staining was significantly stronger in high grade primary lung adenocarcinomas 
compared to low grade (Rodriguez et al., 2014). In contrast, another study showed that there 
was a negative association between Sall4 expression and colorectal carcinoma grades (Hao 
et al., 2016). Finally, other studies have reported that Sall4 expression is not significantly 
associated with grades of lung cancer (Gautam et al., 2015; Han et al., 2014),  particularly 
primary squamous cell carcinoma  (Rodriguez et al., 2014) and hepatocellular carcinoma 
(Han et al., 2014). Therefore, there is contradictory evidence from other tumours relating to 
the relationship between Sall4 and cancer grades.  
The published evidence is also complicated and often at least partially contradictory for the 
association between Sall4 expression and clinical stage. Nuclear Sall4 staining was 
negatively associated with primary lung squamous cell carcinoma stage  T (pT1 vs pT2) 
(Rodriguez et al., 2014). In contrast, in colorectal carcinoma, Sall4 mRNA expression was 
significantly increased in a tumour metastatic to lymph nodes compared to non-metastatic 
tissues (Forghanifard et al., 2013; Rodriguez et al., 2014). Other studies, however, showed 
no significant association between nuclear Sall4 expression and stage of lung (Rodriguez et 
al., 2014; Gautam et al., 2015) and hepatocellular carcinomas (Han et al., 2014). Therefore, 
there is no significant evidence to suggest that an alteration in nuclear Sall4 expression might 
be linked to PCa stages.  
Finally, in terms of a link with relapse, there is only one study which found that Sall4’s level 
in serum increased significantly in HCC recurrence patients compared to those with non- 
recurrence (Han et al., 2014).  Therefore, there is very little evidence to suggest that Sall4 
expression might be linked to PCa relapses.  
Given the evidence described above, it was decided to examine nuclear Sall4 staining in 
prostate tissues, including recurrence and non-recurrence. The hypothesis used predicted that 
nuclear Sall4 staining will be increased in PCa, but will not be associated with primary 
Gleason grades, stage and relapse. The key publications and hypothesis for Sall4 are 








Key publications Hypothesis 
Sall4 
A zinc finger 
transcription 
factor 
 Sall4 was expressed strongly in the nucleus of metastatic germ cell 
tumours, whereas, a small number of metastatic PCa (only 12 cases) 
showed a negative Sall4 expression (Cao et al., 2009). 
 Sall4 mRNA level in colorectal carcinoma was two times higher 
compared to normal colon tissues and was significantly associated with 
lymph node metastasis, using a real-time PCR (Forghanifard et al., 2013). 
 A subset of non-small lung carcinoma showed nuclear expression of 
Sall4, and this expression of Sall4 was significantly stronger in high 
grades of primary lung adenocarcinoma, whereas, there was no a 
significant associated between Sall4 expression and primary squamous 
cell carcinoma grades. Sall4 was also expressed weakly in four from 
seven NP tissues (Rodriguez et al., 2014). 
 Sall4 serum level was increased significantly in hepatocellular 
carcinoma compared to normal controls and was also significantly 
increased in HCC recurrence compared to non- recurrence (Han et al., 
2014; Hang et al., 2012). 
 Sall4 cytoplasmic and membranous expression was high in lung 
cancer compared to normal, and there was not an association between 
Sall4 expression and histopathological parameters, including grades and 
stages (Gautam et al., 2015).  
 Nuclear and cytoplasmic Sall4 expression was significantly reduced 
in colorectal carcinoma compared to normal colon and was negatively 
associated with increasing grade, whereas, it was positively associated 
with advanced stages (Hao et al., 2016). 
















6.1.2 The role of RNAscope ® in prostate cancer  
In situ hybridization (ISH) is a technique used to detect DNA and RNA levels in specific 
cell populations and tissue samples (Jensen, 2014; Grabinski et al., 2015). In clinical use, 
ISH is commonly used to detect DNA biomarkers, whereas, RNA detection is rare (Wang et 
al., 2012) as standard ISH has some difficulties in detecting RNA in samples (Jensen, 2014). 
These difficulties include non-specific binding and low sensitivity (Ambinder and Mann, 
1994), especially in detecting an RNA with a low level of expression  (Grabinski et al., 
2015). 
To overcome the limitations with traditional ISH a previous study developed a novel RNA 
ISH technique called RNAscope® (Wang et al., 2012) that represents a simple 
nonradioisotopic ISH method to detect mRNA in cells or tissues, including FFPE sections 
(Wang et al., 2012; Grabinski et al., 2015). It can be used to detect either single or multiple 
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RNA species using chromogenic or fluorescent methods (Wang et al., 2012; Grabinski et 
al., 2015). It uses twenty double Z probes which bind directly to the target mRNA and then 
this interaction is amplified many times using a cascade of a preamplifier, amplifier, and 
label (Wang et al., 2012) (Figure 1.6). This design helps to improve the specificity and 
sensitivity of the results because of its amplification of the target-specific signals without 
amplifying background staining (Wang et al., 2012; Grabinski et al., 2015). RNAscope® 
represents a significant advance in RNA methodology (Wang et al., 2012). In addition, a 
previous study on thick free-floating rodent brain sections and primary neuronal cultures 
suggested that a combination of  RNAscope®  and IHC is a useful method that can be used 
to detect RNA and protein in the same samples (Grabinski et al., 2015). 
Clinically, RNAscope® has been used to detect Epstein-Barr virus (EBV) -related diseases 
(Ambinder and Mann, 1994; Gulley, 2001). However, it’s still used rarely (Bingham et al., 
2016; Wang et al., 2012), particularly in cancer fields, but it has the potential to have an 
important role in the future diagnosis of PCa and is used in this chapter. 
 
Figure 6. 1 Principle of RNAscope®. (A) RNAscope probe design which consists of 20 double Z probes 
targeting a region of 1000 based and each Z target has three elements: The lower region which is 
complementary to the target RNA for the target, two upper regions which consist of 28 base binding sites and 
link to preamplifier and spacer sequence which links the lower and upper regions. (B) Step 1: The double Z 
paris bind to RNA target in the lower region of the probe (C) Step 2:  The preamplifier hybridizes to the upper 
regions of the Z probe (D) Step 3: Hybridization of multiple amplifiers per preamplifier. (E) Step 4: 
Hybridization of multiple labelled probed per amplifier. These serial steps of hybridization, including 20 
double Z probe, multiple amplifiers and multiple labelled probes leads to form thousands of labelled probes 
per RNA target.   
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6.1.3 Aims  
The goal of this chapter is to test the hypothesis, described above by carrying out the 
following:  
1. To detect the expression levels of Sall4 in normal and malignant prostate tissues from 
the Bath and TMA cohorts using two independent antibodies. 
2. To establish if the expression of Sall4 correlates with clinical features of PCa, 
including primary Gleason grade, clinical stage and biochemical recurrence. 
3. To confirm the specificity of Sall4 staining pattern and IHC results by repeating the 
experiments with a second independent antibody. 
4. To confirm the specificity of the Sall4 IHC staining by using RNAscope® to measure 
the expression of Sall4 mRNA and comparing the mRNA expression pattern to those 
produced using IHC. 
6.2 Results 
6.2.1 Testing of antigen retrieval methods 
Having chosen Sall4 as a candidate biomarker, the next step was to assess its expression 
using IHC. Before this could be carried out, different types of antigen retrieval, including 
citrate and Tris/EDTA were tested to establish which gave the best staining for Sall4.  
The IHC was carried out with an anti-Sall4 antibody from Novus that is referred to here as 
the anti-Sall4 A antibody.  IHC staining with Tris/EDTA buffer showed nuclear anti-Sall4 
A staining in prostate tissues from the Bath cohort (Figure 6.2 B), whereas, the tissue section 
from the same region from prostate tissue showed negative anti-Sall4 A staining when using 
citrate buffer (Figure 6.2 A). This study chose Tris/EDTA buffer as antigen retrieval for anti-







Figure 6. 2 Expression of anti-Sall4 A after different antigen retrieval methods. (A) A negative anti- Sall4 A 
staining (Black arrow) was observed in prostate tissues from the Bath cohort, using citrate buffer. (B) Strong 
nuclear anti-Sall4 A staining (Black arrow) was observed in prostate tissue, using Tris/EDTA buffer. IHC 
staining with Tris/EDTA buffer showed a clear nuclear anti-Sall4 A staining, whereas citrate buffer showed 
negative staining in a section of the similar region of prostate tissues. Scale bars=100µm with inserts at 2x 
zoom. 
6.2.2 Expression of Sall4 in the Bath cohort, using the anti-Sall4 
A antibody 
To test the hypothesis that nuclear Sall4 staining will be increased in PCa but will be not 
associated with PCa clinical features such as Gleason grade, clinical stage and biochemical 
relapse, IHC was carried out with the Bath cohort of prostate tissue samples using the anti-
Sall4 A antibody.  
6.2.2.1 Immunohistochemical staining of anti-Sall4 A in the Bath prostate 
samples 
IHC result showed nuclear anti-Sall4 A staining in NP tissues, which ranged from strong 
(Figure 6.3 A, arrow) to moderate (Figure 6.3 B, arrow). Nuclear anti-Sall4 A staining was 
also observed in PCa tissues and the intensity of signal varied widely, from strong and 
widespread (Figure 6.3 C, arrow), moderate (Figure 6.3 D&E, arrows) to weak and scattered 
(Figure 6.3 F, arrow). Cytoplasmic anti-Sall4 A staining was also detected in some normal 
and malignant prostate tissues, with variable levels between cases, ranging from moderate 
(Figure 6.3 E, arrowhead) to weak (Figure 6.3 A, arrowhead) or negative (Figure 6.3, C). 
Sall4 is expressed in the nucleus of the spermatogonia cells of testis tissues (Eildermann et 
al., 2012) and so this study used normal testis tissues as a positive control for anti-Sall4 A 
and as expected IHC showed nuclear anti-Sall4 A staining in spermatogonia cells (Figure 
6.3 G, arrow). A no primary antibody negative control showed no significant background 
staining in prostate tissue (Figure 6.3 H, arrow).  
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Figure 6. 3 Sall4 A staining in samples from the Bath cohort, using anti-Sall4 A antibody. Anti-Sall4 A staining 
was found heterogeneously in both normal and malignant tissues of the prostate. (A) Strong nuclear (Black 
arrow) and weak cytoplasmic (Black arrowhead) anti-Sall4 A staining in NP. (B) Moderate nuclear (Black 
arrow) anti-Sall4 A staining in NP. (C) Strong nuclear anti-Sall4 A staining (Black arrow) in PCa. (D) Moderate 
nuclear anti-Sall4 A (Black arrow) staining in PCa. (E) Moderate nuclear (Black arrow) and cytoplasmic (Black 
arrowhead) anti-Sall4 A staining in PCa. (F) Weak nuclear anti-Sall4 A staining (Black arrow) in PCa. (H) 
Positive control. Strong nuclear anti-Sall4 A staining (Black arrow) in spermatogonia cells of normal testis 
tissues. (H) Negative control (no primary antibody added) was free from background staining (Black arrow) in 
PCa. Scale bars=100µm with inserts at 2x zoom. 
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6.2.2.2 Association between anti-Sall4 A immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort  
In order to evaluate if there was an association between anti-Sall4 A staining in normal vs 
malignant prostate tissues, primary Gleason grade, clinical stage and biochemical relapse, 
nuclear anti-Sall4 A staining was quantified using the H-score system (described in Chapter 
2.3.1) and then compared to histopathological and clinical features of PCa using the clinical 
data available for the Bath cohort. The range of nuclear anti-Sall4 A H-score varied between 
0 - 160 (Figure 6.4). This study excluded cytoplasmic anti-Sall4 staining for further analysis 
because Sall4 is a transcription factor and is expected to function in the nucleus of the 
prostate tissue and the majority of the previous studies have focused on nuclear Sall4 
staining.   
The first analysis looked at the staining of anti-Sall4 A in normal vs. malignant prostate 
tissues. Quantification of the IHC staining showed that nuclear anti-Sall4 A staining was 
reduced significantly in PCa compared to NP tissues (P= 0.0266) (Figure 6.4 A & Table 
6.2). There was also a significant reduction in the mean of nuclear anti-Sall4 A scores when 
comparing PCa tissues with a primary Gleason grade 4 to those with a grade 3 (p= 0.0455) 
(Figure 6.4 B & Table 6.2).  In contrast, the current study showed no significant association 
between nuclear anti-Sall4 A staining and clinical stage T (p= 0.9072) or biochemical 
recurrence (p= 0.7311) (Table 6.2) 
Figure 6. 4 Quantification of nuclear anti-Sall4 A staining in both normal and malignant Bath prostate tissues. 
Immunohistochemical staining of nuclear anti-Sall4 A was quantified in the Bath cohort using H-score system. 
(A) Nuclear anti-Sall4 A staining was significantly reduced in PCa compared to NP tissues (p=0.0266). (B) 
Nuclear anti-Sall4 staining was reduced significantly in primary Gleason grade 4 tissues compared to grade 3 
tissues (p= 0.0455). Data represent the mean of five random images pre-case. Unpaired t-tests were conducted 
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to determine the statistical difference for each condition. NP (n=5), PCa (n=28), grade 3 (n=11) & grade 4 
(n=15).  
Table 6. 2 Nuclear anti-Sall4 A staining results with the Bath cohort clinical data. 
In summary, nuclear anti-Sall4 A staining was reduced significantly in PCa and was 
negatively associated with increasing primary Gleason grade, but was not associated with 
clinical stage T and biochemical recurrence. The Bath results, however, should be treated as 
preliminary data because of the small sample size. 
6.2.3 Expression of Sall4 in the TMA cohort, using anti-Sall4 A 
antibody 
Sall4 expression was then investigated on prostate tissue samples from the TMA cohort, 
using IHC.  
6.2.3.1 Immunohistochemical staining of anti-Sall4 A in the TMA prostate 
samples 
IHC staining of samples from the TMA showed nuclear anti-Sall4 A staining in NP tissues 
with variable levels of staining, ranging from strong (Figure 6.5 A, arrow) to moderate 
(Figure 6.5 B, arrow). Nuclear Sall4 staining was also detected in PCa tissues and the 
intensity of signal varied widely, from strong and widespread (Figure 6.5 C&D, arrows), 
moderate (Figure 6.5 E, arrow), weak (Figure 6.5 F, arrow) and negative (Figure 6.5 G, 
arrow). In addition, cytoplasmic anti-Sall4 A staining was also observed in normal and 
malignant prostate tissues, but the level varied between cases, ranging from moderate 
(Figure 6.5 C, arrowhead) to weak (Figure 6.5 B, D, arrowheads) or negative (Figure 6.5 G, 
arrow). A negative control showed no significant background staining in prostate tissue 
(Figure 6.5 H, arrow).  
 
Comparison 
Nuclear anti-Sall4 A staining  
Results p. value 
Normal vs malignant Lower in malignant 
0.0266 
Primary Gleason grades (3 & 4) Lower in high grade 
0.0455 
Clinical Stage (T1-2&T3-4) No statistically significant difference 
0.9072 




6.2.3.2 Association between anti-Sall4 A immunostaining and 
histopathological parameters of prostate cancer in the TMA cohort  
Nuclear anti-Sall4 A staining was quantified using the H-score system and compared to 
normal vs. malignant prostate tissues as well as the other histopathological features of PCa, 
including primary Gleason grade, clinical stage and biochemical recurrence using the 
clinical data available for the TMA cohort. The range of nuclear anti-Sall4 A H-score in the 
TMA cohort varied between 2.95 to 247 (Figure 6.6). 
The statistical analysis looked first at the expression of anti-Sall4 A in normal vs tumour of 
prostate tissues. Quantification of the IHC staining showed a significant reduction of nuclear 
anti-Sall4 A staining in PCa compared to NP tissues (p= 0.0003) (Figure 6.6 A & Table 6.3). 
There was also a significant difference in the mean of nuclear anti-Sall4 A H-score among 
primary Gleason grades (p= <0.0001) (Figure 6.6 B & Table 6.3), using an ANOVA test. 
Analysis of the IHC data, using multi comparison Tukey’s tests showed nuclear anti-Sall4 
A staining negatively associated with increasing primary Gleason grades. This significant 
reduction of nuclear anti-Sall4 A staining was shown when comparing PCa patients with a 
primary Gleason grade 5 to those with a grade 3 (p=<0.0001) or a grade 4 (p=0.0050) (Figure 
6.6 B & Table 6.3), whereas there was no a significant difference in the mean of nuclear 
anti-Sall4 A score between primary Gleason grade 3 to grade 4 tissues (p= 0.0782) (Figure 
6.6 B & Table 6.3). In contrast, nuclear anti-Sall4 A staining was not associated significantly 












Figure 6. 5 Sall4 staining in samples from the TMA cohort, using anti-Sall4 A. Anti-Sall4 A was stained 
heterogeneously in both normal and malignant tissues of the prostate.  (A) Strong nuclear anti- Sall4 A staining 
(Black arrow) in NP. (B) Strong to moderate nuclear (Black arrow) and weak cytoplasmic (Black arrowhead) 
anti-Sall4 A staining in NP. (C)  Strong nuclear (Black arrow) and moderate cytoplasmic (Black arrowhead) 
anti-Sall4 A staining in PCa. (D) Strong nuclear (Black arrow) and weak cytoplasmic (Black arrowhead) anti-
Sall4 A staining in PCa. (E) Moderate nuclear (Black arrow) anti-Sall4 A staining in PCa. (F) Weak nuclear 
anti-Sall4 A staining (Black arrow) in PCa. (G) PCa had no anti-Sall4 A staining.  (H) Negative control (no 
primary antibody added) no detectable background staining (Black arrow) in PCa. Scale bars=100µm with 





Figure 6. 6 Quantification of nuclear anti-Sall4 A staining in both normal and malignant TMA prostate tissues. 
Immunohistochemical staining of anti-Sall4 A was quantified in the TMA cohort using H-score system for 
nuclear IHC staining. (A) Nuclear anti-Sall4 A staining was significantly reduced in PCa compared to NP 
tissues (p=0.0003). (B) Nuclear anti-Sall4 A staining showed a significant difference among primary Gleason 
grades, using An ANOVA test (p=< 0.0001). Multi comparison (Tukey) tests showed a significant reduction 
in the mean of nuclear anti-Sall4 A staining when comparing patients with a primary Gleason grade 5 to those 
with a grade 3 (p=<0.0001) or grade 4 (p=0.005). There was no significant association in nuclear anti- Sall4 A 
staining between primary Gleason 4 and to grade 3 (p=0.0705). Data represent the mean of five random images 
per case. Unpaired or one-way ANOVA tests were conducted to determine the statistical difference for each 
set of conditions. NP (n=16), PCa (80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 6. 3 Nuclear anti-Sall4 A staining results with the TMA clinical data. 
In summary, nuclear anti-Sall4 A staining of the TMA samples was reduced significantly in 
PCa compared to NP and was negatively associated with increasing primary Gleason grade, 
but not with the stage (TNM). This result was consistent with Sall4 A results from the Bath 
cohort.  
Comparison 
Nuclear   anti-Sall4 A staining 
Results p. value 
Normal vs malignant 
Lower in malignant 0.0003 
 
Primary Gleason grades 
(3, 4 &5) 
Lower in high Gleason grade 
Anova test <0.0001 
 
Grade 4 vs. Grade 3  
0.0782 
Grade 5 vs.  Grade 3 <0.0001 
Grade 5 vs. Grade 4 0.0050 
Stage (T) No statistically significant difference 0.1744 
Stage (M) No statistically significant difference 0.2207 
Stage (N) No statistically significant difference 0.6314 
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6.2.4 Sall4 Antibody validation 
In order to show that the anti-Sall4 A staining described above was accurately reporting 
changes in Sall4 protein expression, the results should be repeated with an independent 
antibody. To achieve this two possible additional anti-Sall4 antibodies were identified, a 
rabbit monoclonal and a rabbit polyclonal from Abcam that are referred to here as anti-Sall4 
B and anti-Sall4 C, respectively.  
The ideal situation would have been to have the second antibody raised to a distinct part of 
the protein, however, this was not possible as any new antibodies identified were all raised 
using immunogens from a similar region of Sall4 (Figure 6.7). The original antibody, human 
anti-Sall4 A, is a mouse monoclonal antibody raised with an immunogen that was a partial 
recombinant protein fragment of the C-terminal of Sall4 protein (Figure 6.6 A, 1). Human 
anti-Sall4 B is a rabbit monoclonal with a recombinant immunogen from within the same 
region of Sall4 protein  (Figure 6.7 A, 2). Anti-Sall4 C is a rabbit polyclonal antibody raised 
against residues 1000 to the C- terminus of mouse Sall4 protein  (Figure 6.7 B). Mouse anti-
Sall4 C has a few different amino acids to the human anti-Sall4 A&B (Figure 6.7 B,1 black 
Bold), but the antibody is reported to react with human tissues 
(https://www.abcam.com/Sall4-antibody-chip-grade-ab29112.html). Therefore, although 
not raised to different regions of the protein, the three antibodies were raised independently 
(shown by the fact they have different hosts or clonality) and so were chosen for testing on 
normal testis and prostate tissues from the Bath cohort. 
A. Sall4 human protein sequence:  
        
        1 msrrkqakpq hinseedqge qqpqqqtpef adaapaapaa gelgapvnhp gndevasede 
       61 atvkrlrree thvcekccae ffsisefleh kknctknppv limndsegpv psedfsgavl 
      121 shqptspgsk dchrenggss edmkekpdae svvylkteta lpptpqdisy lakgkvantn 
      181 vtlqalrgtk vavnqrsada lpapvpgans ipwvleqilc lqqqqlqqiq lteqiriqvn 
      241 mwashalhss gagadtlktl gshmsqqvsa avallsqkag sqglsldalk qaklphanip 
      301 satsslspgl apftlkpdgt rvlpnvmsrl psallpqapg svlfqspfst valdtskkgk 
      361 gkppnisavd vkpkdeaaly khkckycskv fgtdsslqih lrshtgerpf vcsvcghrft 
      421 tkgnlkvhfh rhpqvkanpq lfaefqdkva agngipyals vpdpidepsl sldskpvlvt 
      481 tsvglpqnls sgtnpkdltg gslpgdlqpg pspeseggpt lpgvgpnyns praggfqgsg 
      541 tpepgsetlk lqqlvenidk attdpnecli chrvlscqss lkmhyrthtg erpfqckicg 
      601 rafstkgnlk thlgvhrtnt siktqhscpi cqkkftnavm lqqhirmhmg gqipntplpe 
      661 npcdftgsep mtvgengstg aichddvies idveevssqe apsssskvpt plpsihsasp 
      721 tlgfammasl dapgkvgpap fnlqrqgsre ngsvesdglt ndssslmgdq eyqsrspdil 
      781 ettsfqalsp ansqaesiks kspdagskae ssensrteme grsslpstfi rapptyvkve 
      841 vpgtfvgpst lspgmtplla aqprrqakqh gctrcgknfs sasalqiher thtgekpfvc 
      901 nicgrafttk gnlkvhymth gannnsarrg rklaientma llgtdgkrvs eifpkeilap 
      961 svnvdpvvwn qytsmlnggl avktneisvi qsggvptlpv slgatsvvnn atvskmdgsq 
     1021 sgisadvekp satdgvpkhq fphfleenki avs 
 
1.  Sall4 Mouse monoclonal (Sall4 A) 
      901 nicgrafttk gnlkvhymth gannnsarrg rklaientma llgtdgkrvs eifpkeilap 
      961 svnvdpvvwn qytsmlnggl avktneisvi qsggvptlpv slgatsvvnn atvskmdgsq 
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     1021 sgisadvekp satdgvpkhq fphfleenki avs 
 
2. Sall4 Rabbit monoclonal (Sall4 B) 
      901 nicgrafttk gnlkvhymth gannnsarrg rklaientma llgtdgkrvs eifpkeilap 
      961 svnvdpvvwn qytsmlnggl avktneisvi qsggvptlpv slgatsvvnn atvskmdgsq 
     1021 sgisadvekp satdgvpkhq fphfleenki avs 
 
 
B. Sall4 Mouse protein sequence: 
         
        1 msrrkqakpq hinseedqge qpqqlpspdl aealaaeepg apvnspgncd easedsipvk 
       61 rprredthic nkccaeffsl sefmehkksc tktppvlimn dsegpvpsed fsraalshql 
      121 gspsnkdslq engsssgdlk klgtdsilyl kteatqpstp qdisylpkgk vantnvtlqa 
      181 lrgtkvavnq rgaeapmapm paaqgipwvl eqilclqqqq lqqiqlteqi rvqvnmwaah 
      241 alhsgvagad tlkalsshvs qqvsvsqqvs aavallsqka snpalsldal kqaklphasv 
      301 psaasplssg ltsftlkpdg trvlpnfvsr lpsallpqtp gsvllqspfs avtldqskkg 
      361 kgkpqnlsas asvldvkakd evvlgkhkcr ycpkvfgtds slqihlrsht gerpyvcpic 
      421 ghrfttkgnl kvhlqrhpev kanpqllaef qdkgavsaas hyalpvpvpa desslsvdae 
      481 pvpvtgtpsl glpqkltsgp nsrdlmggsl pndmqpgpsp eseaglpllg vgmihnppka 
      541 ggfqgtgape sgsetlklqq lvenidkatt dpneclichr vlscqsslkm hyrthtgerp 
      601 fqckicgraf stkgnlkthl gvhrtnttvk tqhscpicqk kftnavmlqq hirmhmggqi 
      661 pntplpespc dftapepvav sengsasgvc qddaaegmea eevcsqdvps gpstvslpvp 
      721 sahlaspslg fsvlasldtq gkgalpalal qrqssrenss leggdtgpan dssllvgdqe 
      781 cqsrspdate tmcyqavspa nsqagsvksr speghkaegv escrvdtegr tslpptfira 
      841 qptfvkvevp gtfvgppsmp sgmppllasq pqprrqakqh cctrcgknfs sasalqiher 
      901 thtgekpfvc nicgrafttk gnlkvhymth gannnsarrg rklaienpma alsaegkrap 
      961 evfskellsp avsvdpaswn qytsvlnggl amktneisvi qsggiptlpv slgassvvsn 
     1021 gtiskldgsq tgvsmpmsgn geklavpdgm akhqfphfle enkiavs 
 
1. Sall4 Rabbit polyclonal (Sall4 C)s 
      961 evfskellsp avsvdpaswn qytsvlnggl amktneisvi qsggiptlpv slgassvvsn 
     1021 gtiskldgsq tgvsmpmsgn geklavpdgm akhqfphfle enkiavs 
 
 
Figure 6. 7 Human and mouse Sall4 proteins sequence with the immunogenic parts of three different antibodies. 
(A) Human Sall4 protein consists of 1053 amino acid and the antibodies raised independently as they have a 
different host or clonality. (1) Sall4 mouse monoclonal (anti-Sall4 A) immunogen is a partial recombinant 
protein with SGT tag (Grey highlighted). (2) Sall4 rabbit monoclonal (anti-Sall4 B) immunogen is a 
recombinant fragment within Human Sall4 amino acid 950 to C- terminus (Grey highlighted).  (B) Anti-Sall4 
C is a rabbit polyclonal antibody raised against residues 1000 to the C- terminus of mouse Sall4 protein. Anti-
Sall4 C immunogen is a synthetic peptide conjugated to KLH derived from residues 1000 to C- terminus of 
mouse Sall4 (Grey highlighted) and the different amino acids from Human Sall4 are shown bold. 
6.2.4.1 Immunohistochemical staining patterns of Sall4 antibodies on testis 
and prostate tissues from the Bath cohort  
IHC was carried out using the three different anti-Sall4 antibodies (anti-Sall4 A, B&C) on 
the section from similar regions of testis and prostate tissues from the Bath cohort. In testis 
tissue, the three antibodies (anti-Sall4 A, B&C)  showed strong nuclear Sall4 staining in the 
spermatogonia cells (Figure 6.8 A, B&C, arrows). In addition to the nuclear staining, anti-
Sall4 C was also observed in the cytoplasm of spermatogonia cells (Figure 6.8 C, 
arrowheads). In prostate tissues, anti-Sall4 A& B staining was observed in nuclei of 
glandular epithelial cells (Figure 6.8 D, E, G &H, arrows). In contrast, a predominant 
cytoplasmic anti-Sall4 C staining (Figure 6.8 F&I, arrowheads), with some weak nuclear 
staining, was observed in prostate tissue. It can be seen that the human anti-Sall4  A& B 
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antibodies had very similar staining patterns in both testis and prostate tissue samples, 
whereas, anti-Sall4 C staining was less similar. For this reason, anti-Sall4 B, and not anti-
Sall4 C,  was used for further analysis.    
Figure 6. 8 Immunohistochemical staining using three distinct Sall4 antibodies in testis and prostate tissue 
samples. (A) Strong nuclear  anti-Sall4 A staining (Black arrow) in spermatogonia cells of the normal testis 
tissues. (B) Strong nuclear anti-Sall4 B staining (Black arrow) in spermatogonia cells of normal testis tissues. 
(C) Moderate nuclear (Black arrow) and weak cytoplasmic (Black arrowheads) anti-Sall4 C staining in 
spermatogonia cells of normal testis tissues. (D) Strong nuclear anti-Sall4 A staining (Black arrow) in the 
glandular regions of prostate tissue. (E) Strong nuclear anti-Sall4 B staining (Black arrow) in the glandular 
regions of prostate tissue. (F) Moderate cytoplasmic anti-Sall4 C staining (Black arrowhead) in the glandular 
regions of prostate tissue. (G) Moderate nuclear anti-Sall4 A staining (Black arrow) in the glandular regions of 
prostate tissue. (H) Moderate cytoplasmic anti-Sall4 C staining  (Black arrowhead) in the glandular regions of 
prostate tissue. (I) Moderate cytoplasmic anti-Sall4 C staining  (Black arrowhead) in the glandular regions of 
prostate tissue. Both human anti-Sall4 A&B antibodies showed the same staining patterns in testis and prostate 
tissues. Mouse anti-Sall4 C showed predominate cytoplasmic staining pattern in testis and prostate tissues.  
Scale bars—100 μm with inserts at 2x zoom. 
6.2.5 Expression of Sall4 in the Bath cohort, using anti-Sall4 B 
Antibody  
After confirming that human anti-Sall4 A & B antibodies had similar staining patterns in 
testis and prostate tissues from the Bath cohort, and to increase the confidence in the anti-
Sall4 A IHC result; anti-Sall4 B staining was investigated on prostate tissue samples from 
the Bath cohort, using IHC.   
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6.2.5.1 Anti-Sall4 B staining in the normal and malignant Bath prostate 
samples 
The IHC staining showed no significant staining for Sall4 in the nucleus of NP tissues, using 
anti-Sall4 B (Figure 6.9 A, arrow). In contrast, nuclear anti-Sall4 B staining was observed 
in PCa tissues and the intensity of signal varied widely, from strong and widespread (Figure 
6.9 B&C, arrows), moderate (Figure 6.9 D, arrow), weak and scattered (Figure 6.9 E&F, 
arrows) and negative. In addition to the nuclear staining, weak cytoplasmic anti-Sall4 B 
staining was also found in a few cases of PCa (Figure 6.9 B & E, arrowheads). Strong nuclear 
anti-Sall4 B staining was detected in the positive control spermatogonia cells of normal testis 
tissue (Figure 6.9 G, arrow). A negative control showed no detectable background staining 
in prostate tissue (Figure 6.9 H, arrow).   
6.2.5.2 Association between anti-Sall4 B immunostaining and 
histopathological parameters of prostate cancer in the Bath cohort 
In order to evaluate if there was an association between anti-Sall4 B staining in normal vs. 
malignant prostate tissues, primary Gleason grades, clinical stages and biochemical relapse, 
nuclear anti-Sall4 B staining was quantified using the H-score system and compared to the 
histopathological and clinical features of PCa using the clinical data available for the Bath 
cohort. The range of nuclear anti-Sall4 B H-score in the Bath cohort varied between 0 - 100 
(Figure 6.10). This analysis was carried out later in the project and the number of samples 
still available from the Bath cohort was reduced (14 PCa vs. 3 NP), for this reason, statistical 
tests were not carried out. 
Quantification of the IHC showed increased nuclear anti-Sall4 B scores in PCa compared to 
NP tissues (Figure 6.10 A). There was a negative association between nuclear anti-Sall4 B 
staining and primary Gleason grade. Four of five (80%) PCa tissues with a low Gleason 
grade (3) had positive nuclear anti-Sall4 B staining, whereas, more than half of primary 
Gleason grade 4 tissues showed negative anti-Sall4 B immunostaining (Figure 6.10 B and 
Table 6.4). Nuclear anti-Sall4 B staining was not associated with clinical stage T (T1-2 vs. 
T3-4) (Table 6.4). There was no biological difference in the nuclear anti-Sall4 B staining 





Figure 6. 9 Sall4 B expressions in samples from the Bath cohort, using anti-Sall4 antibody. Anti-Sall4 B was 
expressed heterogeneously in both normal and malignant tissues of the prostate. (A) NP had no anti-Sall4 B 
immunostaining (Black arrow). (B) Strong nuclear (Black arrow) and weak cytoplasmic (Black arrowhead) 
anti-Sall4 B staining in PCa. (C) Strong nuclear (Black arrow) anti-Sall4 B staining in PCa. (D) Moderate 
nuclear (Black arrow) Sall4 B staining in PCa. (E) Weak nuclear (Black arrow) and cytoplasmic (Black 
arrowhead) anti-Sall4 B staining in PCa. (F) Weak nuclear (Black arrow) anti-Sall4 B staining in PCa. (F) 
Weak nuclear anti-Sall4 staining (Black arrow) in PCa. (H) Strong nuclear anti-Sall4 B staining (Black arrow) 
in spermatogonia cells of normal testis tissues. (H) Negative control (no primary antibody added) showed free 






Figure 6. 10 Quantification of anti-Sall4 B nuclear staining in both normal and malignant Bath prostate tissues. 
Immunohistochemical staining of anti-Sall4 B was quantified in the Bath cohort using the H-score system for 
nuclear IHC staining. (A) Nuclear anti-Sall4 A staining was increased in PCa compared to NP tissues. (B) 
Nuclear anti-Sall4 B staining was reduced in primary Gleason grade 4 tissues compared to grade 3 tissues. 
Data represent the mean of five random images per case. NP (n=3) PCa (n=14), grade 3 (n=5), grade 4(n=7). 
Table 6. 4 Nuclear anti-Sall4 B staining results with the Bath clinical data. 
 
In summary, nuclear anti-Sall4 B staining was increased in PCa compared to NP tissues and 
was negatively associated with increasing primary Gleason grade, but not with clinical stage 
T and biochemical recurrence. IHC Sall4 A&B data in normal vs. malignant prostate tissues 
was contradictory, whereas, the other association data was similar. The staining was repeated 
using the tissue microarray with a larger sample size.  
6.2.6 Expression of Sall4 B in the TMA cohort, using the anti-
Sall4 B antibody 
IHC was carried out on prostate tissue samples from the TMA cohort, using the anti-Sall4 B 
antibody.  
Comparison Nuclear anti-Sall4 B staining  
Normal vs malignant Higher in malignant 
Primary Gleason grades (3 & 4)  Lower in high grade 
Stage (T) (T1-2vs.T3-4) No biological difference 
5 years Biochemical recurrence  No biological difference 
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6.2.6.1 Anti-Sall4 B staining in normal and malignant TMA prostate 
samples 
IHC showed that nuclear anti-Sall4 B staining was not detected in NP tissues (Figure 6.11 
A, arrow). In contrast, nuclear anti-Sall4 B staining was observed in PCa tissues and the 
intensity of signal varied widely, from strong and widespread (Figure 6.11 B&C, arrows), 
moderate (Figure 6.11 D&E, arrows), weak (Figure 6.11 F, arrow) and negative (Figure 6.11 
G, arrow). A negative control showed no significant background staining in prostate tissue 
(Figure 6.11 H, arrow).  
6.2.6.2 Association between anti-Sall4 B staining and histopathological 
parameters of prostate cancer from the TMA cohort 
Having carried out IHC staining, the nuclear anti-Sall4 B staining was quantified using H-
score system as carried out for the Bath cohort samples and then compared to normal vs 
malignant prostate tissues and other histopathological parameters, including primary 
Gleason grade, clinical stage and biochemical recurrence. The range of nuclear anti-Sall4 B 
H-score in the TMA varied between 0-80 (Figure 6.12).  
The first analysis looked at the nuclear anti-Sall4 B staining in normal vs. malignant prostate 
tissues. Quantification of the nuclear anti-Sall4 B showed increased nuclear anti-Sall4 B 
staining significantly in PCa tissues compared to NP tissues from the TMA cohort (p= 
0.0456) (Figure 6.12 A & Table 6.5). There was a significant difference in the mean of 
nuclear anti-Sall4 B scores among primary Gleason grades (p= <0.0001), using an ANOVA 
test (Figure 6.12 B & Table 6.5). Detailed analysis of the IHC data, using multi-comparison 
(Tukey) tests showed nuclear anti-Sall4 B staining negatively associated with increasing 
primary Gleason grades. Nuclear anti-Sall4 B staining was reduced significantly when 
comparing PCa patients with a primary Gleason grade 3 to those with a primary Gleason 
grade 4 (p=0.0002) or a grade 5 (p=<0.0001) (Figure 6.12 B & Table 6.5). There was no 
significant difference in mean of the nuclear anti-Sall4 B score between primary Gleason 
grade 4 and grade 5 tissues (p= 0.2657) (Figure 6.12 B & Table 6.5). In contrast, there was 
no significant association between nuclear anti-Sall4 B staining and clinical stage TNM 






Figure 6. 11 Sall4 B expressions in samples from the TMA cohort, using anti-Sall4 B antibody. Anti-Sall4 B 
was expressed heterogeneously in both normal and malignant tissues of the prostate.  (A) Negative anti-Sall4 
B staining (Black arrow) in NP. (B) Strong nuclear (Black arrow) anti-Sall4 B staining in PCa. (C) Strong 
nuclear anti-Sall4 B staining (Black arrow) in PCa.  (D) Moderate nuclear and widespread anti-Sall4 B staining 
(Black arrow) in PCa. (E) Moderate nuclear (Black arrow) anti- Sall4 B staining in PCa. (F) Weak nuclear anti-
Sall4 B staining (Black arrow) in PCa. (G) PCa had strong staining for anti-Sall4 B (Black arrow). (H) Negative 
control (no primary antibody added) showed free from background staining (Black arrow) in PCa. Scale 







Figure 6. 12 Quantification of anti-Sall4 B nuclear staining in both normal and malignant TMA  prostate tissues. 
Immunohistochemical staining of anti-Sall4 B was quantified in the TMA cohort using H-score system for 
nuclear IHC staining. (A) Nuclear anti-Sall4 B staining was significantly increased in PCa compared with NP 
(p=0.0456). (B) Nuclear anti-Sall4 B staining showed a significant difference among the primary Gleason 
grades, using An ANOVA test (p=< 0.0001). Multi-comparison (Tukey) tests showed a significant reduction 
in the nuclear anti-Sall4 B score when comparing grade 3 to grade 4 (p=0.0002) or grade 5 tissues (p=<0.0001). 
There was no significant difference in the mean of nuclear anti-Sall4 B staining between primary Gleason 5 
and grade 4 (p=0.3657). Data represent the mean of five random images per case. Unpaired or one-way 
ANOVA tests were conducted to determine the statistical difference for each set of conditions. NP (n=16), PCa 
(80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 6. 5 Nuclear anti-Sall4 B staining results with the TMA clinical data. 
In summary, nuclear anti-Sall4 B staining was increased significantly in PCa compared to 
NP and was negatively associated with increasing primary Gleason grade, but not with the 
clinical stage (TNM). These results agreed with anti-Sall4 B results in the Bath cohort 
results. However, they only partially agreed with the Sall4 A results from both cohorts, 
where the Sall4 A antibody showed decreased staining in the malignant prostate. 
Comparison 
Nuclear anti- Sall4 B staining 
Results p. value 
Normal vs malignant Higher in malignant 
0.0456 
 
Primary Gleason grades 
(3, 4 &5). 
Lower in high Gleason grade 
Anova test <0.0001 
 
Grade 4 vs. Grade 3 0.0002 
Grade 5 vs.  Grade 3 <0.0001 
Grade 5 vs. Grade 4 0.2657 
Stage (T) No statistically significant difference 0.5045 
Stage (M) No statistically significant difference 0.5411 
Stage (N) No statistically significant difference 0.0899 
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6.2.7 Analysis of expression of Sall4 mRNA using RNAscope  
The IHC results of anti-Sall4 A&B staining between normal and malignant prostate tissue 
samples were contradictory, with one antibody showing an increase and the other a decrease 
in expression in malignant tissues. Measuring Sall4 mRNA expression using RNAscope 
(Described in Chapter 6.1.2) provided an alternative way of trying to establish which pattern 
was correct, so Sall4 mRNA levels were investigated on normal and malignant prostate 
tissues from the Bath and TMA cohorts using the RNAscope® assay.   
6.2.7.1 Testing the RNAscope protocol  
In order to test if the RNAscope® protocol was working correctly, it was performed with 
positive (PPIB, Homo sapiens peptidylprolyl isomerase B (cyclophilin B), mRNA) and 
negative (Dap B, a bacterial gene) controls on HeLa cells and prostate tissue samples.  
The positive control probe (PPIB) showed strong brown punctate dots located in the nuclei 
and cytoplasm of HeLa cells (Figure 6.13 A) and prostate tissue (Figure 6.12 C). In contrast, 
the negative control probe (Dap B) showed no clear background staining in both HeLa cells 
(Figure 6.13 B) and prostate tissue (Figure 6.13 D). This confirmed that the RNAscope® 
was working as expected and so the technique was then used to investigate Sall4 mRNA 
expression in prostate samples. 
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Figure 6. 13 RNA scope: Positive and negative control expression in HeLa cells and prostate tissue. (A&C)  
Strong nuclear and cytoplasmic PPIB staining in HeLa cells and prostate tissue. (B&D) Dap B showed no clear 
background staining in HeLa cells and prostate tissue. The presence of mRNA is shown in brown dots. Blue 
staining is a hematoxylin counterstain. Scale bars=100µm with inserts at 2x zoom.   
6.2.7.2 Sall4 mRNA expression in prostate tissues from the Bath cohort 
RNAscope® analysis was then carried out on prostate tissue samples from the Bath cohort. 
The result showed that Sall4 mRNA staining was observed in normal and malignant prostate 
tissue samples (Figure 6.14). A quarter of NP tissues (1/4) had Sall4 mRNA staining in the 
nuclei and/ or cytoplasm of glandular epithelial cells (Figure 6.14 A, arrow), whereas three 
quarters (75%) of them had no Sall4 mRNA staining (Figure 6.14 B, arrow). Sall4 mRNA 
staining was also found in PCa tissues and the number of positive cells varied widely, from 
a widespread (Figure 6.14 C&D, arrows), scattered (Figure 6.14 E, arrow) and negative 
(Figure 6.14 F, arrow). In testis tissue, Sall4 mRNA was expressed in spermatogonia cells 
(Figure 6.14 G, arrow). A negative control showed no detectable background staining in 
prostate tissue (Figure 6.14 H, arrow).  
6.2.7.3 Association between Sall4 mRNA staining and histopathological 
parameters of prostate cancer tissues from the Bath cohort  
Histologically normal and malignant prostate tissues were stained for Sall4 mRNA and 
scored using the Sall4 mRNA scoring system (Described in chapter 2.2.3). The range of 
Sall4 mRNA score in the TMA varied between 0-3.6 (Figure 6.15). This analysis was carried 
out later in the study and the number of samples still available from the Bath cohort was 
reduced (12 PCa vs. 4 NP), for this reason, statistical tests were not carried out.  
The RNAscope staining showed increased Sall4 mRNA staining in PCa tissue samples 
compared to NP tissues.  A quarter (1/4) of the NP tissues showed positive staining for Sall4 
mRNA, whereas, 50% (6/12) of PCa had a positive Sall4 mRNA staining (Figure 6.15 A). 
There was also a reduction in the staining of Sall4 mRNA with increasing primary Gleason 
grade. 75% of PCa with grade 3 (3/4 cases) has a positive Sall4 mRNA staining, whereas, 
the percentage of positive Sall4 mRNA staining was reduced to 33% in PCa with a primary 
Gleason grade 4 (2/6 cases) (Figure 6.15 B and Table 6.5). Sall4 mRNA staining in localised 
PCa T1-2 was higher than advanced stage T3-4 (Figure 6.15 C& Table 6.6) and there was a 
negative association between Sall4 mRNA staining and biochemical recurrence. 75% of non 
relapsed PCa had positive staining for Sall4 mRNA, whereas, 100% of relapsed PCa showed 
negative staining for Sall4 mRNA (Figure 6.15 D& Table 6.6).  
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Figure 6. 14 Sall4 mRNA staining in prostate samples from the Bath cohort. (A) Sall4 mRNA staining (Black 
arrow) in some NP epithelial cells (B) No Sall4 mRNA staining in NP tissue (Black arrow). (C) Widespread 
Sall4 mRNA staining  (Black arrow) in PCa tissues. (D) Widespread Sall4 mRNA staining  (Black arrow) in 
PCa tissues. (E) scattered Sall4 mRNA staining (Black arrow) in PCa. (F) No positive staining for Sall4 mRNA 
(Black arrow)  in PCa. (G) Spermatogonia cells of normal testis tissues had a positive Sall4 mRNA staining 
(Black arrow). (H) Negative control showed a free background staining (Black arrow) in PCa. Scale 




Figure 6. 15 Quantification of Sall4 mRNA staining in both normal and malignant Bath prostate tissues. 
RNAscope® staining of Sall4 mRNA was quantified in the Bath cohort using Sall4 mRNA score. (A) Sall4 
mRNA staining was increased in PCa compared with NP tissues (B) Sall4 mRNA staining was negatively 
associated with increasing primary Gleason grade. (C) Sall4 mRNA staining was not associated with the 
clinical stage (T3-4). (D) Sall4 mRNA staining was negatively associated with a biochemical recurrence.  Data 
represent the mean of five random images per case. NP (n=4), PCa (12), grade 3 (n=4), grade 4 (n=6), T1-2 
(n=7), T3-4(n=4), non-recurrent (n=6) and recurrent (n=4). Due to the small sample size, no statistical tests 
were used.  
Table 6. 6 Summary of m RNA Sall4 result with clinical data of the Bath cohort  
In summary, Sall4 mRNA staining was increased in PCa and was negatively associated with 
increasing grade and biochemical relapse. This result largely agreed with the anti-Sall4 B 
results and also partially agreed with anti-Sall4 A staining in both cohorts. However, the data 
is based on a small cohort so RNAscope was used to measure the expression of Sall4 in 
the larger TMA cohort. 
Comparison Sall4 mRNA staining 
Normal vs malignant Higher in malignant 
Primary Gleason grades (3 & 4) Lower in high grade 
Clinical Stage (T) No biological difference 
5 years Biochemical recurrence Lower in biochemical recurrence 
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6.2.8 Sall4 mRNA expression in prostate tissues from the TMA 
cohort 
RNAscope® was carried out on prostate tissue samples from the TMA cohort.  
6.2.8.1. Sall4 mRNA staining in normal vs malignant prostate tissue from 
the TMA cohort 
 NP tissues showed no significant staining for Sall4 mRNA (Figure 6.15 A, arrow). In 
contrast, Sall4 mRNA staining was detected in PCa tissues and the number of positive cells 
varied widely, from widespread (Figure 6.16 B, arrow), scattered (Figure 6.16 C&D, arrows) 
and negative (Figure 6.16 E, arrow). A negative control was free from background staining 
in prostate tissue (Figure 6.16 F, arrow). This result was consistent with Sall4 protein and 
mRNA results in both cohorts.   
6.2.8.2 Association between Sall4 mRNA staining and histopathological 
parameters of prostate cancer from the TMA cohorts 
In order to determine if there an association between Sall4 mRNA staining in normal vs. 
malignant prostate tissues and/or different primary Gleason grades, clinical stages and 
biochemical relapse, Sall4 mRNA staining was assessed using Sall4 mRNA score and then 
compared to histopathological features of PCa using the clinical data available for the TMA 
cohort.  
The first analysis looked at Sall4 mRNA staining in normal and malignant prostate tissues 
from the TMA cohort. Quantification of RNAscope showed that Sall4 mRNA staining was 
significantly increased in PCa compared to NP tissues (p= 0.0007) (Figure 6.17 A & Table 
6.7). There was also a significant difference in the mean of Sall4 mRNA scores among 
primary Gleason grades (p= 0.0109), using an ANOVA test (Figure 6.17 B & Table 6.7). 
Sall4 mRNA staining was significantly reduced when comparing PCa patient with primary 
Gleason grade 3 tissues to those with grade 4 (p=0.0499) or grade 5 tissues (p=0.0081) 
(Figure 6.17 B & Table 6.7). There was no significant difference in the mean of Sall4 mRNA 
score between primary Gleason grade 4 and grade 5 (p= 0.4070) (Figure 6.17 B & Table 
6.7). In contrast, Sall4 mRNA staining was not associated significantly with clinical stage 





Figure 6. 16 Sall4 mRNA expression in prostate samples from the TMA cohort. (A) Negative staining for Sall4 
mRNA (Black arrow) in  NP. (B) Widespread Sall4 mRNA (Black arrow) in PCa. (C) Scattered Sall4 mRNA 
staining (Black arrow) in PCa. (D) Scattered Sall4 mRNA staining (Black arrow) in PCa. (E) Negative staining 
for Sall4 mRNA (Black arrow) in PCa.  (F) The negative control was free from background staining (Black 










 Figure 6. 17 Quantification of Sall4 mRNA staining in both normal and malignant TMA prostate tissues. Sall4 
mRNA staining was quantified in the TMA cohort using Sall4 mRNA score. (A) Sall4 mRNA staining was 
significantly increased in PCa compared with NP tissues (p=0.0007). (B) Sall4 mRNA staining showed a 
significant difference among primary Gleason grades, using An ANOVA test (p=0109). Multi comparison 
(Tukey) tests showed a significant reduction in Sall4 mRNA staining when comparing grade 3 tissues to those 
with a grade 4 (p=0.0499) or grade 5 (p=0.0081). Sall4 mRNA staining was also reduced in Gleason 5 
compared to Grade 4 but this reduction was not significant (p=0.3657). Data represent the mean of five random 
images per case. Unpaired T-test or one-way ANOVA tests were conducted to determine the statistical 
difference for each set of condition. NP (n=16), PCa (n=80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 6. 7 Sall4 mRNA staining results with the TMA clinical data. 
In summary, Sall4 mRNA staining was increased significantly in PCa and was negatively 
associated with increasing primary Gleason grade in the TMA cohort. However, its 
expression was not associated with clinical stage. These results were consistent with those 
from anti-Sall4 B. They were also partially agreed with the anti-Sall4 A results, the main 
significant difference was that anti-Sall4A staining showed a reduction in PCa rather than 
an increase. The results from the two antibodies and the RNAscope with the two cohorts are 
Comparison 
Sall4 mRNA staining 
Results p. value 
Normal vs malignant Higher in malignant 
0.0007 
 
Primary Gleason grades 
(3, 4 &5). 
Lower in high Gleason 
grade 
Anova test 0.0109 
Grade 4 vs. Grade 3 0.0499 
Grade 5 vs.  Grade 3 0.0081 
Grade 5 vs. Grade 4 0.4070 
Stage (T) No statistically significant difference 0.6781 
Stage (M) No statistically significant difference 0.822 
Stage (N) No statistically significant difference 0.4469 
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summarised below (Table 6.8). The Sall4 hypothesis in this study is accepted partially by 
IHC anti Sall4 B and mRNA probe. 
6.2.9 Sall4 results in the Bath and TMA cohorts: testing the 
hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
in Table 5.8. 
Table 6. 8 The summary of Sox7 results in the Bath and TMA cohorts  
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6.3 Discussion  
6.3.1. Summary  
By examining Sall4 expression at protein and mRNA levels in normal and malignant prostate 
tissue samples from the Bath and TMA cohorts, using IHC and RNAscope assays, 
respectively, the present study showed that Sall4 protein and mRNA staining was 
significantly increased in PCa compared to NP tissues from both cohorts, using anti-Sall4 B 
antibody and Sall4 mRNA  probe. In contrast, nuclear anti- Sall4 A was reduced significantly 
in PCa compared to NP tissues from both cohorts. Sall4 protein and mRNA levels were 
negatively associated with increasing primary Gleason grade in both cohorts using two 
different anti-Sall4 antibodies (A&B) and Sall4 mRNA probe. In contrast, Sall4 protein and 
mRNA level did not show a clear association with the clinical stage (TNM) and the risk of 
biochemical recurrent in both cohorts.  In this chapter, I will consider how this pattern of 
expression compares to previous studies, the differences between IHC and RNAscope for 
biomarker analysis and the possible role of Sall4 in PCa.   
Table 6. 9 Confirmed patterns of expression for Sall4. 
 
Biomarker Confirmed patterns of expression 
Anti-Sall4 A 
Anti-Sall4 A staining was reduced significantly in PCa and was negatively associated with 
increasing primary Gleason grade in the Bath and TMA cohorts.  
Anti-Sall4 B 
Anti-Sall4 B staining was increased in PCa and was negatively associated with increasing primary 
Gleason grade in the Bath and TMA cohorts.  
Sall4 mRNA 
Sall4 mRNA staining was increased in PCa and was negatively associated with increasing primary 
Gleason grade in the Bath and TMA cohorts. 
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6.3.2 Sall4 is increased significantly in prostate cancer and is 
negatively associated with increasing primary Gleason grade 
but not clinical stage and biochemical relapse 
This study showed two approaches that Sall4 staining was significantly increased in PCa 
compared to NP tissues. Therefore, it appears most likely that Sall4 expression is increased 
in PCa compared to NP tissues. However, given the contradictory result with the Sall4 A 
antibody, future work should confirm this finding.  
To the best of my knowledge, Sall4 staining in normal vs. malignant prostate tissues and the 
association between expression and primary Gleason grade, clinical stage and biochemical 
relapse has not been previously examined and this study is the first to investigate if there is 
an association between Sall4 and clinical parameters in PCa. However, there are three 
previous studies, focusing on other cancer tissues, that have shown nuclear Sall4 staining in 
normal or malignant prostate tissues. These reports have not determined the association 
between nuclear Sall4 expression in normal vs. malignant prostate tissues or other PCa 
clinical features. For example, a study on non- small cell lung carcinomas used a TMA with 
112 normal tissues as controls, including 7 NP tissues and showed weak nuclear Sall4 
staining in 57% of NP tissues (4/7) (Rodriguez et al., 2014). This result was consistent with 
the Bath cohort data and anti-Sall4 A data in the TMA cohort. Another IHC study with a 
large TMA of human cancer tissues, including 62 PCa showed no nuclear Sall4 staining in 
all tumour tissues of the prostate (Kilic et al., 2016). This result was of some consistency 
with our results in poorly differentiated PCa tissues and because the authors did not mention 
the clinical data of PCa sample and these samples might be poorly differentiated. In addition, 
a third study was on metastatic germ & non-germ cell tumours and showed all metastatic 
PCa tissue samples (12 cases only) had no Sall4 staining (Cao et al., 2009). The work 
presented here did not look at metastatic samples, but high grade tumours did show lower 
levels of Sall4 which is consistent with a model where more advanced tumours such as high 
grade, or metastatic tumours, have lower expression of Sall4. The data in this thesis agrees 
with some previous studies looking at Sall4  in other types of cancers, including lung and 
colon carcinomas (Forghanifard et al., 2013; Rodriguez et al., 2014). However, the anti-
Sall4 B and mRNA data presented here did not agree with the study done by Hao, et al. that 
showed a reduction Sall4 staining in colorectal carcinoma compared to atypical hyperplasia 
or normal colon tissues (Hao et al., 2016). However,  this study was consistent with the anti-
Sall4 A data. Hao et al used a mouse monoclonal antibody but we believe that this antibody 
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is different from our antibodies. The complicated and partially contradictory IHC results for 
nuclear Sall4 staining in normal vs. malignant tissues from different cancers suggests Sall4 
expression might show increased and decreased expression depending on the cancer type. 
However, different studies have also used different antibodies and different concentrations 
that might affect IHC results. Further work needs to be carried out using tissue from large 
cohorts of different cancer types and measuring the expression of both mRNA and protein 
to establish if differences between studies are due to differences between tumour type or the 
reagents used.  
In term of an association between Sall4 staining with primary Gleason grade, the current 
study showed that Sall4 staining was negatively associated with increasing primary Gleason 
grades in both cohorts, using two different antibodies and mRNA probes for Sall4. This 
result was consistent with the previous studies on colorectal carcinoma (Hao et al., 2016) 
and suggests that Sall4 could play a role in promoting cell differentiation in lower grade PCa 
and might be a potential biomarker for PCa prognosis. In contrast, another study showed 
Sall4 mRNA levels in moderate differentiated colorectal cancer tissues were lower than well 
and poorly differentiated tissues, using RT-PCR (Forghanifard et al., 2013). This study, 
however, was on colorectal carcinoma and used RT-PCR as a different diagnostic method 
for measuring Sall4 mRNA. Other reports showed there was no significant association 
between Sall4 expression and grades of cancers, including lung and hepatocellular 
carcinoma (Han et al., 2014; Rodriguez et al., 2014; Gautam et al., 2015). These studies 
used different cancer types, suggesting that there may be multiple roles for  Sall4 in cancer 
depending on cancer types.  
Our data showed no significant association between Sall4 staining and clinical stage in both 
cohorts, suggesting Sall4 expression does not link to PCa clinical stage (TNM). The results 
were consistent with the previous findings in other cancers, including lung cancer (Gautam 
et al., 2015; Rodriguez et al., 2014), oesophagus (Kilic et al., 2016) and hepatocellular 
carcinomas (Han et al., 2014). In colorectal carcinoma, Sall4 mRNA expression was also 
not associated with clinical stage T, but was positively associated with a tumour metastatic 
to lymph nodes (Forghanifard et al., 2013). This could be caused by a difference in tumour 
type, however, it used a small sample size divided into three groups, including  N0: 28, N1:9 
& N2:3. A three-group statistical analysis with this small sample size may not provide a 
reliable guide to show if there is a real biological difference.  
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Finally, the present study suggests that there was no significant association between Sall4 
protein and mRNA staining and a risk of biochemical relapse in the Bath cohort. There was 
no previous study in PCa, but the present study did not agree with the previous study on 
hepatocellular carcinoma that showed increased Sall4 protein in serum of the hepatocellular 
carcinoma relapsed patients compared with non- relapsed, using RT-PCR assay (Han et al., 
2014). The study, however, used the serum samples from hepatocellular carcinoma patients 
and also used a different method of detection. There are also still many questions about our 
data because the Bath prostate sample size was small and the TMA cohort lacked clinical 
data regarding relapse and non-relapse status. It would be very interesting to assess the 
expression of  Sall4 at protein and mRNA level, using IHC and RNAscope in a large TMA 
cohort which has clinical information about a risk of biochemical relapse (see Chapter 8 for 
more details). 
6.3.3 RNAscope vs IHC staining for biomarker analysis 
Different methods are used for PCa diagnosis and prognosis in the clinic, including serum 
PSA level, Gleason score and clinical stage, as well as the identification of tumour markers 
using IHC. Immunohistochemistry represents one of these widely used methods in clinical 
practice and identifies several components of cells and tissues, including proteins (Oliver 
and Jamur, 2010; Wang et al., 2012). However, IHC results can be affected by many factors. 
Using different antibodies, different antibody concentrations or antigen retrieval methods 
may show different IHC results (Whitaker et al., 2008). The absence of a standard protocol 
for IHC represents another disadvantage from using IHC. Finally, IHC can have problems 
with non-specific staining that can show false positive staining (Whitaker et al., 2008).   
RNAscope, the newest ISH method is a highly specific and sensitive method used to 
determine a single mRNA in tissue, using a standard microscope (Wang et al., 2012). This 
method uses a novel double Z probe that binds to the target RNA and then to a cascade of a 
preamplifier, amplifier, and label probe (Wang et al., 2012). This method provides high 
specificity and sensitivity detection due to using the double Z probe design which is able to 
control background staining (Wang et al., 2012; Grabinski et al., 2015).  However, it is an 
expensive method. A previous study on a thick free-floating rodent brain sections and 
primary neuronal cultures suggested that a combination of  RNAscope and IHC is a useful 
method that can be used to address a specific scientific question which is not readily 
answerable with a single technique (Grabinski et al., 2015). Our data also suggest that the 
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use of both techniques on prostate tissues samples may give more accurate expression results 
than using only IHC staining.   
6.3.3 The possible role of  Sall4 in prostate cancer 
Previous reports have proposed many different functional roles of Sall4 in cancer, including 
regulating cell transformation, proliferation, apoptosis, invasive migration and cell stemness 
(Zhang et al., 2015). However, this section will focus on a couple of mechanisms for Sall4 
which could explain its a role in PCa.  
It has been found that cell proliferation and colony formation in the si-Sall4 group was 
significantly lower than in normal controls. In contrast, the apoptotic rate of the si-Sall4 
group was higher than the control group. This study is also found increases in  the pro-
apoptotic protein Bax and decreased anti-apoptotic protein Bcl2 levels in the si-Sall4 group 
compared to normal control, using PCa cell lines (Liu and Shan, 2016). These results suggest 
that increased Sall4 in PCa might play a role in increasing the tumour formation by inhibiting 
apoptosis through Bcl2 and Bax proteins.   
Sall4 might have another possible role in PCa. Sall4 could play a transcriptional activator 
role for the  Bmi-1 gene which plays a role in protecting cells from apoptosis as well as in 
regulating differentiation and self- renewal of SCs (Jiang et al., 2009; Wang et al., 2014b). 
It has been shown that Sall4 can bind to the promoter region of Bmi-1 and regulate its 
expression.  In addition, the Bmi-1 level in Sall4 transgenic mice was higher than wild-type 
controls and showed also a significant association between Sall4 reduction by siRNA in 
leukemic cell line and Bmi-1 level, suggesting there is a strong association between them in 
haematopoietic and leukemic cells (Yang et al., 2007).  These results, when taken together, 
indicate that Sall4 could play a role in PCa initiation through its role in activating Bmi-1 
which promotes proliferation and inhibits apoptosis of cells. Undoubtedly, further work will 
shed more light on the possible role of Bmi-1 in PCa intention and progression as well as its 
association with Sall4.   
PTEN  is a tumour suppressor gene and essential in PCa (Jamaspishvili et al., 2018). PTEN 
converts phosphatidylinositol-3,4,5-trisphosphate (PIP3) to phosphatidylinositol-4,5-
trisphosphate (PIP2), thereby directly inactivating the PI3K/AKT pathway (Leevers et al., 
1999), whereas, losing its function which has been reported in cancers such as PCa, leads to 
activation of the PI3K/AKT pathway which then regulates various of cellular processes, 
including increased cell survival, proliferation and inhibiting of apoptosis (Li and Sun, 1998; 
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Planchon et al., 2008). In addition to its role in promoting proliferation and apoptosis, 
nuclear PTEN shows an important role in chromosome stability, DNA repair, cell cycle 
arrest and cellular stability (Planchon et al., 2008). Interestingly, decreased PTEN expression 
is found in Sall4 B transgenic mice compared to wild-type control, suggesting that Sall4 
inhibits the transcription of PTEN (Lu et al., 2009), suggesting increased Sall4 might play 
an important role in PCa cell formation through its a PTEN inhibitory role.  
In human acute myeloid leukaemia, Sall4 is proposed to have a co-activator role of Wnt/β-
catenin pathway through its direct interaction with β-catenin and enhancing synergistically 
the transcriptional output of the Wnt/β-catenin pathway (Ma et al., 2006). Other studies 
reported that Sall4 could bind directly to c-Myc or TCF/LEF in Wnt/ β-catenin and then 
activate its expression (Bohm et al., 2006; Li et al., 2015a), suggesting Sall4 could contribute 
to PCa formation through activation of the Wnt/β-catenin pathway.  
It is also important to consider that Sall4 appears to be increased in PCa compared to NP but 
decreased in higher grade tumours. This suggests that Sall4 could play a different role in 
tumour initiation than in tumour progression. Sall4 might play a role in regulating cell 
differentiation in PCa. A previous Sall4 immunohistochemical study on normal and 
malignant colon tissues proposed that increased Sall4 might promote cell differentiation in 
colorectal carcinoma (Hao et al., 2016). This result is consistent with our Sall4 data which 
showed decreased Sall4 protein and mRNA level with increasing primary Gleason grade,  
using two different antibodies and mRNA probe. Taken together, increased Sall4 might play 
a role in PCa differentiation.  
 6.3.4 Conclusion   
In conclusion, Sall4 expression appears to be increased in PCa compared to NP tissues and 
its expression is negatively associated with increasing primary Gleason grade, but is not 
associated with clinical stage and risk of biochemical relapse. Sall4 might have a role in 
promoting cell proliferation and differentiation and loss of its expression could be a potential 
indicator for aggressive PCa. Further studies are needed to confirm if there is any association 



























CHAPTER SEVEN   
IDENTIFICATION AND 
ASSESSMENT OF ZSCAN4 
EXPRESSION IN PROSTATE 




7. Identification and Assessment of Zscan4 
expression in prostate tissues from the Bath and 
TMA cohorts 
7.1 Introduction  
Zinc finger and SCAN domain containing 4 (Zscan4) is one of the candidate biomarkers that 
were identified for analysis. This chapter focuses on Zscan4 and describes why the protein 
was selected for analysis and presents all the experimental data that was collected for the 
protein. 
7.1.1 Identification of Zscan4 using the literature searching 
Zscan4 is thought to be a potential transcription factor (Falco et al., 2007) and is expressed 
in ESCs and plays an important role in regulating telomere length and genomic stability in 
ESCs (Zalzman et al., 2010; Ko et al., 2013). The previous study found that Zscan4 is 
expressed predominantly in mouse ESCs and late two-cell embryo stage, suggesting that it 
might play an important role in preimplantation development (Falco et al., 2007). 
There is also some evidence for expression of Zscan4 in adult tissues. An IHC study showed 
nuclear and cytoplasmic Zscan4 staining in a small number of human pancreatic tissues, 
including islets of Langerhans, acini, ducts and oval-shaped cells, and its expression was 
increased in chronic pancreatitis (Ko et al., 2013b). Second, a non-published study by a PhD 
student in our laboratory (Ben Sharpe) showed nuclear Zscan4 staining was increased in a 
subset of PCa tissues compared to those with a normal nature (Sharpe, 2016). Nuclear 
Zscan4 was also found to be higher in biochemical recurrence tissues compared to non-
recurrence (Sharpe, 2016), although this result was non-significant, perhaps because of the 
small sample size. Therefore, previous work in our laboratory suggested that Zscan4 
expression might be linked to PCa formation and possibly biochemical relapse. 
Given the evidence, described above, to suggest a link between Zscan4 staining and PCa and 
a potential role for the protein in SCs, it was decided to examine the expression of the protein 
in more detail. The hypothesis used was based on the recent study from our lab (Sharpe, 
2016) and predicted that nuclear Zscan4 staining would be increased in PCa and might be 
positively associated with PCa relapse. The key publications and hypothesis for Zscan4 are 
summarised in Table 7.1  
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Table 7. 1 The key publications and hypothesis of Zscan4.  
 
7.1.2 Aims  
The goal of this chapter is to test the hypothesis, described above by carrying out the 
following:  
1. To determine the expression of Zscan4 in normal and malignant prostate tissues from 
the Bath and TMA cohorts. 
2. To establish if the expression of Zscan4 correlates with histopathological and clinical 
features of PCa, including primary Gleason grade, clinical stage and biochemical 
recurrence. 
3. To confirm the specificity of the Zscan4 IHC staining using  RNAscope® to measure 
the expression of Zscan4 mRNA. 
7.2 Results  
7.2.1 Testing of antigen retrieval methods 
Having chosen Zscan4 as a candidate biomarker, the next step was to assess its expression 
using IHC. Before this could be carried out, different types of antigen retrieval were tested 
to establish which gave the best staining for Zscan4.   
IHC staining was carried out with an anti-Zscan4 antibody from Novus Biological that is 
referred to here as the anti-Zscan4 A antibody. IHC staining showed nuclear Zscan4 staining 
in prostate tissue using citrate (pH 6) and Tris / EDTA (pH 9) buffers. A citrate buffer was 
chosen for Zscan4 because it showed clear nuclear staining with less little significant 
background staining than a Tris/EDTA buffer (Figure 7.1). 
Name & type of 
Protein  





 Nuclear and cytoplasmic Zscan4 staining was increased in chronic 
pancreatitis compared to normal pancreatic tissues (Ko et al., 2013). 
 
 Nuclear Zscan4 was overexpressed in a subset of PCa tissues 
compared to NP tissues and was not associated significantly with PCa 
histopathological parameters, including Gleason grades and relapse 
(Sharpe, 2016). However, nuclear Zscan4 H-scores were found to be 
higher in patients with PCa relapsed compared to those with non relapsed, 
suggesting that small sample size may explain this non-significant result. 
1. Nuclear Zscan4 
staining will be 
increased in a subset 
of PCa compared to 
NP tissues.  
2. Nuclear Zscan4 







Figure 7. 1 Expression of Zscan4 after the different antigen retrieval methods. (A) Expression of Zscan4 in 
citrate buffer pH 6. (B) Expression of Zscan4 in Tris/EDTA buffer pH 9. IHC staining with citrate buffer 
showed a clearer nuclear Zscan4 staining compared to Tris/EDTA buffer. Scale bar=100μm with inserts at 2x 
zoom. 
7.2.2 Expression of Zscan4 in the Bath cohort, using the anti-
Zscan4 A antibody 
To test the hypothesis that nuclear Zscan4 will be increased in a subset of PCa and will be 
positively associated with biochemical recurrence; IHC was carried out with the Bath cohort 
prostate tissues using the anti- Zscan4 A.  
7.2.2.1 Immunohistochemical expression of anti-Zscan4 A in the Bath 
prostate samples 
IHC was carried out to investigate the expression of Zscan4 on normal and malignant 
prostate tissue samples from the Bath cohort, using the anti-Zscan4 A antibody. IHC showed 
that NP tissues had, at low frequencies, nuclear anti-Zscan4 staining with different levels of 
staining patterns, ranging from moderate (Figure 7.2 A, arrow) to negative (Figure 7.2 B, 
arrow). Nuclear anti-Zscan4 staining was also observed in the glandular epithelium of PCa 
and the intensity of signal varied widely, from strong and widespread (Figure 7.2 C, arrow), 
moderate and scattered (Figure 7.2 D, arrow), weak at low frequency (Figure 7.2 E, arrow) 
and negative (Figure 7.2. F, arrow). 
In addition to the nuclear staining, cytoplasmic Zscan4 staining was found in normal and 
malignant prostate tissues with different levels of staining ranging from moderate (Figure 
7.2 C, arrowhead) to weak (Figure 7.2 A, arrowhead) or negative (Figure 7.2 F). Zscan4 is 
expressed in placenta tissues (Sharpe, 2016) and so this study used normal placental tissue 
as a positive control for anti-Zscan4 A and as expected  IHC showed nuclear anti-Zscan4 A 
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staining in normal placental tissue (Figure 7.2 G, arrows).  A negative control showed no 
detectable background staining in prostate tissue (Figure 7.2 H, arrow).  
7.2.2.2 Association between anti-Zscan4 A immunostaining and 
histopathological and clinical parameters of prostate cancer in the Bath 
cohort 
The previous PhD student, Benjamin Sharpe,  stained 27 PCa vs. 5 NP tissues from the Bath 
cohort. This study added 7 PCa new samples to his data to increase the sample size. Data 
from both studies are included in the results presented below.  
Having carried out IHC staining, the nuclear anti-Zscan4 A staining was quantified using 
the H-score system (Described in Chapter 2.2.2) and then compared to PCa histopathological 
and clinical parameters. The range of nuclear anti-Zscan4 A H-score in the Bath cohort 
varied between 0- 60 (Figure 7.3). The potential association between anti-Zscan4 A IHC 
results and histopathological and clinical parameters of PCa was then analysed and is 
described below.  
The first analysis looked at the expression of anti-Zscan4 A in normal vs. malignant prostate 
tissues. Quantification of the IHC staining showed nuclear anti-Zscan4 staining expressed 
in 87% of PCa tissues compared to a very little expression level in NP tissues, but the result 
was not significant (P= 0.2899) (Figure 7.3 A & Table 7.2). There was no significant 
association between nuclear Zscan4 staining and PCa histopathological and clinical 





Figure 7. 2 Zscan4 staining in samples from the Bath cohort. Zscan4 staining was found heterogeneously in 
both normal and malignant tissues of the prostate, using anti-Zscan4 A antibody.  (A) Moderate nuclear (Black 
arrow) and weak cytoplasmic (Black arrowhead) anti-Zscan4 A staining in NP. (B) NP had no anti-Zscan4 A 
staining. (C) Moderate nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Zscan4 A staining in 
PCa. (D) Moderate nuclear (Black arrow) anti-Zscan4 A staining in PCa. (E) Weak nuclear (Black arrow) anti-
Zscan4 A staining in PCa. (F) Negative anti-Zscan4 A staining in PCa. (H) Positive control: Nuclear anti-
Zscan4 A staining (Black arrows) in placenta tissue. (H) Negative control (no primary antibody added) was 




Figure 7. 3 Quantification of nuclear Zscan4 staining in both normal and malignant Bath prostate tissues, using 
anti-Zscan4 A antibody. Immunohistochemical staining of anti-Zscan4 A was quantified in the Bath cohort 
using H-score for nuclear IHC staining. (A) Nuclear anti-Zscan4 A staining was increased in PCa compared to 
NP (B) Nuclear anti-Zscan4 A staining was not associated with primary Gleason grade (p= 0.2899) (C) Nuclear 
anti-Zscan4 A staining was not associated with primary tumour stage T (p=0.2567). (D) Nuclear anti-Zscan4 
A staining was not associated with biochemical relapse (p= 0.8159). The mean of five random fields was taken 
per prostate sample. Statistical significance was determined with unpaired T-test for each set of conditions. NP 
(n=4), PCa (n= 32), grade 3 (n=14), grade 4 (n=16), T1-2 (n=19), T3-4 (n= 11), recurrent (n=16) and non-
recurrent (n=12). 
Table 7. 2 Nuclear anti-Zscan4 A staining results with Bath cohort clinical data. 
 
Comparison Nuclear anti-Zscan4 A staining  
Results p. value 
Normal vs malignant No statistically significant difference 0.2899 
Gleason grades (Grade 3 & 4) No statistically significant difference 0.4388 
Stage (T) No statistically significant difference 0.2567 
5 years Biochemical recurrence  No statistically significant difference 0. 8159 
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In summary, there was no significant difference between nuclear anti-Zscan4 A staining in 
normal vs. malignant prostate tissues. Nuclear anti-Zscan4 A staining showed also no 
associated with primary Gleason grade, clinical stage and biochemical recurrence. This 
result should be treated as preliminary data because of the sample size, so the staining was 
repeated using a tissue microarray with a larger sample size.  
7.2.3 Expression of Zscan4 in the TMA cohort, using the anti-
Zscan4 A antibody 
7.2.3.1 IHC staining of anti-Zscan4 A in the TMA prostate samples  
IHC was carried out on prostate tissues from the TMA cohort. IHC staining showed that 
Zscan4 staining was not detected in NP tissues, using anti-Zscan4 A (Figure 7.4 A, arrow). 
In contrast, nuclear anti-Zscan4 A staining was found in a subset of PCa tissues and the 
intensity of signal varied widely, from strong and widespread (Figure 7.4 B, arrow), 
moderate (Figure 7.4 C, arrow), weak (Figure 7.4 D, arrow) and negative (Figure 7.4 G, 
arrow). In addition, cytoplasmic anti-Zscan4 A staining was also observed in some cases of 
normal and malignant prostate tissue from the Bath cohort with different levels of staining. 
The different levels of cytoplasmic staining might be important, so quantification was 
included in further analysis. Cytoplasmic anti-Zscan4 A staining was also observed in some 
PCa tissues with different levels of staining patterns, ranging from strong (Figure 7.4 E, 
arrowhead) to weak (Figure 7.4 F, arrowhead) or negative (Figure 7.4 G, arrow). A negative 
















Figure 7. 4 Zscan4 expressions in samples from the TMA cohort. Zscan4 A was expressed heterogeneously in 
both normal and malignant tissues of the prostate, using anti-Zscan4 A antibody.  (A) Negative anti-Zscan4 A 
staining in NP. (B) Strong nuclear (Black arrow ) anti-Zscan4 A staining in PCa. (C) Moderate nuclear (Black 
arrow) anti-Zscan4 A staining in PCa. (D) Weak nuclear (Black arrow) anti-Zscan4 A staining in PCa. (E) 
Strong cytoplasmic anti-Zscan4  A staining (Black arrowhead) in PCa.  (F) Weak cytoplasmic anti-Zscan4  A 
staining (Black arrowhead) in PCa.  (G) PCa tissue had no clear anti-Zscan4 A staining.  (H) Negative control 
(no primary antibody added) shows no clear background staining (Black arrow)  in PCa. Scale bars=100µm 
with inserts at 2x zoom.   
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7.2.3.2 Association between anti-Zscan4 A immunostaining with 
histopathological parameters of prostate cancer in the TMA cohort 
In order to evaluate, if there was an association between anti-Zscan4 A staining in normal 
and malignant prostate tissues, different primary Gleason grades, clinical stages and 
biochemical recurrence, nuclear and cytoplasmic anti-Zscan4 A staining was assessed using 
the H & proportion and intensity 1 scores, respectively and then compared to 
histopathological variables accompanying the TMA. The range of nuclear and cytoplasmic 
anti-Zscan4 A scores in the TMA varied between 0-85.5 and 0-6, respectively (Figure 7.5). 
Quantification of the IHC staining showed nuclear anti-Zscan4 A staining expressed in a 
subset of PCa tissues (21.3%), whereas, all NP tissues had negative staining for anti-Zscan4 
A. However, this result showed no significant difference between groups (p= 0.1076) (Figure 
7.5 A & Table 7.3). Cytoplasmic anti-Zscan4 staining was increased significantly in a subset 
of PCa compared to NP tissues (p= 0.01) (Figure 7.5 B & Table 7.3).  
 
There was no significant difference in the mean of nuclear anti-Zscan4 A staining among 
primary Gleason grade groups (p= 0.4221) (Figure 7.4 C & Table 7.2). In contrast, 
cytoplasmic anti-Zscan4 A staining showed a significant difference between primary 
Gleason grade groups (P = 0.0487) (Figure 7.4 D & Table 7.2). Analysis of the IHC data, 
using multiple comparisons Tukey’s tests showed cytoplasmic anti-Zscan4 A staining was 
reduced significantly when comparing PCa patients with a Gleason grade 5 to those with a 
Gleason grade 4 (p=0.046), but no significant difference between Gleason grade 3 tissues to 
grade 4 (P=0.1644) or grade 5 tissues (p=0.9994). Nuclear and cytoplasmic anti-Zscan4 A 









Figure 7. 5 Quantification of nuclear and cytoplasmic anti-Zscan4 A staining in both normal and malignant 
TMA prostate tissues. Immunohistochemical staining of anti-Zscan4 A was quantified in the TMA cohort using 
H-score and proportion and intensity 1 for nuclear and cytoplasmic IHC staining respectively. (A) Nuclear 
anti-Zscan4 A staining was expressed in a subset of PCa (p=0.1076). (B) Cytoplasmic anti-Zscan4 A was 
increased significantly in PCa compared to NP (p= 0.01). (C) Nuclear anti-Zscan4 A was not associated 
significantly with primary Gleason grade (p=0. 4221). (D) Cytoplasmic anti-Zscan4 A staining showed a 
significant difference among Gleason grade groups (p=0.0487). Multi comparison tests showed a significant 
reduction in the cytoplasmic anti-Zscan4 scores when comparing Gleason grades 5 tissues to Gleason grade 4 
(p=0.046). Data represent the mean of five random images per case. Unpaired t-test or one-way ANOVA with 
multi-comparison (Tukey) tests was conducted for two or three groups respectively to determine the statistical 
difference for each set of conditions. NP (n=16), PCa (80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 7. 3 Nuclear anti-Zscan4 A staining results with the TMA clinical data. 
Comparison Nuclear   anti-Zscan4 A staining Cytoplasmic   anti-Zscan4 A staining 
Results p. value Results p. value 
Normal vs 
malignant 
increased in a subset of 







































0.4031 Grade 5 vs. 
Grade 4 
0.046 
Stage (T) No statistically significant 
difference 
0.1146 No statistically significant 
difference 
0.2764 
Stage (M) No statistically significant 
difference 
0.1861 No statistically significant 
difference 
0.1534 
Stage (N) No statistically 
significant difference 




In summary, nuclear and cytoplasmic anti-Zscan4 staining was increased in a subset of PCa 
compared to NP tissues, although the nuclear staining results were not significant.  Nuclear 
and cytoplasmic anti Zscan4 A staining was not associated significantly with primary 
Gleason grade and clinical stage (except for cytoplasmic staining between grade 4 & 5).  
7.2.4 Expression of Zscan4 in the Bath cohort using the anti-
Zscan4 B antibody 
In order to show that the anti-Zscan4 A staining reported above was accurately showing 
changes in Zscan4 protein expression, the results should be repeated with an independent 
antibody. To achieve this a second independent Zscan4 rabbit polyclonal antibody from 
Abcam, that is referred to here as the anti-Zscan4 B, was identified.  
The original antibody, anti-Zscan4 A is a mouse polyclonal antibody, but the provider did 
not provide us with information about its immunogen (Figure 7.7 A). The second antibody, 
anti-Zscan4 B is a rabbit polyclonal raised with an immunogen that was a fragment of the 
C-terminal of Zscan4 (Figure 7.7 B). Therefore, although we do not know if the two 
antibodies come from different regions of the protein, the two antibodies were raised 
independently (shown by the fact they have different hosts) and so the second antibody was 
chosen for testing on normal placenta and PCa tissues from the Bath cohort, to show if it 
gave similar results to the first antibody. 
Human Zscan4 protein  
        1 maldlrtifq cepsennlgs ensafqqsqg pavqreegis efsrmvlnsf qdsnnsyarq 
       61 elqrlyrifh swlqpekhsk deiisllvle qfmigghcnd kasvkekwks sgknlerfie 
      121 dltddsinpp alvhvhmqgq ealfsedmpl rdvivhltkq vnaqttrean mgtpsqtsqd 
      181 tsletgqgye deqdgwnsss kttrvnenit nqgnqivsli iiqeengprp eeggvssdnp 
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      241 ynskraelvt arsqegsing itfqgvpmvm gagcisqpeq sspesalthq snegnstcev 
      301 hqkgshgvqk sykceecpkv fkylchllah qrrhrnerpf vcpecqkgff qisdlrvhqi 
      361 ihtgkkpftc smckksfshk tnlrsherih tgekpytcpf cktsyrqsst yhrhmrthek 
421 itlpsvpstp eas 
A. Zscan4 mouse polyclonal antibody  
The provider does not specify which part of human Zscan4 the immunogen originated from 
 
B. Zscan4 rabbit polyclonal antibody  
361 ihtgkkpftc smckksfshk tnlrsherih tgekpytcpf cktsyrqsst yhrhmrthek 
      421 itlpsvpstp eas 
 
 
Figure 7. 6 Zscan4 proteins sequence with the immunogenic parts of the two different antibodies highlighted. 
(A) Human Zscan4 protein consists of 433 amino acid and the antibodies were raised independently as they 
have different hosts or clonity. (A) Zscan4 mouse polyclonal (anti-Zscan4 A) immunogen is not provided by 
the company. (B) Zscan4 rabbit polyclonal (anti-Zscan4 B) immunogen was a partial fragment of the C-
terminal of Zscan4 (Grey highlighted).   
7.2.4.1 Immunohistochemical staining patterns of Zscan4 antibodies on the 
placenta and prostate tissues from the Bath cohort  
IHC was carried out using the two different Zscan4 antibodies (anti-Zscan4 A& B) on 
sections from similar regions of the placenta and prostate tissue samples from the Bath 
cohort. Strong to weak scattered nuclear  (Figure 7.7 A, arrows) and weak cytoplasmic 
(Figure 7.7 A, arrowhead)  anti-Zscan4 A staining was observed in placental tissue, whereas, 
strong and widespread nuclear (Figure 7.7, B, arrows) and weak cytoplasmic (Figure 7.7 B, 
arrowhead) anti-Zscan4 B staining was shown in placental tissue.  
Zscan4 was expressed weakly in the cytoplasm of the glandular regions of PCa, using anti 
Zscan4 A  antibody (Figure 7.7 C, arrowhead). In contrast, strong nuclear (Figure 7.8 D, 
arrows) and cytoplasmic (Figure 7.7 D, arrowhead) anti-Zscan4 B staining was detected in 
PCa tissue. Another PCa section showed no clear anti-Zscan4 A staining (Figure 7.7 E, 
arrows), whereas, the similar section from same PCa case had strong nuclear anti-Zscan4 B 
staining (figure 7.7, F, arrow).   
The two different Zscan4 antibodies (A&B) had different staining patterns in both placental 
and prostate tissue samples. So it was decided not to use anti-Zscan4 B for further analysis. 
Rather than test a third antibody, it was decided to use RNAscope to visualise Zscan4 mRNA 








Figure 7. 7 Immunohistochemical staining of using two distinct Zscan4 antibodies in the Bath placental and 
prostate tissue samples. (A) Strong to weak nuclear (Black arrows) and weak cytoplasmic (Black arrowhead) 
anti-Zscan4 A in placental tissues. (B) Strong nuclear (Black arrows) and cytoplasmic (Black arrowhead) anti-
Zscan4 B in placental tissue. (C) Weak nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Zscan4 
A in PCa. (D) Strong nuclear (Black arrow) and cytoplasmic (Black arrowhead) anti-Zscan4 B in PCa. (F) 
Negative staining for anti-Zscan4 A in PCa. (F) Strong nuclear (Black arrow) anti-Zscan4 B in PCa. Both 
antibodies showed different staining patterns in placenta and prostate tissues. Scale bars—100 μm with inserts 
at 2x zoom. 
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7.2.5 Analysis of expression of Zscan4 mRNA using RNAscope® 
7.2.5.1 Zscan4 mRNA expression in prostate tissues from the Bath cohort 
RNAscope® was carried out on prostate tissue samples from the Bath cohort. The result 
showed no significant staining for Zscan4 mRNA in all NP tissues (Figure 7.9 A, arrow). In 
contrast, Zscan4 mRNA staining was observed in PCa tissues and the number of positive 
cells varied, from few positive dots per cell (Figure 7.8 B&C, arrows) to negative (Figure 
7.8 D, arrow). A positive control tissue, placenta showed Zscan4 mRNA staining (Figure 
7.8, E, arrows). The negative control probe showed no background staining in PCa tissue 
(Figure 7.8 H, arrow). 
Figure 7. 8 Zscan4 mRNA staining in prostate samples from the Bath cohort. (A) No Zscan4 mRNA staining 
in NP (Black arrow). (B) Zscan4 mRNA staining (Black arrows) in PCa. (C) Zscan4 mRNA staining (Black 
arrows) in PCa. (D) No Zscan4 mRNA staining (Black arrow)  in PCa. (E) Zscan4 mRNA staining (Black 
arrows) in normal placental tissue. (F) Negative control showed a free background staining (Black arrow)  in 
PCa. Scale bars=100µm with inserts at 2x zoom.    
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7.2.5.2 Association between Zscan4 mRNA staining and histopathological 
parameters of prostate cancer in the Bath cohort 
 Histologically normal and malignant prostate tissues were stained for Zscan4 mRNA and 
scored using the Zscan4 mRNA score (described in Chapter 2.4). The range of Zscan4 
mRNA score in the Bath cohort varied between 0-0.4.  
Statistical analysis was not performed because of the small sample size of the Bath cohort. 
However, the preliminary data showed that Zscan4 at the mRNA level was not expressed in 
all NP tissues, whereas, 33% of PCa had Zscan4 mRNA staining. There was no clear 
association between Zscan4 mRNA staining and other PCa histopathological parameters, 
including primary Gleason grade, clinical stage and biochemical relapse. This data is based 
on small sample size, so RNAscope was repeated to measure the expression of Zscan4 at 
mRNA level in the large TMA cohort.  
7.2.6 Zscan4 mRNA staining in prostate tissues from the TMA 
cohort 
7.2.6.1 Zscan4 mRNA expression in prostate tissues from the TMA cohort 
The RNAscope® result showed no significant Zscan4 mRNA staining in NP tissues (Figure 
7.9 A, arrow), but it was expressed in a subset of PCa tissues and the number of positive 
cells varied widely, from a widespread (Figure 7.9 B&C, arrows), scattered (Figure 7.9 D, 
arrow) and negative (Figure 7.9 E, arrow). A negative control was free of background 
staining in prostate tissue (Figure 7.9 F, arrow). This result was consistent with the Zscan4 





Figure 7. 9 Zscan4 mRNA staining in prostate samples from the TMA cohort. (A) NP tissue had negative 
staining for Zscan4 mRNA (Black arrow). (B) Zscan4 mRNA staining (Black arrow) in PCa. (C) Zscan4 
mRNA staining (Black arrow) in PCa. (D) Zscan4 mRNA staining (Black arrow) in PCa. (E) No Zscan4 mRNA 
staining (Black arrow)  in PCa. (F) Negative control showed a free background staining (Black arrow)  in PCa. 
Scale bars=100µm with inserts at 2x zoom.        
7.2.6.2 Association between Zscan4 mRNA staining and histopathological 
parameters of prostate cancer in the TMA cohort 
Having carried out RNAscope® staining, Zscan4 mRNA staining was then quantified using 
the Zscan4 mRNA score (described in chapter 2.4). The range of Zscan4 mRNA score varied 
between 0-3 (Figure 7.10). The potential association between Zscan4 mRNA staining and 
histopathological parameters of PCa was then analysed and described below.  
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The first analysis looked at the mRNA expression of Zscan4 in normal vs. malignant prostate 
tissues. Quantification of the RNAscope® showed Zscan4 mRNA staining increased 
significantly in a subset of PCa compared to NP tissues (p=0.0465) (Figure 7.10 A& Table 
7.5), but was not associated with other PCa histopathological parameters such as primary 
Gleason grade and clinical stage (Figure 7.10 B & Table 7.5). 
Figure 7. 10 Quantification of Zscan4 mRNA staining in both normal and malignant TMA  prostate tissues. 
Zscan4 mRNA staining was quantified in the TMA cohort using Zscan4 mRNA score. (A) Zscan4 mRNA 
staining was increased significantly in a subset of PCa (p=0.0465). (B) There was no significant difference in 
the mean of Zscan4 mRNA score among Gleason grades (p=0.5136). Data represent the mean of five random 
images per case. Unpaired T-test or one-way ANOVA with Tukey’s multi-comparison tests were conducted 
for two or three groups respectively to determine the statistical difference for each set of conditions. NP (n=16), 
PCa (80), grade 3 (n=13), grade 4 (n=46) and grade 5 (n=18). 
Table 7. 4 Zscan4 mRNA staining results with the TMA clinical data. 
Comparison 
Zscan4 mRNA staining 
Results p. value 
Normal vs malignant Increased in a subset of PCa 
0.0465 
 
Primary Gleason grade 
(3, 4 &5) 






Grade 4 vs. Grade 3 0.5781 
Grade 5 vs.  Grade 3 0.5626 
Grade 5 vs. Grade 4 0.4070 
Stage (T) No statistically significant difference 0.4654 
Stage (M) No statistically significant difference 0.7817 
Stage (N) 




In summary, Zscan4 mRNA staining was increased significantly in a subset of PCa 
compared to NP tissues, but was not associated with primary Gleason grade and clinical 
stage.  
2.5.7 Zscan4 results in the Bath and TMA cohorts: testing the 
hypothesis 
The results from the two cohorts and if the hypothesis is accepted or rejected is summarised 
in Table 7.5. 
Table 7. 5 The summary of Zscan4 results in the Bath and TMA cohorts  
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Not tested N/A NO 
 
7.3 Discussion  
7.3.1 Summary  
This study used IHC and RNAscope® to investigate the expression of Zscan4 protein and 
mRNA levels in normal and malignant prostate tissues from the Bath and TMA cohorts and 
to establish if there was an association between Zscan4 staining and PCa histopathological 
parameters, including primary Gleason grade, clinical stage and biochemical recurrence. 
Two different Zscan4 antibodies and an mRNA probe were used in this study. The staining 
patterns of Zscan4, using two different antibodies was different in prostate and placenta 
tissues form the Bath cohort. However, the mRNA staining and antibody results from the 
first antibody were consistent and confirmed that Zscan4 protein and mRNA levels were 
increased in a subset of PCa compared to NP, but were not associated significantly with 
primary Gleason grade, clinical stage and biochemical recurrence (Figure 7.6). In this 
chapter, I will discuss the key findings for Zscan4 and what is the possible role of Zscan4 in 
PCa. 
Table 7. 6 Confirmed patterns of expression for Zscan4.  
 
 
Zscan4 Confirmed patterns of expression 
Anti-Zscan4 A Nuclear and cytoplasmic anti-Zscan4 A staining was increased in a subset of PCa, 
but was not associated with primary Gleason grade, clinical stage and relapse. 
Zscan4 mRNA Zscan4 mRNA staining was increased in a subset of PCa, but was not associated 
with primary Gleason grade, clinical stage and biochemical relapse. 
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7.3.2 Zscan4 staining is increased in a subset of prostate cancer 
but is not associated with primary Gleason grade, clinical stage 
and biochemical recurrence.  
Data presented in this chapter showed that Zscan4 staining at protein and mRNA levels were 
increased in a subset of PCa compared to NP. There was no significant association between 
Zscan4 staining and the histopathological parameters of PCa, including primary Gleason 
grade, clinical stage and biochemical recurrence. 
There is no published study that has tested Zscan4 expression in cancer tissues, including 
PCa. However, Ko et al. showed nuclear and cytoplasmic Zscan4 staining in a small number 
of human pancreatic tissues, including islets of Langerhans, acini, ducts and oval-shaped 
cells, and its expression level was increased in chronic pancreatitis (Ko et al., 2013). The 
previous unpublished work from our laboratory, carried out by Ben Sharp, showed nuclear 
Zscan4 increased in a subset of PCa compared to NP tissues. In contrast, nuclear Zscan4 
staining was not associated significantly with other PCa histopathological and clinical 
features such as Gleason score and relapse. The data presented here is consistent with the 
previous data from Ben Sharpe (Sharpe, 2016), suggesting Zscan4 might have a role in PCa 
formation. Although my data showed no significant association between Zscan4 protein and 
mRNA levels with a risk of relapse, there are still many questions about this association 
because of the limited numbers of samples in the Bath cohort and no data concerning 
biochemical recurrence in the TMA cohort. It will be very interesting to assess association 
in a large cohort with clinical information about PCa recurrence, using IHC and 
RNAscope®. Additional future work is considered in the final discussion.    
7.3.3 The possible role of Zscan4 in prostate cancer 
In 2007, Zscan4 was shown to be expressed in late 2 cell embryos and embryonic SCs, but 
its functional mechanism remained unknown (Falco et al., 2007). However, a study in 2010 
done by Zalzman, et al reported that Zscan4 has a role in regulating telomere elongation and 
genomic stability and its knockdown showed telomere shortening, increased karyotype 
abnormalities and sister chromatid exchange (Zalzman et al., 2010). Two further studies on 
different cell lines also reported that Zscan4 may have a role in maintaining genomic stability 
by regulating telomere elongation, but this regulation was in independent of the telomerase 
maintenance pathway (Lee and Gollahon, 2014, 2015). There is a direct interaction between 
Zscan4 and a repressor-activator protein 1 (Rap1), one of the shelterin complex (telomere 
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binding factors) and this direct binding may play a role in maintaining telomere length (Lee 
and Gollahon, 2014).  
This evidence for a role for Zscan4 in maintaining telomere length and genomic stability 
raises the possibility that increased Zscan4 in cancer cells might also lead to telomere defects 
and potentially genomic instability. In addition, a previous study demonstrated that Zscan4 
was positively regulated by p110a isoform of PI3-Kinase (Storm et al., 2014). The PI3K-
AKT pathway is activated by the loss of PTEN which is found to be strongly associated with 
adverse oncological outcomes of PCa (Jamaspishvili et al., 2018), suggesting that  Zscan4 
could be activated by the PI3K pathway in PCa. 
7.3.4 Conclusion   
In conclusion, Zscan4 appears to be overexpressed in a subset of PCa compared to NP 
tissues, but its expression was not associated significantly with primary Gleason grade, 
clinical stage and biochemical relapse. Further study needs to test if there is an association 
between Zscan4 expression and risk of relapse in samples from a larger cohort of patients 
and elucidate its molecular function in normal and malignant prostate tissues. Additional 
future work is considered in the final discussion.  



































CHAPTER EIGHT  




8. Final discussion and future research 
8.1 Introduction  
The major goal of this study was to identify proteins that are differentially expressed 
between normal and malignant prostate tissues and/or between different Gleason 
grades, clinical stages and recurrence vs non-recurrence PCa. This is important to 
improve our understanding of the molecular basis of PCa formation and progression 
and potentially help in the development of future biomarkers. To achieve this goal, 
the project involved the identification and evaluation of the expression of proteins in 
prostate samples from two independent cohorts of patients using IHC and 
RNAscope®. 
8.2 Main conclusions  
Eight potential biomarkers were identified using literature searching and their 
expression evaluated by IHC and /or RNAscope®. β-catenin, Sox7, ABCG2, and 
membranous and cytoplasmic NDRG1 staining was decreased in PCa compared to 
NP tissues, whereas, Sall4, Zscan4, nuclear NDRG1 and glandular ALDH1A1 
staining was increased in PCa. There was a negative association between the 
expression of markers β-catenin, Sox7, ABCG2 and Sall4, and primary Gleason 
grade and a positive association was observed between nuclear NDRG1 and primary 
Gleason grade. Finally, three of these biomarkers (Sox7, ABCG2 and stromal 
ALDH1A1) were negatively associated with biochemical relapse. In this chapter, I 
will focus on the four findings I believe to be of most significance. 
 The expression of Sox7, ABCG2 and stromal ALDH1A were negatively 
associated with biochemical relapse.  
 Sox7, β-catenin and ABCG2 expression was reduced in PCa compared to NP 
and was negatively associated with increasing Gleason grade.  
 Sall4 at protein and mRNA levels were increased in PCa compared to NP 
tissues, but the expression of Sall4 was associated negatively with increasing 
primary Gleason grade. 
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 Nuclear NDRG1 expression was increased in PCa and is positively associated 
with increasing Gleason grades and clinical stage.  
8.3 Strengths and limitations of this study 
The work presented in this thesis has a number of strengths. First, the two different 
cohorts allowed confirmation of the results in samples from two independent patient 
groups. Second, the sample size of the TMA cohort was large (16 NP and 80 PCa) 
and comparable to many studies investigating these biomarkers in normal and 
malignant prostate. For example, key recent studies had a sample size of 103 PCa vs 
35 BPH (Ipekci et al., 2015)  or 80 PCa patients (Symes et al., 2013) and sometimes 
better than other studies, such as this study with (10 PCa vs 10 NP ) (Zhong et al., 
2012).  In addition, a second independent antibody and/ or mRNA probe was used to 
validate the expression patterns of three interesting proteins, Sox7, Sall4 and Zscan4. 
This gave greater confidence that the staining was accurately reflecting the expression 
of the target protein. 
The study has some limitations that should be considered in future work aimed at 
extending these findings. A key limitation is that the Bath cohort consists of a small 
number of samples (34 PCa vs 5 NP) and the TMA cohort lacks clinical data 
regarding PCa relapse and non-relapse. This means that any conclusions from this 
work regarding a link to relapse should be treated as preliminary findings. In addition, 
the TMA used had two cores per sample and a previous comparison between TMAs 
and whole sections suggested that the optimal number of tissue cores in a TMA which 
may predict the outcome of the whole tissues of PCa is about 3-4 cores (Rubin et al., 
2002). Another limitation is the amount to validation carried out for the antibodies. 
For three markers a second antibody or RNAscope were used to validate the 
staining pattern, but several other methods can be used to validate antibodies (Uhlen 
et al., 2016). Knockouts are perhaps the most robust method of validation and can 
help support the use of a particular antibody. This method can not be used in human 
tissues, but could be carried out in human cell lines that can then be embedded and 
used for IHC staining. Human knockout cell lines were generated by Horizon 
Company https://www.horizondiscovery.com/ for the following proteins: Sall4 
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(HZGHC57167), Zscan4 (HZGHC201516), Sox7 (HZGHC83595), ABCG2 
(HZGHC9429) and ALDH1A1 (HZGHC216). This would improve the confidence 
that the staining patterns shown by IHC accurately reflect the expression of the 
protein. Knockout cell lines could also be used to validate the RNAscope staining.  
Taken together, although there are limitations, this work represents an important step 
in improving understanding of the molecular basis of PCa formation and progression. 
Further investigation could investigate the functions of the proteins and establish if 
any of them could represent a potential diagnostic biomarker for PCa.   
8.4 Future work 
This section focuses on the four key findings described above and presents a number 
of suggestions for future work stemming from the investigations conducted here. 
In this study, the expression of three potential biomarkers Sox7, ABCG2 and 
ALDH1A1 were negatively associated with a risk of biochemical relapse in the Bath 
cohort. However, the sample size in this cohort is small, so it will be very interesting 
to repeat staining of these proteins with a TMA cohort which has clinical information 
about relapse such as the one used in this study (Nariculam et al., 2009) which has 
82 PCa samples (41 relapsed vs 41 non- relapsed). If the association with relapse was 
confirmed the functional roles of the three proteins in relapse could then be addressed. 
It would be very interesting to study the effect of siRNA mediated silencing of these 
proteins on proliferation and colony formation of PCa cell lines such as PCa C4-2 or 
LNPCa cell lines. MTS and colony formation assays may be used to detect cell 
proliferation and colony formation in cultured PCa cell lines, respectively as 
previously carried out (Liu and Shan, 2016). Additionally, the use of xenograft 
models, for example using nude mice (Stovall, et al., 2013), would be useful to 
address the function of these potential biomarkers. 
Future research is very important to determine the expression patterns of Sall4 and 
Sox7, β-catenin and ABCG2 at protein and mRNA levels using IHC and RNAscope 
in a large TMA cohort from US Bio max (HproA180PGO5), which consists of 90 
PCa and 90 adjacent NP tissues. The current array used in this work only had 16 NP 
cases, so the new array would allow confirmation of the link between expression of 
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these proteins and tumour formation. It would be interesting to try and detect soluble 
Sall4, β-catenin and ABCG2 and NDRG1 levels in serum and/or urine and correlate 
this result with clinical parameters such as different grade and stage of PCa. This has 
been carried out for PSA (Kawakami et al., 2004; Lilja et al., 2008; Dunn and Kazer, 
2011) and Sox7 (Zhong et al., 2012) in PCa patients as well as for Sall4 in 
hepatocellular carcinoma  (Han et al., 2014) using serum samples. In addition, a 
recent study on breast cancer has suggested that Sox7 may have a role in regulating 
Wnt/ β-catenin signalling through its co cooperation with Axin (Liu et al., 2016), so 
it would be very interesting to investigate an association between Sox7 and Axin in 
prostate samples from both cohorts, using IHC and RNAscope. 
Previous experiments on NDRG1 in human pancreatic cancer (Kovacevic et al., 
2013) suggests it may play a role in regulating the PI3K pathway. For this reason, it 
would be interesting to find if there is an association between these potential 
biomarkers and PTEN as a main regulator of the PI3K pathway. This could be carried 
out using IHC, PCR and/or RNAscope. 
Finally, it will be important to validate the expression patterns of potential biomarkers 
such as β-catenin, ABCG2, NDRG1, ALDH1A1 and Sox7, that were stained with a 
single antibody, using either a second independent antibody (IHC) and/ or mRNA 
probe (RNA scope).  
8.5 Final conclusion  
This research suggests that seven of the candidate biomarkers analysed here may play 
a role in prostate tumour formation, aggressiveness and/or relapse and warrant further 
investigation to understand their functions and establish if any of them could 
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